
<html lang="en"     class="pb-page"  data-request-id="7e5a96aa-47e7-4ad6-96b5-21098d867c36"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.6b00389;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2016.59.issue-12;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development" /></meta><meta name="dc.Creator" content="James F.  Blake" /></meta><meta name="dc.Creator" content="Michael  Burkard" /></meta><meta name="dc.Creator" content="Jocelyn  Chan" /></meta><meta name="dc.Creator" content="Huifen  Chen" /></meta><meta name="dc.Creator" content="Kang-Jye  Chou" /></meta><meta name="dc.Creator" content="Dolores  Diaz" /></meta><meta name="dc.Creator" content="Danette A.  Dudley" /></meta><meta name="dc.Creator" content="John J.  Gaudino" /></meta><meta name="dc.Creator" content="Stephen E.  Gould" /></meta><meta name="dc.Creator" content="Jonas  Grina" /></meta><meta name="dc.Creator" content="Thomas  Hunsaker" /></meta><meta name="dc.Creator" content="Lichuan  Liu" /></meta><meta name="dc.Creator" content="Matthew  Martinson" /></meta><meta name="dc.Creator" content="David  Moreno" /></meta><meta name="dc.Creator" content="Lars  Mueller" /></meta><meta name="dc.Creator" content="Christine  Orr" /></meta><meta name="dc.Creator" content="Patricia  Pacheco" /></meta><meta name="dc.Creator" content="Ann  Qin" /></meta><meta name="dc.Creator" content="Kevin  Rasor" /></meta><meta name="dc.Creator" content="Li  Ren" /></meta><meta name="dc.Creator" content="Kirk  Robarge" /></meta><meta name="dc.Creator" content="Sheerin  Shahidi-Latham" /></meta><meta name="dc.Creator" content="Jeffrey  Stults" /></meta><meta name="dc.Creator" content="Francis  Sullivan" /></meta><meta name="dc.Creator" content="Weiru  Wang" /></meta><meta name="dc.Creator" content="Jianping  Yin" /></meta><meta name="dc.Creator" content="Aihe  Zhou" /></meta><meta name="dc.Creator" content="Marcia  Belvin" /></meta><meta name="dc.Creator" content="Mark  Merchant" /></meta><meta name="dc.Creator" content="John  Moffat" /></meta><meta name="dc.Creator" content="Jacob B.  Schwarz" /></meta><meta name="dc.Description" content="The extracellular signal-regulated kinases ERK1/2 represent an essential node within the RAS/RAF/MEK/ERK signaling cascade that is commonly activated by oncogenic mutations in BRAF or RAS or by ups..." /></meta><meta name="Description" content="The extracellular signal-regulated kinases ERK1/2 represent an essential node within the RAS/RAF/MEK/ERK signaling cascade that is commonly activated by oncogenic mutations in BRAF or RAS or by ups..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 7, 2016" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00389" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00389" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00389" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00389" /></link>
        
    
    

<title>Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00389" /></meta><meta property="og:title" content="Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0017.jpeg" /></meta><meta property="og:description" content="The extracellular signal-regulated kinases ERK1/2 represent an essential node within the RAS/RAF/MEK/ERK signaling cascade that is commonly activated by oncogenic mutations in BRAF or RAS or by upstream oncogenic signaling. While targeting upstream nodes with RAF and MEK inhibitors has proven effective clinically, resistance frequently develops through reactivation of the pathway. Simultaneous targeting of multiple nodes in the pathway, such as MEK and ERK, offers the prospect of enhanced efficacy as well as reduced potential for acquired resistance. Described herein is the discovery and characterization of GDC-0994 (22), an orally bioavailable small molecule inhibitor selective for ERK kinase activity." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00389"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00389">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00389&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00389&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00389&amp;href=/doi/10.1021/acs.jmedchem.6b00389" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 5650-5660</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01653" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.5b01448" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1<i>H</i>-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+F.++Blake">James F. Blake</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Burkard">Michael Burkard</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jocelyn++Chan">Jocelyn Chan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Huifen++Chen">Huifen Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kang-Jye++Chou">Kang-Jye Chou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dolores++Diaz">Dolores Diaz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Danette+A.++Dudley">Danette A. Dudley</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+J.++Gaudino">John J. Gaudino</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephen+E.++Gould">Stephen E. Gould</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jonas++Grina">Jonas Grina</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++Hunsaker">Thomas Hunsaker</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lichuan++Liu">Lichuan Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew++Martinson">Matthew Martinson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Moreno">David Moreno</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lars++Mueller">Lars Mueller</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christine++Orr">Christine Orr</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Patricia++Pacheco">Patricia Pacheco</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ann++Qin">Ann Qin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Rasor">Kevin Rasor</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Li++Ren">Li Ren</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kirk++Robarge">Kirk Robarge</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sheerin++Shahidi-Latham">Sheerin Shahidi-Latham</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey++Stults">Jeffrey Stults</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Francis++Sullivan">Francis Sullivan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Weiru++Wang">Weiru Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jianping++Yin">Jianping Yin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aihe++Zhou">Aihe Zhou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marcia++Belvin">Marcia Belvin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Merchant">Mark Merchant</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John++Moffat">John Moffat</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jacob+B.++Schwarz">Jacob B. Schwarz</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 650-225-7732. E-mail: <a href="/cdn-cgi/l/email-protection#2251414a554350580c4843414d406245474c470c414d4f"><span class="__cf_email__" data-cfemail="6417070c1305161e4a0e05070b062403010a014a070b09">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00389&amp;href=/doi/10.1021%2Facs.jmedchem.6b00389" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 5650–5660</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 26, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 March 2016</li><li><span class="item_label"><b>Published</b> online</span>7 June 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 June 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00389" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00389</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5650%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJames%2BF.%2BBlake%252C%2BMichael%2BBurkard%252C%2BJocelyn%2BChan%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D12%26contentID%3Dacs.jmedchem.6b00389%26title%3DDiscovery%2Bof%2B%2528S%2529-1-%25281-%25284-Chloro-3-fluorophenyl%2529-2-hydroxyethyl%2529-4-%25282-%2528%25281-methyl-1H-pyrazol-5-yl%2529amino%2529pyrimidin-4-yl%2529pyridin-2%25281H%2529-one%2B%2528GDC-0994%2529%252C%2Ban%2BExtracellular%2BSignal-Regulated%2BKinase%2B1%252F2%2B%2528ERK1%252F2%2529%2BInhibitor%2Bin%2BEarly%2BClinical%2BDevelopment%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5660%26publicationDate%3DJune%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00389"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5541</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">68</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00389" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;F. Blake&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Burkard&quot;},{&quot;first_name&quot;:&quot;Jocelyn&quot;,&quot;last_name&quot;:&quot;Chan&quot;},{&quot;first_name&quot;:&quot;Huifen&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Kang-Jye&quot;,&quot;last_name&quot;:&quot;Chou&quot;},{&quot;first_name&quot;:&quot;Dolores&quot;,&quot;last_name&quot;:&quot;Diaz&quot;},{&quot;first_name&quot;:&quot;Danette&quot;,&quot;last_name&quot;:&quot;A. Dudley&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;J. Gaudino&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;E. Gould&quot;},{&quot;first_name&quot;:&quot;Jonas&quot;,&quot;last_name&quot;:&quot;Grina&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;Hunsaker&quot;},{&quot;first_name&quot;:&quot;Lichuan&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;Martinson&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Moreno&quot;},{&quot;first_name&quot;:&quot;Lars&quot;,&quot;last_name&quot;:&quot;Mueller&quot;},{&quot;first_name&quot;:&quot;Christine&quot;,&quot;last_name&quot;:&quot;Orr&quot;},{&quot;first_name&quot;:&quot;Patricia&quot;,&quot;last_name&quot;:&quot;Pacheco&quot;},{&quot;first_name&quot;:&quot;Ann&quot;,&quot;last_name&quot;:&quot;Qin&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Rasor&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Kirk&quot;,&quot;last_name&quot;:&quot;Robarge&quot;},{&quot;first_name&quot;:&quot;Sheerin&quot;,&quot;last_name&quot;:&quot;Shahidi-Latham&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;Stults&quot;},{&quot;first_name&quot;:&quot;Francis&quot;,&quot;last_name&quot;:&quot;Sullivan&quot;},{&quot;first_name&quot;:&quot;Weiru&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Jianping&quot;,&quot;last_name&quot;:&quot;Yin&quot;},{&quot;first_name&quot;:&quot;Aihe&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Marcia&quot;,&quot;last_name&quot;:&quot;Belvin&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Merchant&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Moffat&quot;},{&quot;first_name&quot;:&quot;Jacob&quot;,&quot;last_name&quot;:&quot;B. Schwarz&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;5650-5660&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00389&quot;},&quot;abstract&quot;:&quot;The extracellular signal-regulated kinases ERK1/2 represent an essential node within the RAS/RAF/MEK/ERK signaling cascade that is commonly activated by oncogenic mutations in BRAF or RAS or by upstream oncogenic signaling. While targeting upstream nodes with RAF and MEK inhibitors has proven effective clinically, resistance frequently develops through reactivation of the pathway. Simultaneous targeting of multiple nodes in the pathway, such as MEK and ERK, offers the prospect of enhanced efficacy as well as reduced potential for acquired resistance. Described herein is the discovery and characterization of GDC-0994 (22), an orally bioavailable small molecule inhibitor selective for ERK kinase activity.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00389&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00389" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00389&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00389" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00389&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00389" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00389&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00389&amp;href=/doi/10.1021/acs.jmedchem.6b00389" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00389" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00389" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00389%26sid%3Dliteratum%253Aachs%26pmid%3D27227380%26genre%3Darticle%26aulast%3DBlake%26date%3D2016%26atitle%3DDiscovery%2Bof%2B%2528S%2529-1-%25281-%25284-Chloro-3-fluorophenyl%2529-2-hydroxyethyl%2529-4-%25282-%2528%25281-methyl-1H-pyrazol-5-yl%2529amino%2529pyrimidin-4-yl%2529pyridin-2%25281H%2529-one%2B%2528GDC-0994%2529%252C%2Ban%2BExtracellular%2BSignal-Regulated%2BKinase%2B1%252F2%2B%2528ERK1%252F2%2529%2BInhibitor%2Bin%2BEarly%2BClinical%2BDevelopment%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D12%26spage%3D5650%26epage%3D5660%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/jmcmar.2016.59.issue-12/20160623/jmcmar.2016.59.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The extracellular signal-regulated kinases ERK1/2 represent an essential node within the RAS/RAF/MEK/ERK signaling cascade that is commonly activated by oncogenic mutations in BRAF or RAS or by upstream oncogenic signaling. While targeting upstream nodes with RAF and MEK inhibitors has proven effective clinically, resistance frequently develops through reactivation of the pathway. Simultaneous targeting of multiple nodes in the pathway, such as MEK and ERK, offers the prospect of enhanced efficacy as well as reduced potential for acquired resistance. Described herein is the discovery and characterization of GDC-0994 (<b>22</b>), an orally bioavailable small molecule inhibitor selective for ERK kinase activity.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div id="ac_i1" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i1"> </h2><div class="NLM_p">The RAS/RAF/MEK/ERK (MAPK) signal transduction pathway is widely activated in a large subset of human cancers and thus has attracted significant interest as a therapeutic target for cancer.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Constitutive activation of the MAPK pathway by oncogenic RAS and RAF mutations as well as activation or overexpression of growth factor receptors results in sustained activation of the central effector kinases ERK1 and ERK2 (MAPK3 and MAPK1). ERK1/2 phosphorylates more than 50 downstream substrates responsible for cell growth, proliferation, survival, angiogenesis, and differentiation.<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2-4)</a></div><div class="NLM_p">Small molecule inhibitors of BRAF and MEK have shown promising activities in the clinic for a variety of solid tumors. The approval of vemurafenib,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> dabrafenib,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> trametinib,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and cobimetinib<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> as treatments for BRAF-mutant metastatic melanoma validates the approach of targeting the MAPK pathway as an effective way of treating cancer. However, these agents can show limitations in duration of efficacy for some patients due to the acquisition of pathway-reactivating mutations.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Further, outside this indication, the efficacy of these agents has been disappointing, despite apparent MAPK pathway activation and clear therapeutic rationale in BRAF or RAS mutant cancers. Negative feedback loops within the MAPK pathway enable pathway reactivation when targeted with inhibitors of single nodes, driving innate insensitivity of RAS mutant tumors to MEK inhibitors and of some BRAF mutant tumors (e.g., colorectal) to BRAF or MEK inhibitors.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Even when tumors respond to therapy, acquired resistance to receptor tyrosine kinase (RTK) BRAF or MEK inhibitors can limit durable responses, many of which involve bypass or reactivation of the drug target and restoration of persistent MAPK activation resulting in high ERK activity.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">Downstream of MEK, the ERK kinases represent the final single node that would be expected to suppress MAPK signaling. ERK1/2 inhibitors are effector kinases for the MAPK pathway that are responsible for phosphorylating multiple targets to drive gene transcription and protein translation to enable cell growth. Targeting ERK is therefore expected to directly suppress the effector node of the MAPK pathway and potentially address acquired or innately resistant tumors.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> ERK inhibitors could further combine with drugs targeting upstream nodes in the MAPK pathway to drive deeper pathway suppression and reduce the incidence of acquired resistance.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Herein we report the optimization of preclinical potency, selectivity, and pharmacology parameters resulting in the discovery of (<i>S</i>)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1<i>H</i>-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (<b>22</b>), which was advanced to human clinical trials.</div><div class="NLM_p">ERK has been a long-standing target in the pharmaceutical industry, and several highly optimized inhibitors have been reported.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> One of the first examples of potent, selective ERK inhibitors was a pyrrole-based series from Vertex that appeared in 2007.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> A compound that emerged from this work, BVD-523 <b>1</b>, is currently being studied in early clinical development by Biomed Valley Discoveries (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Cyclized variants of <b>1</b>, represented by <b>2</b>, were recently disclosed by researchers at Novartis.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Merck reported in 2013 that the linear indazole <b>3</b> (SCH772984) displayed behaviors typical of both type I and type II kinase inhibitors.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> More recently, covalent ERK2 inhibitors such as <b>4</b> have been disclosed by AstraZeneca.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Highly optimized ERK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We have previously reported the discovery of novel, potent, and selective ERK1/2 inhibitors based on piperidinopyrimidine<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and pyridone<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> scaffolds, as typified by compounds <b>5</b> and <b>6</b>. While compound <b>6</b> in particular possessed a number of desirable attributes, some critical features were identified for further optimization. The human dose projection for <b>6</b> based on PK/PD modeling of the mouse xenograft data and allometric scaling was considered to be unacceptably high (>1 g/day),<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and therefore a strategy to reduce the predicted compound load was developed. Two specific areas for optimization were targeted: improved potency and improved exposure. For the former, recourse to structure-based drug design was available for enhancing potency against ERK1/2. For the latter, we initiated the investigation by considering the metabolic fate of the lead pyridone <b>6</b>.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0014.gif" alt="" id="fx1" /></img></div><div class="NLM_p">Compound <b>6</b> was incubated with human, mouse, dog, rat, and cynomolgus monkey hepatocytes for 3 h and the metabolite profile examined by LC–MS/MS (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). In all species metabolism occurred primarily on the tetrahydropyran (THP) ring, and the major product was determined to be hydroxy acid <b>7</b>. In vivo metabolism studies with <b>6</b> in rat, dog, and monkey confirmed <b>7</b> to be the primary circulating species in plasma as well as urine. Clearly, substitution or outright replacement of the THP moiety would be key to any strategy to enhance the metabolic stability. A number of saturated aliphatic and cyclic THP replacements of <b>6</b> were reported previously,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> but unfortunately none of these resulted in improved metabolic stability. Heteroaromatic replacements were considered to eliminate the methylene soft spots of <b>6</b>. Importantly, the hydrogen bond accepting nature of the THP oxygen atom was a key potency driver for <b>6</b> and would need to be preserved in order to maintain the crucial hydrogen bond interaction with Lys114 of ERK2, thereby considerably limiting the number of suitable candidate motifs.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0015.gif" alt="" id="fx2" /></img></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. UV traces from incubation of <b>6</b> with hepatocytes at <i>t</i> = 3 h (M3 = compound <b>7</b>): h = human, m = mouse, r = rat, d = dog, c = cynomolgus monkey. The most abundant metabolites M1–M6 are labeled. The first peak common to all five traces represents an internal standard.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">THP replacement analogs were prepared by the methods previously described.<a onclick="showRef(event, 'ref20 ref23'); return false;" href="javascript:void(0);" class="ref ref20 ref23">(20, 23)</a> Hence, TBS-protected sulfone <b>8</b> was subjected to S<sub>N</sub>Ar displacement aided by deprotonation of or heating with the appropriate amino heterocycle (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Subsequent deprotection of the silyl protecting group with TBAF or HCl in organic solvent afforded compounds <b>9</b>–<b>28</b> for evaluation. The first THP replacement that was investigated was 2-methylpyridine <b>9</b>. The pyridine nitrogen atom was expected to form a hydrogen bond with the Lys114 side chain. The methyl group was incorporated to thwart potential metabolism at the pyridyl nitrogen atom. Although the mechanistic cell potency of the compound (inhibition of ERK-dependent p90RSK phosphorylation, pRSK) was outstanding, the compound was a potent CYP3A4 inhibitor (IC<sub>50</sub> = 0.34 μM). In addition, compound <b>9</b> showed high clearance and low bioavailability in rat, thereby eliminating it from consideration for further development. Utilization of alternate pyridine substitution patterns or adding or reorganizing heteroatoms in the ring did not afford any useful attenuation of CYP3A4 activity without concomitant loss in activity (data not shown). As a result, we turned our attention toward THP replacement by five-membered ring motifs.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Synthesis of THP replacement analogs <b>9</b>–<b>28</b>. Conditions are the following. (a) For 4-aminopyrazoles: (i) Het-NH<sub>2</sub>, <i>s</i>-BuOH, 120 °C; (ii) TBAF, THF. (b) For 5-aminopyrazoles: (i) NaH, DMF, rt or 150 °C; HCl, EtOAc.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The first replacement of the aminopyridine in <b>9</b> to be studied was 4-aminopyrazole. On the basis of molecular modeling, 4-pyrazoles would present a hydrogen bond acceptor in an ideal orientation to interact with the Lys114 side chain while also providing vectors suitable for substitution to improve selectivity. A number of analogs with subtle alkyl modifications were synthesized and tested (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Compounds were screened for enzyme potency against ERK1 and ERK2, mechanistic potency in HepG2 cells, and metabolic stability in the presence of human microsomes. The simple N-methylated pyrazole <b>10</b> showed enzyme and cell potency similar to <b>6</b>, but adding a second methyl to the adjacent position as in <b>11</b> resulted in a sharp decline in activity. However, if the second methyl was added to the other available carbon as in <b>12</b>, not only was potency restored but an enhancement of selectivity against the cell cycle kinase CDK2 was observed. CDK2 was chosen as the primary antitarget kinase to screen based on its close homology in the binding site to ERK2 (vide infra) and the observation that it was consistently more strongly inhibited than other members of the CDK family in kinase selectivity profiling (not shown). The enhanced selectivity of <b>12</b> against CDK2 may be attributed to the C-3 methyl group which was predicted by docking to point toward the ERK2 Leu107 and insult the larger Phe82 side chain in CDK2. Extension of the <i>C</i>-methyl group of <b>12</b> as in <b>13</b> resulted in loss of potency due to steric clash with the protein, although extension of the <i>N</i>-methyl group (<b>14</b>) was tolerated. Deletion of the <i>C</i>-methyl group of <b>14</b> as in <b>15</b> brought back potency but imparted loss of selectivity, allowing for the conclusion that the <i>C</i>-methyl substituent was a key selectivity driver. Bulking up the N-substitution of <b>15</b> to isopropyl in <b>16</b> resulted in lower potency. In contrast, when the <i>N</i>-substituent of <b>12</b> was removed altogether, a potent and selective compound <b>17</b> was obtained. Having two <i>C</i>-methyl groups on the pyrazole as in <b>18</b> was not tolerated, which was also the case for trifluoromethyl substituted <b>19</b>. Noteworthy was the fact that the pyrazoles did not demonstrate potent inhibition of the various CYP enzymes, unlike pyridine <b>9</b> (data not shown).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Pyridine and 4-Aminopyrazole Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0010.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0011.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Enzyme potency against ERK1 (<i>n</i> > 2 with 95% confidence interval).</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Ratio of CDK2 IC<sub>50</sub> to ERK2 IC<sub>50</sub>.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Inhibition of ERK dependent p90RSK serine 380 phosphorylation in PMA-stimulated HepG2 cells.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Human hepatic clearance predicted from liver microsomes.</p></div></div><div></div></div><div class="NLM_p">Given the similarity in vitro of compound <b>12</b> to the previous lead compound THP <b>6</b>, a PK study was performed in CD-1 mice. Although the clearance was similar for both compounds (extraction ratio ∼30%), pyrazole <b>12</b> showed greater oral bioavailability (95% vs 66% for <b>6</b>), rationalizing further investment in this series to increase potency. Armed with this promising result, a series of substituted 5-aminopyrazoles was investigated (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). The SAR generally tracked with the 4-aminopyrazole series, but the direct comparator to <b>12</b> (compound <b>24</b>) was roughly 2-fold less potent in cells. There was, however, a clear standout from the series in terms of cell potency which was <i>N</i>-methylpyrazole <b>22</b>. It was 10-fold more potent in cells than the next most potent compound (<b>26</b>) in the series. It was also 5-fold more potent in cells than compound <b>12</b>. In addition, it was moderately stable when incubated with human liver microsomes. As a result, we decided to more fully profile compound <b>22</b> as a potential development candidate.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. 5-Aminopyrazole Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0012.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0013.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Enzyme potency against ERK1 (<i>n</i> > 2 with 95% confidence interval).</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Ratio of CDK2 IC<sub>50</sub> to ERK2 IC<sub>50</sub>.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Inhibition of ERK dependent p90RSK serine 380 phosphorylation in PMA-stimulated HepG2 cells.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">Human hepatic clearance predicted from liver microsomes.</p></div></div><div></div></div><div class="NLM_p">To fully characterize the binding interactions, we determined a cocrystal structure of <b>22</b> and ERK2. The overall binding mode is consistent with the predicted docking pose, largely resembling that of <b>6</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K4I">5K4I</a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The 2-aminopyrimidine interacts with the hinge region of ERK2 at Met108 and Leu107 by forming a pair of H-bonds (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A). The pyridone carbonyl makes water mediated H-bonds with gatekeeper Gln105 and catalytic Lys54. The hydroxymethyl group is within H-bond distance from the side chains of Asp167 and Asn154. The fluorochlorophenyl terminal group binds to a hydrophobic pocket under the glycine-rich loop that involves the side chain of Tyr36. The 5-amimopyrazole accepts an H-bond from Lys114, providing the same interaction as the THP oxygen. Comparison with a crystal structure of CDK2 in complex with <b>22</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K4J">5K4J</a>) helped to illustrate the origin of selectivity within the pyrazole series (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> This improved selectivity against CDK2 may be attributed to the <i>N</i>-methyl group which was predicted to point toward the Phe82 residue in CDK2, which is the counterpart of a less sterically demanding Leu107 in ERK2. The <i>N</i>-methyl group on the pyrazole insults the Phe82 side chain but is better tolerated by ERK2.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Additionally, the ERK2 gatekeeper residue Gln105 (which is very rare among kinases) is replaced by Phe80 in CDK2 rendering CDK2 devoid of the polar interactions near the gatekeeper. The structure of <b>22</b> also shifts toward the bulk solvent region in CDK2 structure relative to its position in ERK2, thereby compromising the interactions around the hydroxymethyl linker and the fluorochlorophenyl terminal group. This positional shift of <b>22</b> also affects its interaction with Lys89 of CDK2, the equivalent residue to Lys114 in ERK2. The side chain of Lys89 adopts a rotamer that avoids clashing into the ligand but loses the hydrogen bond with the 5-aminopyrazole. We reason that these multiple critical distinctions in <b>22</b> interactions with ERK2 versus CDK2 collectively contribute to the overall selectivity.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structures of <b>22</b> bound to ERK2 (brown) and CDK2 (purple): (A) compound <b>22</b> bound to ERK2; (B) superposition of ERK2 and CDK2 cocrystal structures with compound <b>22</b>. Red dotted lines indicate hydrogen bonds. Red spheres indicate water molecules.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, the broad kinase selectivity of <b>22</b> was evaluated at 1 μM against the Invitrogen Selectscreen panel containing 279 kinases (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). The top hits were subjected to follow-up IC<sub>50</sub> generation. For all seven kinases identified as potential selectivity flags, at least 50-fold selectivity was observed relative to ERK1 IC<sub>50</sub> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Activity of <b>22</b> against 279 kinases at 1 μM. Illustration reproduced courtesy of Cell Signaling Technology (<a href="http://www.cellsignal.com" class="extLink">www.cellsignal.com</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Kinase Selectivity of Compound <b>22</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">fold selectivity vs ERK1</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PrKX</td><td class="colsep0 rowsep0" align="char" char=".">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GSK3α</td><td class="colsep0 rowsep0" align="char" char=".">121</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CHK2</td><td class="colsep0 rowsep0" align="char" char=".">118</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HIPK4</td><td class="colsep0 rowsep0" align="char" char=".">150</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P38δ</td><td class="colsep0 rowsep0" align="char" char=".">158</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cdk2/CyA</td><td class="colsep0 rowsep0" align="char" char=".">167</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aurora A</td><td class="colsep0 rowsep0" align="char" char=".">217</td></tr></tbody></table></div></div><div class="NLM_p">Having identified compound <b>22</b> as having the best mix of potency and selectivity, we set out to evaluate its DMPK properties. Compound <b>22</b> demonstrated kinetic solubility and permeability in MDCK cells similar to previous lead compound <b>6</b> (29.7 μg/mL, AB = 3.9 × 10<sup>–6</sup> cm/s). Taking into account that the free fraction in mouse plasma was determined to be 5.8%, the target coverage for efficacy in a mouse xenograft study (pRSK IC<sub>50</sub>/<i>f</i><sub>u</sub>) was calculated to be ∼200 nM total concentration in plasma. In CD-1 mice, a 10 mg/kg oral dose of <b>22</b> was sufficient to achieve the desired target coverage for at least 8 h (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> For comparison, a plasma concentration of ∼2 μM for THP <b>6</b> would be required for 8 h to achieve the same target coverage, which was only achievable using a 60 mg/kg po dose.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound exposure vs time in a multidose mouse PK study with compound <b>22</b>, formulated in 40% PEG400/60% (10% HPβCD) water.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, iv/oral crossover PK was surveyed in rat, dog, and cynomolgus monkey (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Interestingly, the in vivo clearance measured across species was well predicted by in vitro incubation with hepatocytes, whereas liver microsomes tended to overpredict the clearance for compound <b>22</b>. Higher clearance was observed exclusively in cynomolgus monkey (extraction ratio of ∼80%). Cross-species metabolite identification in hepatocytes showed very little metabolism except in cynomolgus monkey, where the major product was shown to be glucuronidation (93% vs 5% in human). With the exception of cynomolgus monkey, the in vivo clearance values were significantly lower than those observed for compound <b>6</b>. Given the high predictive value of in vitro clearance hepatocytes for compound <b>22</b>, clearance in human was projected to be low (<5 mL min<sup>–1</sup> kg<sup>–1</sup>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pharmacokinetic Parameters of Compound <b>22</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" align="center">dog</th><th class="colsep0 rowsep0" align="center">cyno</th><th class="colsep0 rowsep0" align="center">human</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vitro predicted CL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver microsomes (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">7.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hepatocytes (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">5.4</td><td class="colsep0 rowsep0" align="left">35</td><td class="colsep0 rowsep0" align="left">4.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PPB (<i>f</i><sub>u</sub>)</td><td class="colsep0 rowsep0" align="left">0.044</td><td class="colsep0 rowsep0" align="left">0.058</td><td class="colsep0 rowsep0" align="left">0.098</td><td class="colsep0 rowsep0" align="left">0.056</td><td class="colsep0 rowsep0" align="left">0.080</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vivo PK</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL<sub>p</sub> (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">6.4</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">t<sub>1/2,iv</sub> (h)</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">6.8</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">35</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">112</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC/<i>D</i><sub>po</sub> (kg·h/L)</td><td class="colsep0 rowsep0" align="left">0.41</td><td class="colsep0 rowsep0" align="left">0.54</td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left">0.09</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div></div><div class="NLM_p">As a result of the promising PK data, <b>22</b> was progressed into in vivo PK/PD and efficacy studies. The HCT116 human colorectal cancer xenograft model was selected as representative of KRAS mutant cancer, which is both a “higher bar” and more representative of the likely clinical indication than BRAF mutant melanoma. A PK/PD study (15, 30, and 100 mg/kg, q.d.) was carried out in nude mice bearing subcutaneous HCT116 tumors. Significant inhibition of pRSK was observed at the 30 and 100 mg/kg doses, with the corresponding pRSK knockdown at the 2 h time point observed to be 65% and 87% (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). As was observed previously for compound <b>6</b>,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> there was an apparent rebound to above baseline levels in phosphorylation of p90RSK at 16 and 24 h for <b>22</b> (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). Pathway reactivation and rebound transiently above basal levels correlate with decreased drug exposure and are consistent with rebound effects observed with other MAPK inhibitors. Next, compound <b>22</b> was evaluated in a proof-of-concept tumor growth inhibition (TGI) study. The compound was administered once daily (q.d.) orally for 21 days in nude mice bearing HCT116 human colorectal cancer subcutaneously implanted xenograft tumors (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>). At doses greater than 30 mg/kg, there was significant tumor growth inhibition with 30, 60, and 100 mg/kg resulting in 49%, 57%, and 80% tumor growth inhibition (TGI), respectively. In comparison, efficacy with the MEK inhibitor, cobimetinib (GDC-0973), at a clinically relevant dose of 7.5 mg/kg (po, q.d.) resulted in 58% TGI. There was no observed body weight loss with treatment by <b>22</b> in this study.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. HCT116 study PK/PD analysis with compound <b>22</b>: PK/PD data for <b>22</b> in the HCT116 mouse xenograft model. HCT116 tumors were established in nude mice to a tumor volume of 400–600 mm<sup>3</sup>. Mice were were treated with a single oral dose of <b>22</b> at 15, 30, or 100 mg/kg versus vehicle control alone (40% PEG400/60% (10% HPβCD)) followed by tumor and plasma collection at 2, 8, 16, and 24 h postdose. Tumor levels of phosphorylated p90RSK (pRSK) relative total p90RSK (tRSK) were measured by quantitative Western blot and were normalized to vehicle control at 2 h postdose (set to 100%). Plasma and tumor concentrations were measured by LC–MS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. HCT116 mouse xenograft data with compound <b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Preclinical safety findings for compound <b>22</b> were consistent with those of other MEK and ERK inhibitors, namely, phosphorus dysregulation with soft tissue mineralization, decreased albumin levels, and skin toxicity in rats and gastrointestinal toxicity in dogs.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> On the basis of the favorable efficacy and tolerability profile reported herein, compound <b>22</b> (GDC-0994) was advanced into human clinical trials.</div><div class="NLM_p">A first-in-human, phase 1 dose escalation study was conducted in patients with locally advanced or metastatic solid tumors. Compound <b>22</b> (mesylate) was administered orally once daily as powder in capsule on a 21-day on/7-day off schedule. The plasma concentration vs time PK profiles of 50, 100, and 200 mg (three patients each) at steady state are shown in <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>. In general, exposures increased with dose from 50 to 200 mg.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Mean <b>22</b> (±SD) human PK concentrations at steady state by dose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In summary, targeting the RAS-RAF-MEK-ERK pathway has given rise to a number of FDA-approved medicines to treat various cancers. Inhibition of ERK1/2 has not been as well explored as inhibition of RAFs and MEK. Nonetheless, targeting the ERK node in the MAPK pathway is rationalized by ERKs acting as the effector kinases for the MAPK pathway and ERK phosphorylation being a central feature in therapeutic resistance. The addition of potent and selective ERK inhibitors further enables the rational targeting of multiple nodes in the MAPK pathway in order to achieve maximal efficacy. Previously, we reported compound <b>6</b> to have many desirable traits as an ERK inhibitor, but the projected human dose based on preclinical PK and efficacy studies was unacceptably high. Hence, a campaign to lower the predicted dose using a combination of improved potency and/or PK was launched. Replacement of the metabolically labile THP ring of <b>6</b> with an <i>N</i>-methylpyrazole as in compound <b>22</b> led to a compound requiring approximately 10-fold lower total concentration and projected human dose relative to <b>6</b> to achieve target coverage. On the basis of preclinical PK/PD and efficacy experiments, coupled with a relatively safe profile in tolerability studies, compound <b>22</b> was advanced into human clinical trials. Human PK data with <b>22</b> support the predicted low clearance and feasibility of attaining target coverage at achievable doses.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68786" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68786" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> General Methods</h3><div class="NLM_p last">Melting points were determined with a DSC Q100 instrument, and HRMS was conducted with a Dionex LC Ultimate3000 and ThermoScientific Q Exactive orbitrap mass spectrometer. Samples were prepared in a mixture of MeOH/acetonitrile/water (4:4:1 v/v/v) with 200 μM concentration for high resolution LCMS analysis. Samples of 5 μL were injected into the LCMS system and were analyzed by 10 min gradient HPLC and HRMS with electrospray ionization. Bruker instruments (400 and 500 MHz) were used for NMR characterization. Compounds in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> were prepared by the method previously described for <b>6</b>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> All final compounds were purified to >95% chemical purity, as assayed by HPLC (Waters Acquity UPLC column, 21 mm × 50 mm, 1.7 μm) with a gradient of 0–90% acetonitrile (containing 0.038% TFA) in 0.1% aqueous TFA, with UV detection at λ = 254 and 210 nm and with CAD detection with an ESA Corona detector. Protein expression, purification, and crystallization of CDK2 and ERK2 were performed by the methods previously described.<a onclick="showRef(event, 'ref21 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref23">(21, 23)</a></div></div><div id="secz" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> General Procedure for Preparation of Compounds in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a></h3><div class="NLM_p last">To a solution of compound <b>8</b> (1 equiv) and the pyrazole (2 equiv) in DMF (0.03 M) was added sodium hydride (2.5 equiv, 60% dispersion in mineral oil). The mixture was stirred at room temperature or heated in a sealed tube until the addition was complete. The mixture was partitioned between EtOAc and water, the phases were separated, the aqueous phase was extracted with EtOAc, the combined organic phases were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. To the residue in EtOAc (0.02 M) was added a saturated solution of HCl in EtOAc. The mixture was stirred until complete (∼15 min), concentrated, and purified by HPLC.</div></div><div id="sec2_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-(2-methylpyridin-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one, <b>9</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.16 (s, 1H), 8.72 (d, <i>J</i> = 5.1 Hz, 1H), 8.26 (d, <i>J</i> = 5.6 Hz, 1H), 7.98 (d, <i>J</i> = 7.3 Hz, 1H), 7.61 (ddd, <i>J</i> = 16.2, 9.5, 4.4 Hz, 4H), 7.45 (dd, <i>J</i> = 10.6, 1.7 Hz, 1H), 7.20 (dd, <i>J</i> = 20.6, 5.1 Hz, 2H), 6.97 (dd, <i>J</i> = 7.3, 2.0 Hz, 1H), 5.99 (dd, <i>J</i> = 7.8, 5.6 Hz, 1H), 5.34 (s, 1H), 4.19 (dd, <i>J</i> = 11.7, 8.1 Hz, 1H), 4.05 (d, <i>J</i> = 5.6 Hz, 1H), 2.42 (s, 3H). <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 452.2.</div></div><div id="sec2_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-(1-methyl-1<i>H</i>-pyrazol-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one, <b>10</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.61 (s, 1H), 8.55 (d, <i>J</i> = 5.0 Hz, 1H), 7.93 (d, <i>J</i> = 7.3 Hz, 1H), 7.87 (s, 1H), 7.64–7.52 (m, 2H), 7.45 (dd, <i>J</i> = 10.6, 1.9 Hz, 1H), 7.31 (d, <i>J</i> = 5.1 Hz, 1H), 7.21–7.14 (m, 2H), 6.93 (dd, <i>J</i> = 7.3, 1.8 Hz, 1H), 5.99 (dd, <i>J</i> = 7.7, 5.5 Hz, 1H), 5.34 (t, <i>J</i> = 5.3 Hz, 1H), 4.23–4.13 (m, 1H), 4.10–4.01 (m, 1H), 3.82 (s, 3H). <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 441.1.</div></div><div id="sec2_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-(1,5-dimethyl-1<i>H</i>-pyrazol-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one, <b>11</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.87 (s, 1H), 8.47 (d, <i>J</i> = 4.9 Hz, 1H), 7.90 (d, <i>J</i> = 7.3 Hz, 1H), 7.57 (dd, <i>J</i> = 17.1, 9.0 Hz, 2H), 7.49–7.38 (m, 1H), 7.27 (d, <i>J</i> = 5.1 Hz, 1H), 7.19–7.05 (m, 2H), 6.84 (t, <i>J</i> = 15.6 Hz, 1H), 5.97 (dd, <i>J</i> = 7.8, 5.6 Hz, 1H), 5.32 (t, <i>J</i> = 5.3 Hz, 1H), 4.15 (ddd, <i>J</i> = 13.4, 7.9, 5.7 Hz, 1H), 4.03 (dt, <i>J</i> = 21.4, 7.5 Hz, 1H), 3.71 (d, <i>J</i> = 9.7 Hz, 3H), 2.17 (d, <i>J</i> = 8.2 Hz, 3H). <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 455.1.</div></div><div id="sec2_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-(1,3-dimethyl-1<i>H</i>-pyrazol-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one, <b>12</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.90 (s, 1H), 8.50 (d, <i>J</i> = 5.1 Hz, 1H), 7.91 (d, <i>J</i> = 7.3 Hz, 1H), 7.80 (s, 1H), 7.64–7.53 (m, 1H), 7.43 (dt, <i>J</i> = 19.1, 9.5 Hz, 1H), 7.28 (dd, <i>J</i> = 9.7, 5.1 Hz, 1H), 7.21–7.07 (m, 2H), 6.89 (d, <i>J</i> = 5.9 Hz, 1H), 6.04–5.92 (m, 1H), 5.34 (t, <i>J</i> = 5.2 Hz, 1H), 4.24–4.10 (m, 1H), 4.10–3.97 (m, 1H), 3.80–3.70 (m, 3H), 2.11 (s, 3H). <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 455.1.</div></div><div id="sec2_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-(3-ethyl-1-methyl-1<i>H</i>-pyrazol-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one, <b>13</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.85 (s, 1H), 8.48 (t, <i>J</i> = 8.0 Hz, 1H), 7.91 (d, <i>J</i> = 7.3 Hz, 1H), 7.79 (s, 1H), 7.58 (t, <i>J</i> = 8.1 Hz, 1H), 7.49–7.38 (m, 1H), 7.27 (t, <i>J</i> = 5.6 Hz, 1H), 7.21–7.05 (m, 2H), 6.88 (d, <i>J</i> = 6.6 Hz, 1H), 5.98 (dd, <i>J</i> = 7.8, 5.5 Hz, 1H), 5.33 (t, <i>J</i> = 5.2 Hz, 1H), 4.16 (ddd, <i>J</i> = 13.4, 7.9, 5.6 Hz, 1H), 4.11–3.96 (m, 1H), 3.75 (d, <i>J</i> = 3.9 Hz, 3H), 2.54 (dd, <i>J</i> = 15.1, 7.5 Hz, 2H), 1.11 (dd, <i>J</i> = 8.8, 6.3 Hz, 3H). <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 469.1.</div></div><div id="sec2_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-(1-ethyl-3-methyl-1<i>H</i>-pyrazol-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one, <b>14</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.89 (s, 1H), 8.50 (d, <i>J</i> = 5.1 Hz, 1H), 7.91 (t, <i>J</i> = 5.3 Hz, 1H), 7.84 (s, 1H), 7.58 (t, <i>J</i> = 8.1 Hz, 1H), 7.43 (dd, <i>J</i> = 10.6, 1.9 Hz, 1H), 7.28 (d, <i>J</i> = 5.1 Hz, 1H), 7.15 (dd, <i>J</i> = 9.6, 7.9 Hz, 2H), 6.88 (d, <i>J</i> = 6.6 Hz, 1H), 5.97 (dd, <i>J</i> = 7.8, 5.4 Hz, 1H), 5.32 (t, <i>J</i> = 5.1 Hz, 1H), 4.21–4.12 (m, 1H), 4.06–3.99 (m, 3H), 2.12 (s, 3H), 1.35 (t, <i>J</i> = 7.2 Hz, 3H). <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 469.1.</div></div><div id="sec2_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-(1-ethyl-1<i>H</i>-pyrazol-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one, <b>15</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.59 (s, 1H), 8.62–8.51 (m, 1H), 7.97–7.88 (m, 2H), 7.59 (t, <i>J</i> = 8.1 Hz, 2H), 7.45 (dd, <i>J</i> = 10.5, 1.6 Hz, 1H), 7.30 (d, <i>J</i> = 5.1 Hz, 1H), 7.16 (t, <i>J</i> = 5.0 Hz, 2H), 6.93 (dd, <i>J</i> = 7.2, 1.6 Hz, 1H), 6.02–5.96 (m, 1H), 5.33 (s, 1H), 4.23–4.02 (m, 4H), 1.36 (t, <i>J</i> = 7.3 Hz, 3H). <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 455.1.</div></div><div id="sec2_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-(1-isopropyl-1<i>H</i>-pyrazol-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one, <b>16</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.58 (s, 1H), 8.55 (d, <i>J</i> = 5.0 Hz, 1H), 7.96–7.89 (m, 2H), 7.59 (t, <i>J</i> = 8.1 Hz, 2H), 7.45 (dd, <i>J</i> = 10.6, 1.7 Hz, 1H), 7.30 (d, <i>J</i> = 5.1 Hz, 1H), 7.22–7.13 (m, 2H), 6.92 (dd, <i>J</i> = 7.3, 1.8 Hz, 1H), 6.04–5.94 (m, 1H), 5.33 (t, <i>J</i> = 5.2 Hz, 1H), 4.46 (dt, <i>J</i> = 13.3, 6.6 Hz, 1H), 4.21–4.13 (m, 1H), 4.10–4.02 (m, 1H), 1.41 (d, <i>J</i> = 6.7 Hz, 6H). <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 469.1.</div></div><div id="sec2_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-(3-methyl-1<i>H</i>-pyrazol-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one, <b>17</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.28 (d, <i>J</i> = 50.5 Hz, 1H), 8.87 (s, 1H), 8.49 (s, 1H), 7.91 (d, <i>J</i> = 7.3 Hz, 1H), 7.65 (dd, <i>J</i> = 64.2, 56.0 Hz, 2H), 7.43 (dd, <i>J</i> = 10.6, 2.0 Hz, 1H), 7.27 (d, <i>J</i> = 5.1 Hz, 1H), 7.21–7.06 (m, 2H), 6.87 (d, <i>J</i> = 6.6 Hz, 1H), 5.98 (dd, <i>J</i> = 7.7, 5.5 Hz, 1H), 5.32 (t, <i>J</i> = 5.3 Hz, 1H), 4.23–4.11 (m, 1H), 4.11–4.00 (m, 1H), 2.16 (s, 3H). <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 444.1.</div></div><div id="sec2_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-(3,5-dimethyl-1<i>H</i>-pyrazol-4-ylamino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one, <b>18</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.04 (s, 1H), 8.48 (d, <i>J</i> = 34.0 Hz, 2H), 7.88 (d, <i>J</i> = 6.9 Hz, 1H), 7.57 (t, <i>J</i> = 8.1 Hz, 1H), 7.42 (dd, <i>J</i> = 10.5, 1.9 Hz, 1H), 7.24 (d, <i>J</i> = 5.1 Hz, 1H), 7.14 (d, <i>J</i> = 8.3 Hz, 1H), 7.04 (s, 1H), 6.79 (s, 1H), 6.01–5.91 (m, 1H), 5.31 (t, <i>J</i> = 5.2 Hz, 1H), 4.14 (s, 1H), 4.08–3.99 (m, 1H), 2.13–1.93 (m, 6H). <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 455.1.</div></div><div id="sec2_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-3-(trifluoromethyl)-1<i>H</i>-pyrazol-4-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one, <b>19</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.90 (s, 1H), 8.52 (d, <i>J</i> = 5.0 Hz, 1H), 8.07 (d, <i>J</i> = 10.3 Hz, 1H), 7.89 (d, <i>J</i> = 7.3 Hz, 1H), 7.57 (t, <i>J</i> = 8.1 Hz, 1H), 7.42 (ddd, <i>J</i> = 23.6, 22.8, 8.8 Hz, 2H), 7.23–7.03 (m, 2H), 6.84 (t, <i>J</i> = 5.7 Hz, 1H), 5.98 (dd, <i>J</i> = 12.8, 7.3 Hz, 1H), 5.31 (s, 1H), 4.14 (d, <i>J</i> = 8.3 Hz, 1H), 4.05 (s, 1H), 3.97–3.85 (m, 3H). <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 509.1.</div></div><div id="sec2_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> (<i>S</i>)-4-(2-((1<i>H</i>-Pyrazol-5-yl)amino)pyrimidin-4-yl)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)pyridin-2(1<i>H</i>)-one, <b>20</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.95 (d, <i>J</i> = 5.2 Hz, 1H), 8.06–7.91 (m, 2H), 7.59 (t, <i>J</i> = 8.1 Hz, 1H), 7.44 (dd, <i>J</i> = 9.2, 6.1 Hz, 2H), 7.25 (d, <i>J</i> = 1.9 Hz, 1H), 7.18 (d, <i>J</i> = 8.4 Hz, 1H), 6.97 (dd, <i>J</i> = 7.3, 1.9 Hz, 1H), 6.72 (s, 2H), 6.04–5.94 (m, 1H), 5.46 (d, <i>J</i> = 1.6 Hz, 1H), 5.34 (t, <i>J</i> = 5.2 Hz, 1H), 4.24–4.12 (m, 1H), 4.11–4.00 (m, 1H). <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 427.1.</div></div><div id="sec2_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1<i>H</i>-pyrazol-3-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one, <b>21</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.90 (s, 1H), 8.56 (d, <i>J</i> = 5.1 Hz, 1H), 7.92 (t, <i>J</i> = 9.9 Hz, 1H), 7.63–7.54 (m, 2H), 7.45 (dd, <i>J</i> = 10.6, 2.0 Hz, 1H), 7.37 (d, <i>J</i> = 5.1 Hz, 1H), 7.17 (dt, <i>J</i> = 4.9, 2.4 Hz, 2H), 6.92 (dd, <i>J</i> = 7.3, 2.0 Hz, 1H), 6.62 (d, <i>J</i> = 2.2 Hz, 1H), 5.99 (dd, <i>J</i> = 7.9, 5.5 Hz, 1H), 5.36–5.29 (m, 1H), 4.23–4.12 (m, 1H), 4.10–4.01 (m, 1H), 3.76 (s, 3H). <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 444.1.</div></div><div id="sec2_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1<i>H</i>-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one, <b>22</b></h3><div class="NLM_p last">mp = 304.4 °C, [α]<sub>D</sub><sup>23</sup> +113.8 (<i>c</i> 0.29, MeOH); IR 1660, 1582, 1557 cm<sup>–1</sup>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.69–9.52 (s, 1H), 8.69–8.49 (d, <i>J</i> = 5.1 Hz, 1H), 8.09–7.77 (d, <i>J</i> = 7.3 Hz, 1H), 7.61–7.56 (t, <i>J</i> = 8.1 Hz, 1H), 7.50–7.47 (d, <i>J</i> = 5.1 Hz, 1H), 7.46–7.42 (dd, <i>J</i> = 10.6, 2.0 Hz, 1H), 7.38–7.36 (d, <i>J</i> = 1.9 Hz, 1H), 7.22–7.08 (m, 2H), 6.98–6.79 (dd, <i>J</i> = 7.3, 2.1 Hz, 1H), 6.35–6.23 (d, <i>J</i> = 1.9 Hz, 1H), 6.06–5.90 (dd, <i>J</i> = 8.1, 5.4 Hz, 1H), 5.40–5.23 (d, <i>J</i> = 5.2 Hz, 1H), 4.24–3.97 (m, 2H), 3.80–3.56 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.18, 161.53, 160.88, 160.55, 157.59 (d, <i>J</i><sub>CF</sub> = 246.83 Hz), 147.19, 140.09 (d, <i>J</i><sub>CF</sub> = 6.47 Hz), 138.30, 137.75, 137.42, 131.20, 125.53 (d, <i>J</i><sub>CF</sub> = 3.45 Hz), 119.29 (d, <i>J</i><sub>CF</sub> = 17.45 Hz), 117.74, 116.61 (d, <i>J</i><sub>CF</sub> = 21.68 Hz), 109.68, 103.34, 99.36, 61.24, 59.20, 35.93. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>18</sub>ClFN<sub>6</sub>O<sub>2</sub>, 441.1242; found, 441.1230.</div></div><div id="sec2_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-ethyl-1<i>H</i>-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one, <b>23</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.64–8.52 (d, <i>J</i> = 5.1 Hz, 1H), 7.98–7.87 (d, <i>J</i> = 7.4 Hz, 1H), 7.66–7.52 (t, <i>J</i> = 8.1 Hz, 1H), 7.47–7.45 (d, <i>J</i> = 5.1 Hz, 1H), 7.45–7.41 (dd, <i>J</i> = 10.5, 2.0 Hz, 1H), 7.40–7.38 (d, <i>J</i> = 1.9 Hz, 1H), 7.21–7.05 (m, 2H), 6.92–6.77 (dd, <i>J</i> = 7.3, 2.0 Hz, 1H), 6.33–6.18 (d, <i>J</i> = 1.8 Hz, 1H), 6.03–5.90 (dd, <i>J</i> = 8.0, 5.5 Hz, 1H), 4.24–4.07 (dd, <i>J</i> = 11.8, 8.2 Hz, 1H), 4.11–3.93 (q, <i>J</i> = 7.0 Hz, 3H), 1.41–1.13 (t, <i>J</i> = 7.2 Hz, 3H). <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 455.1.</div></div><div id="sec2_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1,3-dimethyl-1<i>H</i>-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one, <b>24</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.54 (s, 1H), 8.59 (d, <i>J</i> = 5.1 Hz, 1H), 7.92 (t, <i>J</i> = 9.6 Hz, 1H), 7.58 (t, <i>J</i> = 8.1 Hz, 1H), 7.45 (dd, <i>J</i> = 11.5, 7.9 Hz, 2H), 7.20–7.08 (m, 2H), 6.87 (d, <i>J</i> = 7.3 Hz, 1H), 6.04 (s, 1H), 6.02–5.92 (m, 1H), 5.34 (t, <i>J</i> = 5.2 Hz, 1H), 4.24–4.10 (m, 1H), 4.10–4.00 (m, 1H), 3.59 (s, 3H), 2.12 (s, 3H). <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 455.1.</div></div><div id="sec2_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-ethyl-3-methyl-1<i>H</i>-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one, <b>25</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.44 (s, 1H), 8.57 (d, <i>J</i> = 5.1 Hz, 1H), 7.92 (d, <i>J</i> = 7.3 Hz, 1H), 7.58 (t, <i>J</i> = 8.1 Hz, 1H), 7.49–7.37 (m, 2H), 7.14 (dd, <i>J</i> = 13.4, 4.8 Hz, 2H), 6.86 (d, <i>J</i> = 7.2 Hz, 1H), 6.03 (s, 1H), 6.00–5.90 (m, 1H), 5.31 (t, <i>J</i> = 5.2 Hz, 1H), 4.22–4.09 (m, 1H), 4.08–3.99 (m, 1H), 3.94 (q, <i>J</i> = 7.2 Hz, 2H), 2.14 (s, 3H), 1.25 (t, <i>J</i> = 7.2 Hz, 3H). <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 469.1.</div></div><div id="sec2_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((3-ethyl-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one, <b>26</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.48 (s, 1H), 8.58 (d, <i>J</i> = 5.1 Hz, 1H), 7.92 (d, <i>J</i> = 7.3 Hz, 1H), 7.57 (t, <i>J</i> = 8.1 Hz, 1H), 7.49–7.37 (m, 2H), 7.15 (dd, <i>J</i> = 8.6, 6.0 Hz, 2H), 6.86 (dd, <i>J</i> = 7.3, 1.9 Hz, 1H), 6.07 (s, 1H), 5.97 (dd, <i>J</i> = 7.8, 5.6 Hz, 1H), 5.30 (s, 1H), 4.16 (s, 1H), 4.04 (d, <i>J</i> = 11.9 Hz, 1H), 3.60 (s, 3H), 2.52 (d, <i>J</i> = 6.1 Hz, 1H), 2.47 (s, 1H), 1.16 (t, <i>J</i> = 7.6 Hz, 3H). <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 469.1.</div></div><div id="sec2_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1,4-dimethyl-1<i>H</i>-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one, <b>27</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.21 (s, 1H), 8.54 (d, <i>J</i> = 5.1 Hz, 1H), 7.90 (d, <i>J</i> = 7.3 Hz, 1H), 7.57 (t, <i>J</i> = 8.1 Hz, 1H), 7.41 (dd, <i>J</i> = 7.8, 3.4 Hz, 2H), 7.25 (s, 1H), 7.14 (d, <i>J</i> = 8.4 Hz, 1H), 7.07 (s, 1H), 6.79 (s, 1H), 6.02–5.88 (m, 1H), 5.30 (t, <i>J</i> = 5.1 Hz, 1H), 4.14 (dd, <i>J</i> = 15.2, 9.9 Hz, 1H), 4.08–3.96 (m, 1H), 3.58 (s, 3H), 1.83 (s, 3H). <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 455.1.</div></div><div id="sec2_1_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-3-(trifluoromethyl)-1<i>H</i>-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one, <b>28</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.90 (s, 1H), 8.65 (d, <i>J</i> = 5.1 Hz, 1H), 7.94 (d, <i>J</i> = 7.3 Hz, 1H), 7.57 (dd, <i>J</i> = 15.4, 6.7 Hz, 2H), 7.43 (dd, <i>J</i> = 10.6, 1.9 Hz, 1H), 7.16 (dd, <i>J</i> = 9.7, 1.6 Hz, 2H), 6.86 (dd, <i>J</i> = 7.3, 1.9 Hz, 1H), 6.74 (s, 1H), 5.97 (dd, <i>J</i> = 7.8, 5.6 Hz, 1H), 5.30 (t, <i>J</i> = 5.2 Hz, 1H), 4.17 (ddd, <i>J</i> = 13.4, 8.0, 5.7 Hz, 1H), 4.09–3.97 (m, 1H), 3.80 (s, 3H). <i>m</i>/<i>z</i> (APCI-pos) M + 1 = 509.1.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00389">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72657" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72657" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00389" class="ext-link">10.1021/acs.jmedchem.6b00389</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental procedures for the crystal structure determination of ERK2 and CDK2 complexes with <b>22</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00389/suppl_file/jm6b00389_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00389/suppl_file/jm6b00389_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00389/suppl_file/jm6b00389_si_001.pdf">jm6b00389_si_001.pdf (116.36 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00389/suppl_file/jm6b00389_si_002.csv">jm6b00389_si_002.csv (1.73 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00389" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37340" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37340" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacob B. Schwarz</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#aad9c9c2ddcbd8d084c0cbc9c5c8eacdcfc4cf84c9c5c7"><span class="__cf_email__" data-cfemail="7d0e1e150a1c0f0753171c1e121f3d1a181318531e1210">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James F. Blake</span> - <span class="hlFld-Affiliation affiliation">Array
BioPharma Inc., 3200
Walnut Street, Boulder, Colorado 80301, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Burkard</span> - <span class="hlFld-Affiliation affiliation">Array
BioPharma Inc., 3200
Walnut Street, Boulder, Colorado 80301, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jocelyn Chan</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huifen Chen</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kang-Jye Chou</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dolores Diaz</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Danette A. Dudley</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John J. Gaudino</span> - <span class="hlFld-Affiliation affiliation">Array
BioPharma Inc., 3200
Walnut Street, Boulder, Colorado 80301, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen E. Gould</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonas Grina</span> - <span class="hlFld-Affiliation affiliation">Array
BioPharma Inc., 3200
Walnut Street, Boulder, Colorado 80301, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas Hunsaker</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lichuan Liu</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew Martinson</span> - <span class="hlFld-Affiliation affiliation">Array
BioPharma Inc., 3200
Walnut Street, Boulder, Colorado 80301, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Moreno</span> - <span class="hlFld-Affiliation affiliation">Array
BioPharma Inc., 3200
Walnut Street, Boulder, Colorado 80301, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lars Mueller</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christine Orr</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patricia Pacheco</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ann Qin</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Rasor</span> - <span class="hlFld-Affiliation affiliation">Array
BioPharma Inc., 3200
Walnut Street, Boulder, Colorado 80301, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Ren</span> - <span class="hlFld-Affiliation affiliation">Array
BioPharma Inc., 3200
Walnut Street, Boulder, Colorado 80301, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kirk Robarge</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sheerin Shahidi-Latham</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey Stults</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francis Sullivan</span> - <span class="hlFld-Affiliation affiliation">Array
BioPharma Inc., 3200
Walnut Street, Boulder, Colorado 80301, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weiru Wang</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianping Yin</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aihe Zhou</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marcia Belvin</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Merchant</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Moffat</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i30" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i30"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i31" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i31"> Abbreviations Used</h2><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">LC–MS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">TBAF</td><td class="NLM_def"><p class="first last">tetrabutylammonium fluoride</p></td></tr><tr><td class="NLM_term">RSK</td><td class="NLM_def"><p class="first last">ribosomal s6 kinase</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamics</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madin–Darby canine kidney</p></td></tr><tr><td class="NLM_term">po</td><td class="NLM_def"><p class="first last">per os (by mouth)</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">HCT</td><td class="NLM_def"><p class="first last">human colorectal carcinoma</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68006" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68006" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 27 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3291</span><span class="NLM_x">–</span> <span class="NLM_lpage">3310</span><span class="refDoi"> DOI: 10.1038/sj.onc.1210422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1038%2Fsj.onc.1210422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=17496923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3291-3310&author=P.+J.+Robertsauthor=C.+J.+Der&title=Targeting+the+Raf-MEK-ERK+mitogen-activated+protein+kinase+cascade+for+the+treatment+of+cancer&doi=10.1038%2Fsj.onc.1210422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span></div><div class="casAuthors">Roberts, P. J.; Der, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3291-3310</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in the regulation of normal cell proliferation, survival and differentiation.  Aberrant regulation of MAPK cascades contribute to cancer and other human diseases.  In particular, the extracellular signal-regulated kinase (ERK) MAPK pathway has been the subject of intense research scrutiny leading to the development of pharmacol. inhibitors for the treatment of cancer.  ERK is a downstream component of an evolutionarily conserved signaling module that is activated by the Raf serine/threonine kinases.  Raf activates the MAPK/ERK kinase (MEK)1/2 dual-specificity protein kinases, which then activate ERK1/2.  The mutational activation of Raf in human cancers supports the important role of this pathway in human oncogenesis.  Addnl., the Raf-MEK-ERK pathway is a key downstream effector of the Ras small GTPase, the most frequently mutated oncogene in human cancers.  Finally, Ras is a key downstream effector of the epidermal growth factor receptor (EGFR), which is mutationally activated and/or overexpressed in a wide variety of human cancers.  ERK activation also promotes upregulated expression of EGFR ligands, promoting an autocrine growth loop crit. for tumor growth.  Thus, the EGFR-Ras-Raf-MEK-ERK signaling network has been the subject of intense research and pharmaceutical scrutiny to identify novel target-based approaches for cancer treatment.  In this review, we summarize the current status of the different approaches and targets that are under evaluation and development for the therapeutic intervention of this key signaling pathway in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7hdVDVyRBHrVg90H21EOLACvtfcHk0lhB4qEwBhzzyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D&md5=bf56109e3b4defc12004471da30178c0</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210422%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DTargeting%2520the%2520Raf-MEK-ERK%2520mitogen-activated%2520protein%2520kinase%2520cascade%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3291%26epage%3D3310%26doi%3D10.1038%2Fsj.onc.1210422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Seger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krebs, E. G.</span><span> </span><span class="NLM_article-title">The MAPK signaling cascade</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">726</span><span class="NLM_x">–</span> <span class="NLM_lpage">735</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1096%2Ffasebj.9.9.7601337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=7601337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADyaK2MXmvFCltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1995&pages=726-735&author=R.+Segerauthor=E.+G.+Krebs&title=The+MAPK+signaling+cascade"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The MAPK signaling cascade</span></div><div class="casAuthors">Seger, Rony; Krebs, Edwin G.</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">726-35</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review with 99 refs.  The transmission of extracellular signals into their intracellular targets is mediated by a network of interacting proteins that regulate a large no. of cellular processes.  Cumulative efforts from many labs. over the past decade have allowed the elucidation of one such signaling mechanism, which involves activations of several membranal signaling mols. followed by a sequential stimulation of several cytoplasmic protein kinases collectively known as mitogen-activated protein kinase (MAPK) signaling cascade.  Up to six tiers in this cascade contribute to the amplification and specificity of the transmitted signals that eventually activate several regulatory mols. in the cytoplasm and in the nucleus to initiate cellular processes such as proliferation, differentiation, and development.  Moreover, because many oncogenes have been shown to encode proteins that transmit mitogenic signals upstream of this cascade, the MAPK pathway provides a simple unifying explanation for the mechanism of action of most, if not all, non-nuclear oncogenes.  The pattern of MAPK cascade is not restricted to growth factor signaling and it is now known that signaling pathways initiated by phorbol esters, ionophores, heat shock, and ligands for seven transmembrane receptors use distinct MAPK cascades with little or no cross-reactivity between them.  Emphasis is on the first MAPK cascade to be discovered that uses the MEK and ERK isoforms and their involvement in different cellular processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUHfD1KXEalbVg90H21EOLACvtfcHk0lhB4qEwBhzzyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmvFCltb0%253D&md5=575ee254997b2992062952b598304c61</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1096%2Ffasebj.9.9.7601337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffasebj.9.9.7601337%26sid%3Dliteratum%253Aachs%26aulast%3DSeger%26aufirst%3DR.%26aulast%3DKrebs%26aufirst%3DE.%2BG.%26atitle%3DThe%2520MAPK%2520signaling%2520cascade%26jtitle%3DFASEB%2520J.%26date%3D1995%26volume%3D9%26spage%3D726%26epage%3D735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Lewis, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, N. G.</span><span> </span><span class="NLM_article-title">Signal transduction through MAP kinase cascades</span> <span class="citation_source-journal">Adv. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">139</span><span class="refDoi"> DOI: 10.1016/S0065-230X(08)60765-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1016%2FS0065-230X%2808%2960765-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=9561267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADyaK1cXivVSls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=1998&pages=49-139&author=T.+S.+Lewisauthor=P.+S.+Shapiroauthor=N.+G.+Ahn&title=Signal+transduction+through+MAP+kinase+cascades&doi=10.1016%2FS0065-230X%2808%2960765-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction through MAP kinase cascades</span></div><div class="casAuthors">Lewis, Timothy S.; Shapiro, Paul S.; Ahn, Natalie G.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">49-139</span>CODEN:
                <span class="NLM_cas:coden">ACRSAJ</span>;
        ISSN:<span class="NLM_cas:issn">0065-230X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press, Inc.</span>)
        </div><div class="casAbstract">A review with many refs., on the title topic, discussing the MAP kinase (MAPK) module; mammalian MAPK pathways; regulation of MAPK pathways by protein phosphatases; ce;;i;ar substrates pf <AP kinases; responses to MAPK pathways: growth and differentiation; yeast MAPK pathways; intracellular targeting and spatial regulation MAPK pathway components; and future perspectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5MNvA1uEbjbVg90H21EOLACvtfcHk0lhB4qEwBhzzyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXivVSls70%253D&md5=32d30666cdf7cf8c2f08d48132af76e4</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0065-230X%2808%2960765-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-230X%252808%252960765-4%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DT.%2BS.%26aulast%3DShapiro%26aufirst%3DP.%2BS.%26aulast%3DAhn%26aufirst%3DN.%2BG.%26atitle%3DSignal%2520transduction%2520through%2520MAP%2520kinase%2520cascades%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D1998%26volume%3D74%26spage%3D49%26epage%3D139%26doi%3D10.1016%2FS0065-230X%2808%2960765-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Pearson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karandikar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobb, M. H.</span><span> </span><span class="NLM_article-title">Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions</span> <span class="citation_source-journal">Endocr. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span><span class="refDoi"> DOI: 10.1210/edrv.22.2.0428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1210%2Fedrv.22.2.0428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=11294822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsFSntL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2001&pages=153-183&author=G.+Pearsonauthor=F.+Robinsonauthor=T.+B.+Gibsonauthor=B.+Xuauthor=M.+Karandikarauthor=K.+Bermanauthor=M.+H.+Cobb&title=Mitogen-activated+protein+%28MAP%29+kinase+pathways%3A+regulation+and+physiological+functions&doi=10.1210%2Fedrv.22.2.0428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions</span></div><div class="casAuthors">Pearson, Gray; Robinson, Fred; Gibson, Tara Beers; Xu, Bing-E.; Karandikar, Mahesh; Berman, Kevin; Cobb, Melanie H.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-183</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review with 445 refs.  Mitogen-activated protein (MAP) kinases comprise a family of ubiquitous proline-directed, protein-serine/threonine kinases, which participate in signal transduction pathways that control intracellular events including acute responses to hormones and major developmental changes in organisms.  MAP kinases lie in protein kinase cascades.  This review discusses the regulation and functions of mammalian MAP kinases.  Nonenzymic mechanisms that impact MAP kinase functions and findings from gene disruption studies are highlighted.  Particular emphasis is on ERK1/2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8XhR5CgJu3bVg90H21EOLACvtfcHk0ljG0FlVXv3N8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsFSntL4%253D&md5=9b32d20e4d606ec928759848c6542e78</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1210%2Fedrv.22.2.0428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fedrv.22.2.0428%26sid%3Dliteratum%253Aachs%26aulast%3DPearson%26aufirst%3DG.%26aulast%3DRobinson%26aufirst%3DF.%26aulast%3DGibson%26aufirst%3DT.%2BB.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DKarandikar%26aufirst%3DM.%26aulast%3DBerman%26aufirst%3DK.%26aulast%3DCobb%26aufirst%3DM.%2BH.%26atitle%3DMitogen-activated%2520protein%2520%2528MAP%2529%2520kinase%2520pathways%253A%2520regulation%2520and%2520physiological%2520functions%26jtitle%3DEndocr.%2520Rev.%26date%3D2001%26volume%3D22%26spage%3D153%26epage%3D183%26doi%3D10.1210%2Fedrv.22.2.0428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasothan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Vemurafenib</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">811</span><span class="NLM_x">–</span> <span class="NLM_lpage">812</span><span class="refDoi"> DOI: 10.1038/nrd3579</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1038%2Fnrd3579" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=22037033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyis77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=811-812&author=K.+T.+Flahertyauthor=U.+Yasothanauthor=P.+Kirkpatrick&title=Vemurafenib&doi=10.1038%2Fnrd3579"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Vemurafenib</span></div><div class="casAuthors">Flaherty, Keith. T.; Yasothan, Uma; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">811-812</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAFV600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjMMlDZWY_BbVg90H21EOLACvtfcHk0ljG0FlVXv3N8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyis77I&md5=571edc546d25485f37890e3d62ea90a1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd3579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3579%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DVemurafenib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D811%26epage%3D812%26doi%3D10.1038%2Fnrd3579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Ballantyne, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnock-Jones, K. P.</span><span> </span><span class="NLM_article-title">Dabrafenib: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1367</span><span class="NLM_x">–</span> <span class="NLM_lpage">1376</span><span class="refDoi"> DOI: 10.1007/s40265-013-0095-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1007%2Fs40265-013-0095-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=23881668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWmtLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1367-1376&author=A.+D.+Ballantyneauthor=K.+P.+Garnock-Jones&title=Dabrafenib%3A+first+global+approval&doi=10.1007%2Fs40265-013-0095-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib: First Global Approval</span></div><div class="casAuthors">Ballantyne, Anita D.; Garnock-Jones, Karly P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1367-1376</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Dabrafenib (Tafinlar), a mutant-BRAF kinase inhibitor, emerged from GlaxoSmithKline's research program for the discovery of selective inhibitors of mutant BRAF kinase activity, for the treatment of solid tumors; mutations in the BRAF gene are assocd. with increased growth and proliferation of cancer cells.  GlaxoSmithKline has focused the development of dabrafenib on the treatment of malignant melanoma, as BRAF mutations are present in 50 % of these cancers.  Dabrafenib is approved in the US as a single agent treatment for unresectable or metastatic melanoma in patients with the BRAF V600E mutation, and has received a pos. opinion in the EU in this indication.  Submissions have also been made in the US and the EU for the use of dabrafenib in combination with trametinib for the treatment of metastatic melanoma with a BRAF V600E/K mutation.  Global phase III development of dabrafenib as a monotherapy and as a combination therapy is ongoing in the treatment of malignant melanoma.  Phase II development is ongoing for the treatment of malignant melanoma that has metastasised to the brain, and for colorectal and non-small cell lung cancers.  Dabrafenib is intended to treat the patient population with a BRAF V600E/K mutation.  GlaxoSmithKline's dabrafenib application in the US included the treatment of this population as detected by a US FDA-approved test.  GlaxoSmithKline, in collaboration with bioMerieux and Response Genetics, has developed a mol. theranostic test to identify BRAF V600E/K mutations.  Pre-Market approval of the test has been granted by the FDA.  This article summarises the milestones in the development of dabrafenib leading to this first approval as a single agent treatment for unresectable or metastatic melanoma in patients with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4KpEYZJGtALVg90H21EOLACvtfcHk0ljG0FlVXv3N8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWmtLzN&md5=60ccc73dcdbbe08426a3e288fa5db56d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0095-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0095-2%26sid%3Dliteratum%253Aachs%26aulast%3DBallantyne%26aufirst%3DA.%2BD.%26aulast%3DGarnock-Jones%26aufirst%3DK.%2BP.%26atitle%3DDabrafenib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1367%26epage%3D1376%26doi%3D10.1007%2Fs40265-013-0095-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Wright, C. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormack, P. L.</span><span> </span><span class="NLM_article-title">Trametinib: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1245</span><span class="NLM_x">–</span> <span class="NLM_lpage">1254</span><span class="refDoi"> DOI: 10.1007/s40265-013-0096-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1007%2Fs40265-013-0096-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=23846731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A280%3ADC%252BC3sfgtFSjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1245-1254&author=C.+J.+M.+Wrightauthor=P.+L.+McCormack&title=Trametinib%3A+first+global+approval&doi=10.1007%2Fs40265-013-0096-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Trametinib: first global approval</span></div><div class="casAuthors">Wright Cameron J M; McCormack Paul L</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1245-54</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Trametinib is an orally bioavailable mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor with antineoplastic activity.  The compound specifically binds to MEK1 and MEK2, resulting in inhibition of growth factor-mediated cell signalling and cellular proliferation in various cancers.  Originally developed by Japan Tobacco, GlaxoSmithKline has licensed exclusive worldwide rights to the compound and conducted development in a number of different cancer types.  Trametinib, as a monotherapy, has been approved in the US for the treatment of unresectable or metastatic malignant melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.  The compound, as a monotherapy, has also been submitted for regulatory review in the EU for BRAF mutation-positive malignant melanoma, and is in phase III development in Europe, Argentina, Canada and Oceania.  Phase II development is underway for pancreatic cancer, non-small cell lung cancer and relapsed or refractory leukaemias.  GlaxoSmithKline is also developing trametinib for use in combination with dabrafenib in BRAF V600 mutation-positive metastatic cutaneous melanoma; the combination is at the preregistration stage in the EU and a phase III clinical programme is underway worldwide.  Phase II development for this combination is also underway in colorectal cancer.  Several phase I trials have also been initiated to evaluate trametinib in combination with other drugs for the treatment of various solid tumours and haematological malignancies.  A paediatric oral solution formulation has been assessed against the oral tablet formulation in a phase I trial.  This article summarizes the milestones in the development of trametinib leading to this first approval for unresectable or metastatic BRAF mutation-positive malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRw3yHtWXvrR2BAiYWy6n3SfW6udTcc2eYYJ6a57r0SYrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfgtFSjtg%253D%253D&md5=133d953030ec0c3f62fbba730fabbfa9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0096-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0096-1%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DC.%2BJ.%2BM.%26aulast%3DMcCormack%26aufirst%3DP.%2BL.%26atitle%3DTrametinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1245%26epage%3D1254%26doi%3D10.1007%2Fs40265-013-0096-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Garnock-Jones, K. P.</span><span> </span><span class="NLM_article-title">Cobimetinib: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1823</span><span class="NLM_x">–</span> <span class="NLM_lpage">1830</span><span class="refDoi"> DOI: 10.1007/s40265-015-0477-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1007%2Fs40265-015-0477-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=26452567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1yltbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1823-1830&author=K.+P.+Garnock-Jones&title=Cobimetinib%3A+first+global+approval&doi=10.1007%2Fs40265-015-0477-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cobimetinib: First Global Approval</span></div><div class="casAuthors">Garnock-Jones, Karly P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1823-1830</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Genentech (a subsidiary of Roche) and Exelixis are developing cobimetinib, an orally available small mol., for the treatment of various cancers, including malignant melanoma and breast cancer.  Cobimetinib inhibits the MEK (mitogen-activated protein kinase) component of the MAPK/ERK signalling pathway, which is frequently over-activated in human tumors.  The product has been approved in Switzerland in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-pos. melanoma, and is under regulatory review for the same indication in several countries, including the USA and the EU.  This article summarizes the milestones in the development of cobimetinib leading to this first approval for unresectable or metastatic BRAF V600 mutation-pos. melanoma melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_AwqkxEJ58rVg90H21EOLACvtfcHk0ljOLcTciMb5mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1yltbrI&md5=de1c1a3f2d81b0cc2bde73d6994f8250</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0477-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0477-8%26sid%3Dliteratum%253Aachs%26aulast%3DGarnock-Jones%26aufirst%3DK.%2BP.%26atitle%3DCobimetinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1823%26epage%3D1830%26doi%3D10.1007%2Fs40265-015-0477-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Moriceau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hugo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samatar, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanlou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruchalski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seifert, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlman, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Algazi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span> </span><span class="NLM_article-title">Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span><span class="refDoi"> DOI: 10.1016/j.ccell.2014.11.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1016%2Fj.ccell.2014.11.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=25600339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKgtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=240-256&author=G.+Moriceauauthor=W.+Hugoauthor=A.+Hongauthor=H.+Shiauthor=X.+Kongauthor=C.+C.+Yuauthor=R.+C.+Koyaauthor=A.+A.+Samatarauthor=N.+Khanlouauthor=J.+Braunauthor=K.+Ruchalskiauthor=H.+Seifertauthor=J.+Larkinauthor=K.+B.+Dahlmanauthor=D.+B.+Johnsonauthor=A.+Algaziauthor=J.+A.+Sosmanauthor=A.+Ribasauthor=R.+S.+Lo&title=Tunable-combinatorial+mechanisms+of+acquired+resistance+limit+the+efficacy+of+BRAF%2FMEK+cotargeting+but+result+in+melanoma+drug+addiction&doi=10.1016%2Fj.ccell.2014.11.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction</span></div><div class="casAuthors">Moriceau, Gatien; Hugo, Willy; Hong, Aayoung; Shi, Hubing; Kong, Xiangju; Yu, Clarissa C.; Koya, Richard C.; Samatar, Ahmed A.; Khanlou, Negar; Braun, Jonathan; Ruchalski, Kathleen; Seifert, Heike; Larkin, James; Dahlman, Kimberly B.; Johnson, Douglas B.; Algazi, Alain; Sosman, Jeffrey A.; Ribas, Antoni; Lo, Roger S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-256</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Combined BRAF- and MEK-targeted therapy improves upon BRAF inhibitor (BRAFi) therapy but is still beset by acquired resistance.  We show that melanomas acquire resistance to combined BRAF and MEK inhibition by augmenting or combining mechanisms of single-agent BRAFi resistance.  These double-drug resistance-assocd. genetic configurations significantly altered mol. interactions underlying MAPK pathway reactivation. V600EBRAF, expressed at supraphysiol. levels because of V600EBRAF ultra-amplification, dimerized with and activated CRAF.  In addn., MEK mutants enhanced interaction with overexpressed V600EBRAF via a regulatory interface at R662 of V600EBRAF.  Importantly, melanoma cell lines selected for resistance to BRAFi+MEKi, but not those to BRAFi alone, displayed robust drug addiction, providing a potentially exploitable therapeutic opportunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWdJyJ2wlmALVg90H21EOLACvtfcHk0ljOLcTciMb5mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKgtrg%253D&md5=42788605b6c22cf70ff49304bf65ca19</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2014.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2014.11.018%26sid%3Dliteratum%253Aachs%26aulast%3DMoriceau%26aufirst%3DG.%26aulast%3DHugo%26aufirst%3DW.%26aulast%3DHong%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DC.%2BC.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26aulast%3DKhanlou%26aufirst%3DN.%26aulast%3DBraun%26aufirst%3DJ.%26aulast%3DRuchalski%26aufirst%3DK.%26aulast%3DSeifert%26aufirst%3DH.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDahlman%26aufirst%3DK.%2BB.%26aulast%3DJohnson%26aufirst%3DD.%2BB.%26aulast%3DAlgazi%26aufirst%3DA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DTunable-combinatorial%2520mechanisms%2520of%2520acquired%2520resistance%2520limit%2520the%2520efficacy%2520of%2520BRAF%252FMEK%2520cotargeting%2520but%2520result%2520in%2520melanoma%2520drug%2520addiction%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D27%26spage%3D240%26epage%3D256%26doi%3D10.1016%2Fj.ccell.2014.11.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Sale, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, S. J.</span><span> </span><span class="NLM_article-title">Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">776</span><span class="NLM_x">–</span> <span class="NLM_lpage">783</span><span class="refDoi"> DOI: 10.1042/BST20140129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1042%2FBST20140129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=25109957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlWktLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=776-783&author=M.+J.+Saleauthor=S.+J.+Cook&title=Intrinsic+and+acquired+resistance+to+MEK1%2F2+inhibitors+in+cancer&doi=10.1042%2FBST20140129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer</span></div><div class="casAuthors">Sale, Matthew J.; Cook, Simon J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">776-783</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent clin. data with BRAF and MEK1/2 [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase 1/2] inhibitors have demonstrated the remarkable potential of targeting the RAF-MEK1/2-ERK1/2 signalling cascade for the treatment of certain cancers.  Despite these advances, however, only a subset of patients respond to these agents in the first instance, and, of those that do, acquired resistance invariably develops after several months.  Studies in vitro have identified various mechanisms that can underpin intrinsic and acquired resistance to MEK1/2 inhibitors, and these frequently recapitulate those obsd. clin.  In the present article, we review these mechanisms and also discuss recent advances in our understanding of how MEK1/2 inhibitor activity is influenced by pathway feedback.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkmrcuVF7iqLVg90H21EOLACvtfcHk0ljI3FJKAXliNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlWktLzM&md5=98e908f603f5d0ee2cd747610531b968</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1042%2FBST20140129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20140129%26sid%3Dliteratum%253Aachs%26aulast%3DSale%26aufirst%3DM.%2BJ.%26aulast%3DCook%26aufirst%3DS.%2BJ.%26atitle%3DIntrinsic%2520and%2520acquired%2520resistance%2520to%2520MEK1%252F2%2520inhibitors%2520in%2520cancer%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2014%26volume%3D42%26spage%3D776%26epage%3D783%26doi%3D10.1042%2FBST20140129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">603</span><span class="NLM_x">–</span> <span class="NLM_lpage">604</span><span class="refDoi"> DOI: 10.1016/j.ccell.2014.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1016%2Fj.ccell.2014.10.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=603-604&author=P.+B.+Chapmanauthor=D.+B.+Solitauthor=N.+Rosen&title=Combination+of+RAF+and+MEK+inhibition+for+the+treatment+of+BRAF-mutated+melanoma%3A+feedback+is+not+encouraged&doi=10.1016%2Fj.ccell.2014.10.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2014.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2014.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DCombination%2520of%2520RAF%2520and%2520MEK%2520inhibition%2520for%2520the%2520treatment%2520of%2520BRAF-mutated%2520melanoma%253A%2520feedback%2520is%2520not%2520encouraged%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26spage%3D603%26epage%3D604%26doi%3D10.1016%2Fj.ccell.2014.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Yu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lv, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span> </span><span class="NLM_article-title">The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles of effective cancer therapy</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">–</span> <span class="NLM_lpage">289</span><span class="refDoi"> DOI: 10.4155/fmc.14.143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.4155%2Ffmc.14.143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=25826360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFaltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=269-289&author=Z.+Yuauthor=S.+Yeauthor=G.+Huauthor=M.+Lvauthor=Z.+Tuauthor=K.+Zhouauthor=Q.+Li&title=The+RAF-MEK-ERK+pathway%3A+targeting+ERK+to+overcome+obstacles+of+effective+cancer+therapy&doi=10.4155%2Ffmc.14.143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy</span></div><div class="casAuthors">Yu, Zutao; Ye, Shiqi; Hu, Gaoyun; Lv, Meng; Tu, Zhijun; Zhou, Kun; Li, Qianbin</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-289</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Aim: Currently, dozens of BRAF inhibitors and MEK inhibitors targeting RAF-MEK-ERK pathway have been introduced into clin. trials for cancer therapy.  However, after 6-8 mo of initial response, acquired drug resistance among the majority of those treated patients sharply diminished their clin. efficacy.  Discussion: Important mechanisms responsible for acquired resistance of BRAF inhibitors and MEK inhibitors have been elucidated.  Continually, ERK1/2 locates in the crit. position and features unique characteristics, such as activating hundreds of substrates, participating in feedback regulation, being catalyzed by MEK specifically and no acquired resistant mutation.  Conclusion: Taking in account the inspiring outcomes of ERK inhibitors in preclin. research, ERK1/2 might be the optimal target to overcome acquired drug resistance in RAF-MEK-ERK pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYVooAYz4COrVg90H21EOLACvtfcHk0ljI3FJKAXliNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFaltbY%253D&md5=7f7253af9023521511a9504c42cd6199</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.143%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DLv%26aufirst%3DM.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DQ.%26atitle%3DThe%2520RAF-MEK-ERK%2520pathway%253A%2520targeting%2520ERK%2520to%2520overcome%2520obstacles%2520of%2520effective%2520cancer%2520therapy%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D269%26epage%3D289%26doi%3D10.4155%2Ffmc.14.143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Goetz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghandi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treacy, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagle, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span> </span><span class="NLM_article-title">ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">7079</span><span class="NLM_x">–</span> <span class="NLM_lpage">7089</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-2073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1158%2F0008-5472.CAN-14-2073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=25320010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVWhsrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=7079-7089&author=E.+M.+Goetzauthor=M.+Ghandiauthor=D.+J.+Treacyauthor=N.+Wagleauthor=L.+A.+Garraway&title=ERK+mutations+confer+resistance+to+mitogen-activated+protein+kinase+pathway+inhibitors&doi=10.1158%2F0008-5472.CAN-14-2073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors</span></div><div class="casAuthors">Goetz, Eva M.; Ghandi, Mahmoud; Treacy, Daniel J.; Wagle, Nikhil; Garraway, Levi A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7079-7089</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Identification of ERK1/2 mutations may provide insights for resistance to therapies targeting this pathway.  The use of targeted therapeutics directed against BRAFV600-mutant metastatic melanoma improves progression-free survival in many patients; however, acquired drug resistance remains a major medical challenge.  By far, the most common clin. resistance mechanism involves reactivation of the MAPK (RAF/MEK/ERK) pathway by a variety of mechanisms.  Thus, targeting ERK itself has emerged as an attractive therapeutic concept, and several ERK inhibitors have entered clin. trials.  We sought to preemptively det. mutations in ERK1/2 that confer resistance to either ERK inhibitors or combined RAF/MEK inhibition in BRAFV600-mutant melanoma.  Using a random mutagenesis screen, we identified multiple point mutations in ERK1 (MAPK3) and ERK2 (MAPK1) that could confer resistance to ERK or RAF/MEK inhibitors.  ERK inhibitor-resistant alleles were sensitive to RAF/MEK inhibitors and vice versa, suggesting that the future development of alternating RAF/MEK and ERK inhibitor regimens might help circumvent resistance to these agents.  Cancer Res; 74(23); 7079-89. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTZOJd289ow7Vg90H21EOLACvtfcHk0ljI3FJKAXliNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVWhsrjF&md5=7902051fc3fe20837e2377cb14bb81a9</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-2073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-2073%26sid%3Dliteratum%253Aachs%26aulast%3DGoetz%26aufirst%3DE.%2BM.%26aulast%3DGhandi%26aufirst%3DM.%26aulast%3DTreacy%26aufirst%3DD.%2BJ.%26aulast%3DWagle%26aufirst%3DN.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26atitle%3DERK%2520mutations%2520confer%2520resistance%2520to%2520mitogen-activated%2520protein%2520kinase%2520pathway%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D7079%26epage%3D7089%26doi%3D10.1158%2F0008-5472.CAN-14-2073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Yap, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worlikar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKerell, A. D.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, S.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors of the ERK signaling pathway: towards novel anticancer therapeutics</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">48</span><span class="refDoi"> DOI: 10.1002/cmdc.201000354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1002%2Fcmdc.201000354" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=38-48&author=J.+L.+Yapauthor=S.+Worlikarauthor=A.+D.+MacKerellauthor=P.+Shapiroauthor=S.+Fletcher&title=Small-molecule+inhibitors+of+the+ERK+signaling+pathway%3A+towards+novel+anticancer+therapeutics&doi=10.1002%2Fcmdc.201000354"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000354%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DJ.%2BL.%26aulast%3DWorlikar%26aufirst%3DS.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26aulast%3DShapiro%26aufirst%3DP.%26aulast%3DFletcher%26aufirst%3DS.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520the%2520ERK%2520signaling%2520pathway%253A%2520towards%2520novel%2520anticancer%2520therapeutics%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26spage%3D38%26epage%3D48%26doi%3D10.1002%2Fcmdc.201000354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Aronov, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germann, U. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maltais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Botella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namchuk, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X.</span><span> </span><span class="NLM_article-title">Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1280</span><span class="NLM_x">–</span> <span class="NLM_lpage">1287</span><span class="refDoi"> DOI: 10.1021/jm061381f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061381f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1280-1287&author=A.+M.+Aronovauthor=C.+Bakerauthor=G.+W.+Bemisauthor=J.+Caoauthor=G.+Chenauthor=P.+J.+Fordauthor=U.+A.+Germannauthor=J.+Greenauthor=M.+R.+Haleauthor=M.+Jacobsauthor=J.+W.+Janetkaauthor=F.+Maltaisauthor=G.+Martinez-Botellaauthor=M.+N.+Namchukauthor=J.+Straubauthor=Q.+Tangauthor=X.+Xie&title=Flipped+out%3A+structure-guided+design+of+selective+pyrazolylpyrrole+ERK+inhibitors&doi=10.1021%2Fjm061381f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm061381f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061381f%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DBaker%26aufirst%3DC.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DFord%26aufirst%3DP.%2BJ.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DHale%26aufirst%3DM.%2BR.%26aulast%3DJacobs%26aufirst%3DM.%26aulast%3DJanetka%26aufirst%3DJ.%2BW.%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DMartinez-Botella%26aufirst%3DG.%26aulast%3DNamchuk%26aufirst%3DM.%2BN.%26aulast%3DStraub%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DXie%26aufirst%3DX.%26atitle%3DFlipped%2520out%253A%2520structure-guided%2520design%2520of%2520selective%2520pyrazolylpyrrole%2520ERK%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1280%26epage%3D1287%26doi%3D10.1021%2Fjm061381f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span>Biomed Valley Discoveries, BVD-523. <a href="https://biomed-valley.com/portfolio/bvd-523" class="extLink">https://biomed-valley.com/portfolio/bvd-523</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Biomed+Valley+Discoveries%2C+BVD-523.+https%3A%2F%2Fbiomed-valley.com%2Fportfolio%2Fbvd-523."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Bagdanoff, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madiera, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poon, D.</span><span> </span><span class="NLM_article-title">Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3788</span><span class="NLM_x">–</span> <span class="NLM_lpage">3792</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1016%2Fj.bmcl.2015.07.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=26259804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KrtLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3788-3792&author=J.+T.+Bagdanoffauthor=R.+Jainauthor=W.+Hanauthor=S.+Zhuauthor=A.-M.+Madieraauthor=P.+S.+Leeauthor=X.+Maauthor=D.+Poon&title=Tetrahydropyrrolo-diazepenones+as+inhibitors+of+ERK2+kinase&doi=10.1016%2Fj.bmcl.2015.07.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase</span></div><div class="casAuthors">Bagdanoff, Jeffrey T.; Jain, Rama; Han, Wooseok; Zhu, Shejin; Madiera, Ann-Marie; Lee, Patrick S.; Ma, Xiaolei; Poon, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3788-3792</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of structure based drug design hypotheses and focused screening efforts led to the identification of tetrahydropyrrolo-diazepenones with striking potency against ERK2 kinase.  The role of fluorination in mitigating microsomal clearance was systematically explored.  Ultimately, it was found that fluorination of a cyclopentanol substructure provided significant improvement in both potency and human metabolic stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHXEHIlXy0QLVg90H21EOLACvtfcHk0ljhb4yay4epiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KrtLnF&md5=d94c52debb8203a3b9e655319ea32754</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.091%26sid%3Dliteratum%253Aachs%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DJain%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DMadiera%26aufirst%3DA.-M.%26aulast%3DLee%26aufirst%3DP.%2BS.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DPoon%26aufirst%3DD.%26atitle%3DTetrahydropyrrolo-diazepenones%2520as%2520inhibitors%2520of%2520ERK2%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3788%26epage%3D3792%26doi%3D10.1016%2Fj.bmcl.2015.07.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Morris, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Restaino, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayananth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNunzio, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windsor, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angagaw, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinheiro, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipps, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hruza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paliwal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babu, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daublain, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutterbach, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelletier, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philippar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siliphaivanh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschmeier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fawell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samatar, A. A.</span><span> </span><span class="NLM_article-title">Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1158%2F2159-8290.CD-13-0070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=23614898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=742-750&author=E.+J.+Morrisauthor=S.+Jhaauthor=C.+R.+Restainoauthor=P.+Dayananthauthor=H.+Zhuauthor=A.+Cooperauthor=D.+Carrauthor=Y.+Dengauthor=W.+Jinauthor=S.+Blackauthor=B.+Longauthor=J.+Liuauthor=E.+DiNunzioauthor=W.+Windsorauthor=R.+Zhangauthor=S.+Zhaoauthor=M.+H.+Angagawauthor=E.+M.+Pinheiroauthor=J.+Desaiauthor=L.+Xiaoauthor=G.+Shippsauthor=A.+Hruzaauthor=J.+Wangauthor=J.+Kellyauthor=S.+Paliwalauthor=X.+Gaoauthor=B.+S.+Babuauthor=L.+Zhuauthor=P.+Daublainauthor=L.+Zhangauthor=B.+A.+Lutterbachauthor=M.+R.+Pelletierauthor=U.+Philipparauthor=P.+Siliphaivanhauthor=D.+Witterauthor=P.+Kirschmeierauthor=W.+R.+Bishopauthor=D.+Hicklinauthor=D.+G.+Gillilandauthor=L.+Jayaramanauthor=L.+Zawelauthor=S.+Fawellauthor=A.+A.+Samatar&title=Discovery+of+a+novel+ERK+inhibitor+with+activity+in+models+of+acquired+resistance+to+BRAF+and+MEK+inhibitors&doi=10.1158%2F2159-8290.CD-13-0070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors</span></div><div class="casAuthors">Morris, Erick J.; Jha, Sharda; Restaino, Clifford R.; Dayananth, Priya; Zhu, Hugh; Cooper, Alan; Carr, Donna; Deng, Yongi; Jin, Weihong; Black, Stuart; Long, Brian; Liu, Jenny; DiNunzio, Edward; Windsor, William; Zhang, Rumin; Zhao, Shuxia; Angagaw, Minilik H.; Pinheiro, Elaine M.; Desai, Jagdish; Xiao, Li; Shipps, Gerald; Hruza, Alan; Wang, James; Kelly, Joe; Paliwal, Sunil; Gao, Xiaolei; Babu, Boga Sobhana; Zhu, Liang; Daublain, Pierre; Zhang, Ling; Lutterbach, Bart A.; Pelletier, Marc R.; Philippar, Ulrike; Siliphaivanh, Phieng; Witter, David; Kirschmeier, Paul; Bishop, W. Robert; Hicklin, Daniel; Gilliland, D. Gary; Jayaraman, Lata; Zawel, Leigh; Fawell, Stephen; Samatar, Ahmed A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">742-750</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway.  Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clin. efficacy in patients with melanoma.  However, the majority of responses are transient, and resistance is often assocd. with pathway reactivation of the extracellular signal-regulated kinase (ERK) signaling pathway.  Here, we describe the identification and characterization of SCH772984, a novel and selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors.  SCH772984 has nanomolar cellular potency in tumor cells with mutations in BRAF, NRA5, or KRAS and induces tumor regressions in xenograft models at tolerated doses.  Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor-resistant models as well as in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors.  These data support the clin. development of ERK inhibitors for tumors refractory to MAPK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4HJ4HhYmLL7Vg90H21EOLACvtfcHk0lgKAEYC7OxDYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE&md5=1f26a4a5bb1fab64bdd6c38c16b3f4e3</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0070%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DE.%2BJ.%26aulast%3DJha%26aufirst%3DS.%26aulast%3DRestaino%26aufirst%3DC.%2BR.%26aulast%3DDayananth%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDiNunzio%26aufirst%3DE.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DAngagaw%26aufirst%3DM.%2BH.%26aulast%3DPinheiro%26aufirst%3DE.%2BM.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DShipps%26aufirst%3DG.%26aulast%3DHruza%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DBabu%26aufirst%3DB.%2BS.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDaublain%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DPelletier%26aufirst%3DM.%2BR.%26aulast%3DPhilippar%26aufirst%3DU.%26aulast%3DSiliphaivanh%26aufirst%3DP.%26aulast%3DWitter%26aufirst%3DD.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DHicklin%26aufirst%3DD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DJayaraman%26aufirst%3DL.%26aulast%3DZawel%26aufirst%3DL.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520ERK%2520inhibitor%2520with%2520activity%2520in%2520models%2520of%2520acquired%2520resistance%2520to%2520BRAF%2520and%2520MEK%2520inhibitors%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D742%26epage%3D750%26doi%3D10.1158%2F2159-8290.CD-13-0070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Challinor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debreczeni, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckersley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairley, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feron, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flemington, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenwood, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopcroft, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renshaw, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snow, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, K.</span><span> </span><span class="NLM_article-title">Structure-guided design of highly selective and potent covalent inhibitors of ERK1/2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4790</span><span class="NLM_x">–</span> <span class="NLM_lpage">4801</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00466</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00466" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVChs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4790-4801&author=R.+A.+Wardauthor=N.+Colcloughauthor=M.+Challinorauthor=J.+E.+Debreczeniauthor=K.+Eckersleyauthor=G.+Fairleyauthor=L.+Feronauthor=V.+Flemingtonauthor=C.+R.+Grahamauthor=R.+Greenwoodauthor=P.+Hopcroftauthor=T.+D.+Howardauthor=M.+Jamesauthor=C.+D.+Jonesauthor=C.+R.+Jonesauthor=J.+Renshawauthor=K.+Robertsauthor=L.+Snowauthor=M.+Tongeauthor=K.+Yeung&title=Structure-guided+design+of+highly+selective+and+potent+covalent+inhibitors+of+ERK1%2F2&doi=10.1021%2Facs.jmedchem.5b00466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2</span></div><div class="casAuthors">Ward, Richard A.; Colclough, Nicola; Challinor, Mairi; Debreczeni, Judit E.; Eckersley, Kay; Fairley, Gary; Feron, Lyman; Flemington, Vikki; Graham, Mark A.; Greenwood, Ryan; Hopcroft, Philip; Howard, Tina D.; James, Michael; Jones, Clifford D.; Jones, Christopher R.; Renshaw, Jonathan; Roberts, Karen; Snow, Lindsay; Tonge, Michael; Yeung, Kay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4790-4801</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The RAS/RAF/MEK/ERK signaling pathway has been targeted with a no. of small mol. inhibitors in oncol. clin. development across multiple disease indications.  Importantly, cell lines with acquired resistance to B-RAF and MEK inhibitors have been shown to maintain sensitivity to ERK1/2 inhibition by small mol. inhibitors.  There are a no. of selective, noncovalent ERK1/2 inhibitors reported along with the promiscuous hypothemycin (and related analogs) that act via a covalent mechanism of action.  This article reports the identification of multiple series of highly selective covalent ERK1/2 inhibitors informed by structure-based drug design (SBDD).  As a starting point for these covalent inhibitors, reported ERK1/2 inhibitors and a chem. series identified via high-throughput screening were exploited.  These approaches resulted in the identification of selective covalent tool compds. for potential in vitro and in vivo studies to assess the risks and or benefits of targeting this pathway through such a mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLDLwUCW_ANrVg90H21EOLACvtfcHk0lgKAEYC7OxDYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVChs7c%253D&md5=40b47d8671c966434434f056ac88b3a7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00466%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChallinor%26aufirst%3DM.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DEckersley%26aufirst%3DK.%26aulast%3DFairley%26aufirst%3DG.%26aulast%3DFeron%26aufirst%3DL.%26aulast%3DFlemington%26aufirst%3DV.%26aulast%3DGraham%26aufirst%3DC.%2BR.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DHopcroft%26aufirst%3DP.%26aulast%3DHoward%26aufirst%3DT.%2BD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DJones%26aufirst%3DC.%2BR.%26aulast%3DRenshaw%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DSnow%26aufirst%3DL.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DYeung%26aufirst%3DK.%26atitle%3DStructure-guided%2520design%2520of%2520highly%2520selective%2520and%2520potent%2520covalent%2520inhibitors%2520of%2520ERK1%252F2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4790%26epage%3D4801%26doi%3D10.1021%2Facs.jmedchem.5b00466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudino, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Meese, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chicarelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siedem, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolakowski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacheco, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi-Latham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, J. B.</span><span> </span><span class="NLM_article-title">Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2635</span><span class="NLM_x">–</span> <span class="NLM_lpage">2639</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.04.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1016%2Fj.bmcl.2014.04.068" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2635-2639&author=J.+F.+Blakeauthor=J.+J.+Gaudinoauthor=J.+De+Meeseauthor=P.+Mohrauthor=M.+Chicarelliauthor=H.+Tianauthor=R.+Garreyauthor=A.+Thomasauthor=C.+S.+Siedemauthor=M.+B.+Welchauthor=G.+Kolakowskiauthor=R.+Kausauthor=M.+Burkardauthor=M.+Martinsonauthor=H.+Chenauthor=B.+Deanauthor=D.+A.+Dudleyauthor=S.+E.+Gouldauthor=P.+Pachecoauthor=S.+Shahidi-Lathamauthor=W.+Wangauthor=K.+Westauthor=J.+Yinauthor=J.+Moffatauthor=J.+B.+Schwarz&title=Discovery+of+5%2C6%2C7%2C8-tetrahydropyrido%5B3%2C4-d%5Dpyrimidine+inhibitors+of+Erk2&doi=10.1016%2Fj.bmcl.2014.04.068"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.04.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.04.068%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DGaudino%26aufirst%3DJ.%2BJ.%26aulast%3DDe%2BMeese%26aufirst%3DJ.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DChicarelli%26aufirst%3DM.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DGarrey%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DSiedem%26aufirst%3DC.%2BS.%26aulast%3DWelch%26aufirst%3DM.%2BB.%26aulast%3DKolakowski%26aufirst%3DG.%26aulast%3DKaus%26aufirst%3DR.%26aulast%3DBurkard%26aufirst%3DM.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DDean%26aufirst%3DB.%26aulast%3DDudley%26aufirst%3DD.%2BA.%26aulast%3DGould%26aufirst%3DS.%2BE.%26aulast%3DPacheco%26aufirst%3DP.%26aulast%3DShahidi-Latham%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWest%26aufirst%3DK.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DSchwarz%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%25205%252C6%252C7%252C8-tetrahydropyrido%255B3%252C4-d%255Dpyrimidine%2520inhibitors%2520of%2520Erk2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2635%26epage%3D2639%26doi%3D10.1016%2Fj.bmcl.2014.04.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Ren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudino, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacheco, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi-Latham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, J. B.</span><span> </span><span class="NLM_article-title">Discovery of highly potent, selective and efficacious small molecule inhibitors of ERK1/2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1976</span><span class="NLM_x">–</span> <span class="NLM_lpage">1991</span><span class="refDoi"> DOI: 10.1021/jm501921k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501921k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1976-1991&author=L.+Renauthor=J.+Grinaauthor=D.+Morenoauthor=J.+F.+Blakeauthor=J.+J.+Gaudinoauthor=R.+Garreyauthor=A.+T.+Metcalfauthor=M.+Burkardauthor=M.+Martinsonauthor=K.+Rasorauthor=H.+Chenauthor=B.+Deanauthor=S.+E.+Gouldauthor=P.+Pachecoauthor=S.+Shahidi-Lathamauthor=J.+Yinauthor=K.+Westauthor=W.+Wangauthor=J.+G.+Moffatauthor=J.+B.+Schwarz&title=Discovery+of+highly+potent%2C+selective+and+efficacious+small+molecule+inhibitors+of+ERK1%2F2&doi=10.1021%2Fjm501921k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm501921k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501921k%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DL.%26aulast%3DGrina%26aufirst%3DJ.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DGaudino%26aufirst%3DJ.%2BJ.%26aulast%3DGarrey%26aufirst%3DR.%26aulast%3DMetcalf%26aufirst%3DA.%2BT.%26aulast%3DBurkard%26aufirst%3DM.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DRasor%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DDean%26aufirst%3DB.%26aulast%3DGould%26aufirst%3DS.%2BE.%26aulast%3DPacheco%26aufirst%3DP.%26aulast%3DShahidi-Latham%26aufirst%3DS.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DWest%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26aulast%3DSchwarz%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%2520highly%2520potent%252C%2520selective%2520and%2520efficacious%2520small%2520molecule%2520inhibitors%2520of%2520ERK1%252F2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1976%26epage%3D1991%26doi%3D10.1021%2Fjm501921k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="note"><p class="first last">The projected human dose for <b>6</b> was calculated using the predicted human clearance from simple allometry and the AUC<sub>last</sub> for a dose that effected ∼70% TGI.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Blake, J. F.; Chen, H.; Chicarelli, M. J.; Demeese, J.; Garrey, R.; Gaudino, J. J.; Kaus, R. J.; Kolakowski, G. R.; Marlow, A. L.; Mohr, P. J.; Ren, L.; Schwarz, J.; Siedem, C. S.; Thomas, A. A.; Wallace, E.; Wenglowsky, S. M.</span><span> </span><span class="NLM_article-title">Pyridopyrimidine derivatives as ERK inhibitors and their preparation and use for the treatment of hyperproliferative diseases</span>. PCT Int. Appl. WO 2012118850,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>251 pp.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.+F.+Blake&author=H.+Chen&author=M.+J.+Chicarelli&author=J.+Demeese&author=R.+Garrey&author=J.+J.+Gaudino&author=R.+J.+Kaus&author=G.+R.+Kolakowski&author=A.+L.+Marlow&author=P.+J.+Mohr&author=L.+Ren&author=J.+Schwarz&author=C.+S.+Siedem&author=A.+A.+Thomas&author=E.+Wallace&author=S.+M.+Wenglowsky&title=Pyridopyrimidine+derivatives+as+ERK+inhibitors+and+their+preparation+and+use+for+the+treatment+of+hyperproliferative+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26atitle%3DPyridopyrimidine%2520derivatives%2520as%2520ERK%2520inhibitors%2520and%2520their%2520preparation%2520and%2520use%2520for%2520the%2520treatment%2520of%2520hyperproliferative%2520diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><div class="note"><p class="first last">Expression, purification, and crystallization of CDK2 has been previously described:</p></div><span class="NLM_contrib-group">Hanan, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heald, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lainchbury, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purkey, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seward, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zilberleyb, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span> </span><span class="NLM_article-title">Discovery of selective and noncovalent diaminopyrimdine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">10176</span><span class="NLM_x">–</span> <span class="NLM_lpage">10191</span><span class="refDoi"> DOI: 10.1021/jm501578n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501578n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10176-10191&author=E.+J.+Hananauthor=C.+Eigenbrotauthor=M.+C.+Bryanauthor=D.+J.+Burdickauthor=B.+K.+Chanauthor=Y.+Chenauthor=J.+Dotsonauthor=R.+A.+Healdauthor=P.+S.+Jacksonauthor=H.+Laauthor=M.+D.+Lainchburyauthor=S.+Malekauthor=H.+E.+Purkeyauthor=G.+Schaeferauthor=S.+Schmidtauthor=E.+M.+Sewardauthor=S.+Siderisauthor=C.+Tamauthor=S.+Wangauthor=S.+K.+Yeapauthor=I.+Yenauthor=J.+Yinauthor=C.+Yuauthor=I.+Zilberleybauthor=T.+P.+Heffron&title=Discovery+of+selective+and+noncovalent+diaminopyrimdine-based+inhibitors+of+epidermal+growth+factor+receptor+containing+the+T790M+resistance+mutation&doi=10.1021%2Fjm501578n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm501578n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501578n%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DJackson%26aufirst%3DP.%2BS.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLainchbury%26aufirst%3DM.%2BD.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYeap%26aufirst%3DS.%2BK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DDiscovery%2520of%2520selective%2520and%2520noncovalent%2520diaminopyrimdine-based%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520containing%2520the%2520T790M%2520resistance%2520mutation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10176%26epage%3D10191%26doi%3D10.1021%2Fjm501578n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><div class="note"><p class="first last">A similar strategy was employed to gain selectivity for Plk1 over CDK2:</p></div><span class="NLM_contrib-group">Kothe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohls, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennie, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feru, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y.-H.</span><span> </span><span class="NLM_article-title">Selectivity-determining residues in Plk1</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">540</span><span class="NLM_x">–</span> <span class="NLM_lpage">546</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00594.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1111%2Fj.1747-0285.2007.00594.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=18005335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=540-546&author=M.+Kotheauthor=D.+Kohlsauthor=S.+Lowauthor=R.+Coliauthor=G.+R.+Rennieauthor=F.+Feruauthor=C.+Kuhnauthor=Y.-H.+Ding&title=Selectivity-determining+residues+in+Plk1&doi=10.1111%2Fj.1747-0285.2007.00594.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity-determining residues in Plk1</span></div><div class="casAuthors">Kothe, Michael; Kohls, Darcy; Low, Simon; Coli, Rocco; Rennie, Glen R.; Feru, Frederic; Kuhn, Cyrille; Ding, Yuan-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">540-546</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Polo-like kinase 1 is an important regulator of cell cycle progression whose over-expression is often assocd. with oncogenesis.  Polo-like kinase 1 hence represents an attractive target for cancer intervention.  BI 2536 (Boehringer Ingelheim, Ingelheim, Germany), a Polo-like kinase 1 inhibitor currently in clin. trials, exhibits nanomolar potency against Polo-like kinase isoforms and high selectivity against other kinases.  The authors have previously published the crystal structures of the Polo-like kinase 1 domain in complex with AMPPNP and an Aurora A inhibitor.  In this work, the authors present the cocrystal structure of Polo-like kinase 1 with BI 2536.  The structure, in combination with selectivity data for BI 2536 and related compds., illustrates important features for potency and selectivity.  In particular, the authors show that the methoxy group of BI 2536 is an important specificity determinant against non-Polo-like kinases by taking advantage of a small pocket generated by Leu 132 in the hinge region of Polo-like kinase 1.  The work presented here provides a framework for structure-based drug design of Polo-like kinase 1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjA3mwWD7K0bVg90H21EOLACvtfcHk0liXGJ6Hcv3c2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsbrJ&md5=0f976bb98fe7d0413e8d2314abc68e2b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00594.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00594.x%26sid%3Dliteratum%253Aachs%26aulast%3DKothe%26aufirst%3DM.%26aulast%3DKohls%26aufirst%3DD.%26aulast%3DLow%26aufirst%3DS.%26aulast%3DColi%26aufirst%3DR.%26aulast%3DRennie%26aufirst%3DG.%2BR.%26aulast%3DFeru%26aufirst%3DF.%26aulast%3DKuhn%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DY.-H.%26atitle%3DSelectivity-determining%2520residues%2520in%2520Plk1%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D70%26spage%3D540%26epage%3D546%26doi%3D10.1111%2Fj.1747-0285.2007.00594.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="note"><p class="first last">The increase in concentration of <b>22</b> at 6–8 h may be due to dose/solubility limited absorption where there is continued absorption during compound transit in the gut.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Diaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allamneni, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarrant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewin-Koh, S.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhawan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cain, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiraragi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bheddah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dambach, D. M.</span><span> </span><span class="NLM_article-title">Phosphorous dysregulation induced by MEK small molecule inhibitors in the rat involves blockade of FGF-23 signaling in the kidney</span> <span class="citation_source-journal">Toxicol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span><span class="refDoi"> DOI: 10.1093/toxsci/kfr263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1093%2Ftoxsci%2Fkfr263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=21976371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFOjtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2012&pages=187-195&author=D.+Diazauthor=K.+Allamneniauthor=J.+M.+Tarrantauthor=S.-C.+Lewin-Kohauthor=R.+Paiauthor=P.+Dhawanauthor=G.+R.+Cainauthor=C.+Kozlowskiauthor=H.+Hiraragiauthor=N.+Laauthor=D.+P.+Hartleyauthor=X.+Dingauthor=B.+J.+Deanauthor=S.+Bheddahauthor=D.+M.+Dambach&title=Phosphorous+dysregulation+induced+by+MEK+small+molecule+inhibitors+in+the+rat+involves+blockade+of+FGF-23+signaling+in+the+kidney&doi=10.1093%2Ftoxsci%2Fkfr263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorous dysregulation induced by MEK small molecule inhibitors in the rat involves blockade of FGF-23 signaling in the kidney</span></div><div class="casAuthors">Diaz, Dolores; Allamneni, Krishna; Tarrant, Jacqueline M.; Lewin-Koh, Sock-Cheng; Pai, Rama; Dhawan, Preeti; Cain, Gary R.; Kozlowski, Cleopatra; Hiraragi, Hajime; La, Nghi; Hartley, Dylan P.; Ding, Xiao; Dean, Brian J.; Bheddah, Sheila; Dambach, Donna M.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">187-195</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">MEK, a kinase downstream of Ras and Raf oncogenes, constitutes a high priority target in oncol. research.  MEK small mol. inhibitors cause soft tissue mineralization in rats secondary to blood serum inorg. phosphorus (iP) elevation, but the mol. mechanism for this toxicity remains undetd.  We performed investigative studies with structurally distinct MEK inhibitors GEN-A and PD325901 (PD-901) in Sprague-Dawley rats.  Our data support a mechanism that involves FGF-23 signal blockade in the rat kidney, causing transcriptional upregulation of 25-hydroxyvitamin D3 1-alpha-hydroxylase (Cyp27b1), the rate-limiting enzyme in vitamin D activation, and downregulation of 1,25-dihydroxyvitamin D3 24-hydroxylase (Cyp24a1), the enzyme that initiates the degrdn. of the active form of vitamin D.  These transcriptional changes increase serum vitamin D levels, which in turn drive the increase in serum iP, leading to soft tissue mineralization in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRrTYSDeZ1nLVg90H21EOLACvtfcHk0lgHihEx08djhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFOjtb0%253D&md5=5248ebee99e0c81bbf33cfd5285cb920</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfr263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfr263%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DD.%26aulast%3DAllamneni%26aufirst%3DK.%26aulast%3DTarrant%26aufirst%3DJ.%2BM.%26aulast%3DLewin-Koh%26aufirst%3DS.-C.%26aulast%3DPai%26aufirst%3DR.%26aulast%3DDhawan%26aufirst%3DP.%26aulast%3DCain%26aufirst%3DG.%2BR.%26aulast%3DKozlowski%26aufirst%3DC.%26aulast%3DHiraragi%26aufirst%3DH.%26aulast%3DLa%26aufirst%3DN.%26aulast%3DHartley%26aufirst%3DD.%2BP.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DDean%26aufirst%3DB.%2BJ.%26aulast%3DBheddah%26aufirst%3DS.%26aulast%3DDambach%26aufirst%3DD.%2BM.%26atitle%3DPhosphorous%2520dysregulation%2520induced%2520by%2520MEK%2520small%2520molecule%2520inhibitors%2520in%2520the%2520rat%2520involves%2520blockade%2520of%2520FGF-23%2520signaling%2520in%2520the%2520kidney%26jtitle%3DToxicol.%2520Sci.%26date%3D2012%26volume%3D125%26spage%3D187%26epage%3D195%26doi%3D10.1093%2Ftoxsci%2Fkfr263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':[],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':[],'ref27':['cit27']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 68 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Hongfang Li, Ijaz Khan, Meiqi Li, Zheng Wang, Xue Wu, Kuiling Ding, <span class="NLM_string-name hlFld-ContribAuthor">Yong Jian Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Pd-Catalyzed Regio- and Enantioselective Aminoarylation of Allenols with Aryl Iodides and 2-Pyridones. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (9)
                                     , 3567-3572. <a href="https://doi.org/10.1021/acs.orglett.1c00959" title="DOI URL">https://doi.org/10.1021/acs.orglett.1c00959</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.1c00959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.1c00959%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DPd-Catalyzed%252BRegio-%252Band%252BEnantioselective%252BAminoarylation%252Bof%252BAllenols%252Bwith%252BAryl%252BIodides%252Band%252B2-Pyridones%26aulast%3DLi%26aufirst%3DHongfang%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D22032021%26date%3D15042021%26volume%3D23%26issue%3D9%26spage%3D3567%26epage%3D3572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Steven K. Albanese, John D. Chodera, Andrea Volkamer, Simon Keng, Robert Abel, <span class="NLM_string-name hlFld-ContribAuthor">Lingle Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Is Structure-Based Drug Design Ready for Selectivity Optimization?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (12)
                                     , 6211-6227. <a href="https://doi.org/10.1021/acs.jcim.0c00815" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c00815</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c00815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c00815%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DIs%252BStructure-Based%252BDrug%252BDesign%252BReady%252Bfor%252BSelectivity%252BOptimization%25253F%26aulast%3DAlbanese%26aufirst%3DSteven%2BK.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17072020%26date%3D29102020%26volume%3D60%26issue%3D12%26spage%3D6211%26epage%3D6227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Guan Wang, Yuqian Zhao, Yao Liu, Dejuan Sun, Yongqi Zhen, Jie Liu, Leilei Fu, Lan Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Liang Ouyang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Novel Dual-Target Inhibitor of ERK1 and ERK5 That Induces Regulated Cell Death to Overcome Compensatory Mechanism in Specific Tumor Types. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 3976-3995. <a href="https://doi.org/10.1021/acs.jmedchem.9b01896" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01896</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01896%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BNovel%252BDual-Target%252BInhibitor%252Bof%252BERK1%252Band%252BERK5%252BThat%252BInduces%252BRegulated%252BCell%252BDeath%252Bto%252BOvercome%252BCompensatory%252BMechanism%252Bin%252BSpecific%252BTumor%252BTypes%26aulast%3DWang%26aufirst%3DGuan%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D14112019%26date%3D05032020%26date%3D20022020%26volume%3D63%26issue%3D8%26spage%3D3976%26epage%3D3995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas Boström</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sobhana Babu Boga, Yongqi Deng, Liang Zhu, Yang Nan, Alan B. Cooper, Gerald W. Shipps, Jr., Ronald Doll, Neng-Yang Shih, Hugh Zhu, Robert Sun, Tong Wang, Sunil Paliwal, Hon-Chung Tsui, Xiaolei Gao, Xin Yao, Jagdish Desai, James Wang, Abdul Basit Alhassan, Joseph Kelly, Mehul Patel, Kiran Muppalla, Subrahmanyam Gudipati, Li-Kang Zhang, Alexei Buevich, David Hesk, Donna Carr, Priya Dayananth, Stuart Black, Hong Mei, Kathleen Cox, Bradley Sherborne, Alan W. Hruza, Li Xiao, Weihong Jin, Brian Long, Gongjie Liu, Stacey A. Taylor, Paul Kirschmeier, William T. Windsor, Robert Bishop, <span class="NLM_string-name hlFld-ContribAuthor">Ahmed A. Samatar</span>. </span><span class="cited-content_cbyCitation_article-title">MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (7)
                                     , 761-767. <a href="https://doi.org/10.1021/acsmedchemlett.8b00220" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00220</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00220%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DMK-8353%25253A%252BDiscovery%252Bof%252Ban%252BOrally%252BBioavailable%252BDual%252BMechanism%252BERK%252BInhibitor%252Bfor%252BOncology%26aulast%3DBoga%26aufirst%3DSobhana%2BBabu%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D11052018%26date%3D14062018%26date%3D02072018%26date%3D14062018%26volume%3D9%26issue%3D7%26spage%3D761%26epage%3D767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tom D. Heightman, Valerio Berdini, Hannah Braithwaite, Ildiko M. Buck, Megan Cassidy, Juan Castro, Aurélie Courtin, James E. H. Day, Charlotte East, Lynsey Fazal, Brent Graham, Charlotte M. Griffiths-Jones, John F. Lyons, Vanessa Martins, Sandra Muench, Joanne M. Munck, David Norton, Marc O’Reilly, Nick Palmer, Puja Pathuri, Michael Reader, David C. Rees, Sharna J. Rich, Caroline Richardson, Harpreet Saini, Neil T. Thompson, Nicola G. Wallis, Hugh Walton, Nicola E. Wilsher, Alison J.-A. Woolford, Michael Cooke, David Cousin, Stuart Onions, Jonathan Shannon, John Watts, <span class="NLM_string-name hlFld-ContribAuthor">Christopher W. Murray</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (11)
                                     , 4978-4992. <a href="https://doi.org/10.1021/acs.jmedchem.8b00421" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00421</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00421%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFragment-Based%252BDiscovery%252Bof%252Ba%252BPotent%25252C%252BOrally%252BBioavailable%252BInhibitor%252BThat%252BModulates%252Bthe%252BPhosphorylation%252Band%252BCatalytic%252BActivity%252Bof%252BERK1%25252F2%26aulast%3DHeightman%26aufirst%3DTom%2BD.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D14032018%26date%3D31052018%26date%3D18052018%26volume%3D61%26issue%3D11%26spage%3D4978%26epage%3D4992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Xin    Linghu </span><span class="hlFld-ContribAuthor "> Nicholas    Wong </span><span class="hlFld-ContribAuthor "> James F.    Blake </span><span class="hlFld-ContribAuthor "> John J.    Gaudino </span><span class="hlFld-ContribAuthor "> John G.    Moffat </span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Development of GDC-0994: A Selective and Efficacious Small Molecule Inhibitor of ERK1/2. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 1-28. <a href="https://doi.org/10.1021/bk-2018-1307.ch001" title="DOI URL">https://doi.org/10.1021/bk-2018-1307.ch001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2018-1307.ch001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2018-1307.ch001%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Band%252BDevelopment%252Bof%252BGDC-0994%25253A%252BA%252BSelective%252Band%252BEfficacious%252BSmall%252BMolecule%252BInhibitor%252Bof%252BERK1%25252F2%26aulast%3DLinghu%26aufirst%3DXin%26date%3D2018%26date%3D2018%26spage%3D1%26epage%3D28%26atitle%3DComplete%252BAccounts%252Bof%252BIntegrated%252BDrug%252BDiscovery%252Band%252BDevelopment%25253A%252BRecent%252BExamples%252Bfrom%252Bthe%252BPharmaceutical%252BIndustry%252BVolume%252B1%26aulast%3DAbdel-Magid%26aufirst%3DAhmed%2BF.%26date%3D2018%26date%3D2018%26volume%3D1307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bernhard C.  Lechtenberg</span>, <span class="hlFld-ContribAuthor ">Peter D.  Mace</span>, <span class="hlFld-ContribAuthor ">E. Hampton  Sessions</span>, <span class="hlFld-ContribAuthor ">Robert  Williamson</span>, <span class="hlFld-ContribAuthor ">Romain  Stalder</span>, <span class="hlFld-ContribAuthor ">Yann  Wallez</span>, <span class="hlFld-ContribAuthor ">Gregory P.  Roth</span>, <span class="hlFld-ContribAuthor ">Stefan J.  Riedl</span>, and <span class="hlFld-ContribAuthor ">Elena B.  Pasquale</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Guided Strategy for the Development of Potent Bivalent ERK Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (7)
                                     , 726-731. <a href="https://doi.org/10.1021/acsmedchemlett.7b00127" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00127</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00127%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure-Guided%252BStrategy%252Bfor%252Bthe%252BDevelopment%252Bof%252BPotent%252BBivalent%252BERK%252BInhibitors%26aulast%3DLechtenberg%26aufirst%3DBernhard%2BC.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D22032017%26date%3D12062017%26date%3D15062017%26date%3D13072017%26date%3D12062017%26volume%3D8%26issue%3D7%26spage%3D726%26epage%3D731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard A.  Ward</span>, <span class="hlFld-ContribAuthor ">Paul  Bethel</span>, <span class="hlFld-ContribAuthor ">Calum  Cook</span>, <span class="hlFld-ContribAuthor ">Emma  Davies</span>, <span class="hlFld-ContribAuthor ">Judit E.  Debreczeni</span>, <span class="hlFld-ContribAuthor ">Gary  Fairley</span>, <span class="hlFld-ContribAuthor ">Lyman  Feron</span>, <span class="hlFld-ContribAuthor ">Vikki  Flemington</span>, <span class="hlFld-ContribAuthor ">Mark A.  Graham</span>, <span class="hlFld-ContribAuthor ">Ryan  Greenwood</span>, <span class="hlFld-ContribAuthor ">Nicola  Griffin</span>, <span class="hlFld-ContribAuthor ">Lyndsey  Hanson</span>, <span class="hlFld-ContribAuthor ">Philip  Hopcroft</span>, <span class="hlFld-ContribAuthor ">Tina D.  Howard</span>, <span class="hlFld-ContribAuthor ">Julian  Hudson</span>, <span class="hlFld-ContribAuthor ">Michael  James</span>, <span class="hlFld-ContribAuthor ">Clifford D.  Jones</span>, <span class="hlFld-ContribAuthor ">Christopher R.  Jones</span>, <span class="hlFld-ContribAuthor ">Scott  Lamont</span>, <span class="hlFld-ContribAuthor ">Richard  Lewis</span>, <span class="hlFld-ContribAuthor ">Nicola  Lindsay</span>, <span class="hlFld-ContribAuthor ">Karen  Roberts</span>, <span class="hlFld-ContribAuthor ">Iain  Simpson</span>, <span class="hlFld-ContribAuthor ">Steve  St-Gallay</span>, <span class="hlFld-ContribAuthor ">Steve  Swallow</span>, <span class="hlFld-ContribAuthor ">Jia  Tang</span>, <span class="hlFld-ContribAuthor ">Michael  Tonge</span>, <span class="hlFld-ContribAuthor ">Zhenhua  Wang</span>, and <span class="hlFld-ContribAuthor ">Baochang  Zhai</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (8)
                                     , 3438-3450. <a href="https://doi.org/10.1021/acs.jmedchem.7b00267" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00267</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00267%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Guided%252BDiscovery%252Bof%252BPotent%252Band%252BSelective%252BInhibitors%252Bof%252BERK1%25252F2%252Bfrom%252Ba%252BModestly%252BActive%252Band%252BPromiscuous%252BChemical%252BStart%252BPoint%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D21022017%26date%3D14042017%26date%3D27042017%26date%3D04042017%26volume%3D60%26issue%3D8%26spage%3D3438%26epage%3D3450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Yueshan  Li</span>, <span class="hlFld-ContribAuthor ">Liang  Xiong</span>, <span class="hlFld-ContribAuthor ">Wenjing  Wang</span>, <span class="hlFld-ContribAuthor ">Ming  Wu</span>, <span class="hlFld-ContribAuthor ">Ting  Yuan</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Chenyu  Tian</span>, <span class="hlFld-ContribAuthor ">Zhuang  Miao</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2021,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-021-00572-w" title="DOI URL">https://doi.org/10.1038/s41392-021-00572-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-021-00572-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-021-00572-w%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DSmall%252Bmolecules%252Bin%252Btargeted%252Bcancer%252Btherapy%25253A%252Badvances%25252C%252Bchallenges%25252C%252Band%252Bfuture%252Bperspectives%26aulast%3DZhong%26aufirst%3DLei%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samira  Mansouri</span>, <span class="hlFld-ContribAuthor ">Himanshu  Gogoi</span>, <span class="hlFld-ContribAuthor ">Mauricio  Pipkin</span>, <span class="hlFld-ContribAuthor ">Tiago N.  Machuca</span>, <span class="hlFld-ContribAuthor ">Amir M.  Emtiazjoo</span>, <span class="hlFld-ContribAuthor ">Ashish K.  Sharma</span>, <span class="hlFld-ContribAuthor ">Lei  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">In vivo reprogramming of pathogenic lung TNFR2
              +
              cDC2s by IFNβ inhibits HDM-induced asthma. </span><span class="cited-content_cbyCitation_journal-name">Science Immunology</span><span> <strong>2021,</strong> <em>6 </em>
                                    (61)
                                     , eabi8472. <a href="https://doi.org/10.1126/sciimmunol.abi8472" title="DOI URL">https://doi.org/10.1126/sciimmunol.abi8472</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/sciimmunol.abi8472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fsciimmunol.abi8472%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Immunology%26atitle%3DIn%252Bvivo%252Breprogramming%252Bof%252Bpathogenic%252Blung%252BTNFR2%252B%25252B%252BcDC2s%252Bby%252BIFN%2525CE%2525B2%252Binhibits%252BHDM-induced%252Basthma%26aulast%3DMansouri%26aufirst%3DSamira%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D61%26spage%3Deabi8472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Victor CY  Mak</span>, <span class="hlFld-ContribAuthor ">Xinran  Li</span>, <span class="hlFld-ContribAuthor ">Ling  Rao</span>, <span class="hlFld-ContribAuthor ">Yuan  Zhou</span>, <span class="hlFld-ContribAuthor ">Sai-Wah  Tsao</span>, <span class="hlFld-ContribAuthor ">Lydia WT  Cheung</span>. </span><span class="cited-content_cbyCitation_article-title">p85β alters response to EGFR inhibitor in ovarian cancer through p38 MAPK-mediated regulation of DNA repair. </span><span class="cited-content_cbyCitation_journal-name">Neoplasia</span><span> <strong>2021,</strong> <em>23 </em>
                                    (7)
                                     , 718-730. <a href="https://doi.org/10.1016/j.neo.2021.05.009" title="DOI URL">https://doi.org/10.1016/j.neo.2021.05.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neo.2021.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neo.2021.05.009%26sid%3Dliteratum%253Aachs%26jtitle%3DNeoplasia%26atitle%3Dp85%2525CE%2525B2%252Balters%252Bresponse%252Bto%252BEGFR%252Binhibitor%252Bin%252Bovarian%252Bcancer%252Bthrough%252Bp38%252BMAPK-mediated%252Bregulation%252Bof%252BDNA%252Brepair%26aulast%3DMak%26aufirst%3DVictor%2BCY%26date%3D2021%26volume%3D23%26issue%3D7%26spage%3D718%26epage%3D730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana  Portelinha</span>, <span class="hlFld-ContribAuthor ">Scott  Thompson</span>, <span class="hlFld-ContribAuthor ">Roger A.  Smith</span>, <span class="hlFld-ContribAuthor ">Mariana  Da Silva Ferreira</span>, <span class="hlFld-ContribAuthor ">Zahra  Asgari</span>, <span class="hlFld-ContribAuthor ">Andrea  Knezevic</span>, <span class="hlFld-ContribAuthor ">Venkatraman  Seshan</span>, <span class="hlFld-ContribAuthor ">Elisa  de Stanchina</span>, <span class="hlFld-ContribAuthor ">Sandeep  Gupta</span>, <span class="hlFld-ContribAuthor ">Louis  Denis</span>, <span class="hlFld-ContribAuthor ">Anas  Younes</span>, <span class="hlFld-ContribAuthor ">Sanjeeva  Reddy</span>. </span><span class="cited-content_cbyCitation_article-title">ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. </span><span class="cited-content_cbyCitation_journal-name">Cell Reports Medicine</span><span> <strong>2021,</strong> <em>2 </em>
                                    (7)
                                     , 100350. <a href="https://doi.org/10.1016/j.xcrm.2021.100350" title="DOI URL">https://doi.org/10.1016/j.xcrm.2021.100350</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.xcrm.2021.100350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.xcrm.2021.100350%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Reports%2520Medicine%26atitle%3DASN007%252Bis%252Ba%252Bselective%252BERK1%25252F2%252Binhibitor%252Bwith%252Bpreferential%252Bactivity%252Bagainst%252BRAS-and%252BRAF-mutant%252Btumors%26aulast%3DPortelinha%26aufirst%3DAna%26date%3D2021%26volume%3D2%26issue%3D7%26spage%3D100350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Zhu</span>, <span class="hlFld-ContribAuthor ">Jingxiang  Wang</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Mingjing  Gao</span>, <span class="hlFld-ContribAuthor ">Bingbing  Guo</span>, <span class="hlFld-ContribAuthor ">Miaomiao  Gao</span>, <span class="hlFld-ContribAuthor ">Jiarui  Liu</span>, <span class="hlFld-ContribAuthor ">Yanqiu  Yu</span>, <span class="hlFld-ContribAuthor ">Liang  Wang</span>, <span class="hlFld-ContribAuthor ">Weikaixin  Kong</span>, <span class="hlFld-ContribAuthor ">Yongpan  An</span>, <span class="hlFld-ContribAuthor ">Zurui  Liu</span>, <span class="hlFld-ContribAuthor ">Xinpei  Sun</span>, <span class="hlFld-ContribAuthor ">Zhuo  Huang</span>, <span class="hlFld-ContribAuthor ">Hong  Zhou</span>, <span class="hlFld-ContribAuthor ">Ning  Zhang</span>, <span class="hlFld-ContribAuthor ">Ruimao  Zheng</span>, <span class="hlFld-ContribAuthor ">Zhengwei  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Prediction of drug efficacy from transcriptional profiles with deep learning. </span><span class="cited-content_cbyCitation_journal-name">Nature Biotechnology</span><span> <strong>2021,</strong> <em>60 </em><a href="https://doi.org/10.1038/s41587-021-00946-z" title="DOI URL">https://doi.org/10.1038/s41587-021-00946-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41587-021-00946-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41587-021-00946-z%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Biotechnology%26atitle%3DPrediction%252Bof%252Bdrug%252Befficacy%252Bfrom%252Btranscriptional%252Bprofiles%252Bwith%252Bdeep%252Blearning%26aulast%3DZhu%26aufirst%3DJie%26date%3D2021%26date%3D2021%26volume%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rahim  Ullah</span>, <span class="hlFld-ContribAuthor ">Qing  Yin</span>, <span class="hlFld-ContribAuthor ">Aidan H.  Snell</span>, <span class="hlFld-ContribAuthor ">Lixin  Wan</span>. </span><span class="cited-content_cbyCitation_article-title">RAF-MEK-ERK pathway in cancer evolution and treatment. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2021,</strong> <em>84 </em><a href="https://doi.org/10.1016/j.semcancer.2021.05.010" title="DOI URL">https://doi.org/10.1016/j.semcancer.2021.05.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2021.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2021.05.010%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DRAF-MEK-ERK%252Bpathway%252Bin%252Bcancer%252Bevolution%252Band%252Btreatment%26aulast%3DUllah%26aufirst%3DRahim%26date%3D2021%26volume%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jens  Köhler</span>, <span class="hlFld-ContribAuthor ">Yutong  Zhao</span>, <span class="hlFld-ContribAuthor ">Jiaqi  Li</span>, <span class="hlFld-ContribAuthor ">Prafulla C.  Gokhale</span>, <span class="hlFld-ContribAuthor ">Hong L.  Tiv</span>, <span class="hlFld-ContribAuthor ">Aine R.  Knott</span>, <span class="hlFld-ContribAuthor ">Margaret K.  Wilkens</span>, <span class="hlFld-ContribAuthor ">Kara M.  Soroko</span>, <span class="hlFld-ContribAuthor ">Mika  Lin</span>, <span class="hlFld-ContribAuthor ">Chiara  Ambrogio</span>, <span class="hlFld-ContribAuthor ">Monica  Musteanu</span>, <span class="hlFld-ContribAuthor ">Atsuko  Ogino</span>, <span class="hlFld-ContribAuthor ">Jihyun  Choi</span>, <span class="hlFld-ContribAuthor ">Magda  Bahcall</span>, <span class="hlFld-ContribAuthor ">Arrien A.  Bertram</span>, <span class="hlFld-ContribAuthor ">Emily S.  Chambers</span>, <span class="hlFld-ContribAuthor ">Cloud P.  Paweletz</span>, <span class="hlFld-ContribAuthor ">Shripad V.  Bhagwat</span>, <span class="hlFld-ContribAuthor ">Jason R.  Manro</span>, <span class="hlFld-ContribAuthor ">Ramon V.  Tiu</span>, <span class="hlFld-ContribAuthor ">Pasi A.  Jänne</span>. </span><span class="cited-content_cbyCitation_article-title">ERK Inhibitor LY3214996-Based Treatment Strategies for
              RAS
              -Driven Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2021,</strong> <em>20 </em>
                                    (4)
                                     , 641-654. <a href="https://doi.org/10.1158/1535-7163.MCT-20-0531" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-20-0531</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-20-0531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-20-0531%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DERK%252BInhibitor%252BLY3214996-Based%252BTreatment%252BStrategies%252Bfor%252BRAS%252B-Driven%252BLung%252BCancer%26aulast%3DK%25C3%25B6hler%26aufirst%3DJens%26date%3D2021%26date%3D2021%26volume%3D20%26issue%3D4%26spage%3D641%26epage%3D654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhipeng  Wu</span>, <span class="hlFld-ContribAuthor ">Langhai  Xu</span>, <span class="hlFld-ContribAuthor ">Yuzhe  He</span>, <span class="hlFld-ContribAuthor ">Kai  Xu</span>, <span class="hlFld-ContribAuthor ">Zhonggai  Chen</span>, <span class="hlFld-ContribAuthor ">Safwat Adel Abdo  Moqbel</span>, <span class="hlFld-ContribAuthor ">Chiyuan  Ma</span>, <span class="hlFld-ContribAuthor ">Lifeng  Jiang</span>, <span class="hlFld-ContribAuthor ">Jisheng  Ran</span>, <span class="hlFld-ContribAuthor ">Lidong  Wu</span>, <span class="hlFld-ContribAuthor ">Ying  Zhong</span>. </span><span class="cited-content_cbyCitation_article-title">DUSP5 suppresses interleukin-1β-induced chondrocyte inflammation and ameliorates osteoarthritis in rats. </span><span class="cited-content_cbyCitation_journal-name">Aging</span><span> <strong>2020,</strong> <em>12 </em>
                                    (24)
                                     , 26029-26046. <a href="https://doi.org/10.18632/aging.202252" title="DOI URL">https://doi.org/10.18632/aging.202252</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/aging.202252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Faging.202252%26sid%3Dliteratum%253Aachs%26jtitle%3DAging%26atitle%3DDUSP5%252Bsuppresses%252Binterleukin-1%2525CE%2525B2-induced%252Bchondrocyte%252Binflammation%252Band%252Bameliorates%252Bosteoarthritis%252Bin%252Brats%26aulast%3DWu%26aufirst%3DZhipeng%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D24%26spage%3D26029%26epage%3D26046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingzhi  Zhang</span>, <span class="hlFld-ContribAuthor ">Qiurong  Ju</span>, <span class="hlFld-ContribAuthor ">Jinjin  Sun</span>, <span class="hlFld-ContribAuthor ">Lei  Huang</span>, <span class="hlFld-ContribAuthor ">Shiqi  Wu</span>, <span class="hlFld-ContribAuthor ">Shuping  Wang</span>, <span class="hlFld-ContribAuthor ">Yin  Li</span>, <span class="hlFld-ContribAuthor ">Zhe  Guan</span>, <span class="hlFld-ContribAuthor ">Qihua  Zhu</span>, <span class="hlFld-ContribAuthor ">Yungen  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Dual Extracellular Regulated Protein Kinases (ERK) and Phosphoinositide 3-Kinase (PI3K) Inhibitors as a Promising Strategy for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (23)
                                     , 5693. <a href="https://doi.org/10.3390/molecules25235693" title="DOI URL">https://doi.org/10.3390/molecules25235693</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25235693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25235693%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDiscovery%252Bof%252BNovel%252BDual%252BExtracellular%252BRegulated%252BProtein%252BKinases%252B%252528ERK%252529%252Band%252BPhosphoinositide%252B3-Kinase%252B%252528PI3K%252529%252BInhibitors%252Bas%252Ba%252BPromising%252BStrategy%252Bfor%252BCancer%252BTherapy%26aulast%3DZhang%26aufirst%3DLingzhi%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D23%26spage%3D5693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seham S.  El-Hawwary</span>, <span class="hlFld-ContribAuthor ">Fatema R.  Saber</span>, <span class="hlFld-ContribAuthor ">Hanan M.  Abd Almaksoud</span>, <span class="hlFld-ContribAuthor ">Hanan  Elimam</span>, <span class="hlFld-ContribAuthor ">Ahmed M.  Sayed</span>, <span class="hlFld-ContribAuthor ">Usama Ramadan  Abdelmohsen</span>. </span><span class="cited-content_cbyCitation_article-title">Cytotoxic potential of three Sabal species grown in Egypt: a metabolomic and docking-based study. </span><span class="cited-content_cbyCitation_journal-name">Natural Product Research</span><span> <strong>2020,</strong> <em>11 </em>, 1-6. <a href="https://doi.org/10.1080/14786419.2020.1851228" title="DOI URL">https://doi.org/10.1080/14786419.2020.1851228</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14786419.2020.1851228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14786419.2020.1851228%26sid%3Dliteratum%253Aachs%26jtitle%3DNatural%2520Product%2520Research%26atitle%3DCytotoxic%252Bpotential%252Bof%252Bthree%252BSabal%252Bspecies%252Bgrown%252Bin%252BEgypt%25253A%252Ba%252Bmetabolomic%252Band%252Bdocking-based%252Bstudy%26aulast%3DEl-Hawwary%26aufirst%3DSeham%2BS.%26date%3D2020%26date%3D2020%26volume%3D11%26spage%3D1%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ulrich  Grädler</span>, <span class="hlFld-ContribAuthor ">Michael  Busch</span>, <span class="hlFld-ContribAuthor ">Birgitta  Leuthner</span>, <span class="hlFld-ContribAuthor ">Michael  Raba</span>, <span class="hlFld-ContribAuthor ">Lars  Burgdorf</span>, <span class="hlFld-ContribAuthor ">Martin  Lehmann</span>, <span class="hlFld-ContribAuthor ">Nina  Linde</span>, <span class="hlFld-ContribAuthor ">Christina  Esdar</span>. </span><span class="cited-content_cbyCitation_article-title">Biochemical, cellular and structural characterization of novel and selective ERK3 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (22)
                                     , 127551. <a href="https://doi.org/10.1016/j.bmcl.2020.127551" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127551</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127551%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DBiochemical%25252C%252Bcellular%252Band%252Bstructural%252Bcharacterization%252Bof%252Bnovel%252Band%252Bselective%252BERK3%252Binhibitors%26aulast%3DGr%25C3%25A4dler%26aufirst%3DUlrich%26date%3D2020%26volume%3D30%26issue%3D22%26spage%3D127551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Colin  Weekes</span>, <span class="hlFld-ContribAuthor ">Albert  Lockhart</span>, <span class="hlFld-ContribAuthor ">Patricia  LoRusso</span>, <span class="hlFld-ContribAuthor ">Elaine  Murray</span>, <span class="hlFld-ContribAuthor ">Erica  Park</span>, <span class="hlFld-ContribAuthor ">Mike  Tagen</span>, <span class="hlFld-ContribAuthor ">Jatinder  Singh</span>, <span class="hlFld-ContribAuthor ">Indrani  Sarkar</span>, <span class="hlFld-ContribAuthor ">Lars  Mueller</span>, <span class="hlFld-ContribAuthor ">Hatem  Dokainish</span>, <span class="hlFld-ContribAuthor ">Geoffrey  Shapiro</span>, <span class="hlFld-ContribAuthor ">Howard  Burris</span>. </span><span class="cited-content_cbyCitation_article-title">A Phase Ib Study to Evaluate the
              MEK
              Inhibitor Cobimetinib in Combination with the
              ERK1
              /2 Inhibitor
              GDC
              ‐0994 in Patients with Advanced Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">The Oncologist</span><span> <strong>2020,</strong> <em>25 </em>
                                    (10)
                                     , 833. <a href="https://doi.org/10.1634/theoncologist.2020-0292" title="DOI URL">https://doi.org/10.1634/theoncologist.2020-0292</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1634/theoncologist.2020-0292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1634%2Ftheoncologist.2020-0292%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Oncologist%26atitle%3DA%252BPhase%252BIb%252BStudy%252Bto%252BEvaluate%252Bthe%252BMEK%252BInhibitor%252BCobimetinib%252Bin%252BCombination%252Bwith%252Bthe%252BERK1%252B%25252F2%252BInhibitor%252BGDC%252B%2525E2%252580%2525900994%252Bin%252BPatients%252Bwith%252BAdvanced%252BSolid%252BTumors%26aulast%3DWeekes%26aufirst%3DColin%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D10%26spage%3D833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rory  Mitchell</span>, <span class="hlFld-ContribAuthor ">Marta  Mikolajczak</span>, <span class="hlFld-ContribAuthor ">Christian  Kersten</span>, <span class="hlFld-ContribAuthor ">Sue  Fleetwood-Walker</span>. </span><span class="cited-content_cbyCitation_article-title">ErbB1-dependent signalling and vesicular trafficking in primary afferent nociceptors associated with hypersensitivity in neuropathic pain. </span><span class="cited-content_cbyCitation_journal-name">Neurobiology of Disease</span><span> <strong>2020,</strong> <em>142 </em>, 104961. <a href="https://doi.org/10.1016/j.nbd.2020.104961" title="DOI URL">https://doi.org/10.1016/j.nbd.2020.104961</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nbd.2020.104961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nbd.2020.104961%26sid%3Dliteratum%253Aachs%26jtitle%3DNeurobiology%2520of%2520Disease%26atitle%3DErbB1-dependent%252Bsignalling%252Band%252Bvesicular%252Btrafficking%252Bin%252Bprimary%252Bafferent%252Bnociceptors%252Bassociated%252Bwith%252Bhypersensitivity%252Bin%252Bneuropathic%252Bpain%26aulast%3DMitchell%26aufirst%3DRory%26date%3D2020%26volume%3D142%26spage%3D104961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryan H.  Takahashi</span>, <span class="hlFld-ContribAuthor ">Jessica M.  Grandner</span>, <span class="hlFld-ContribAuthor ">Sudheer  Bobba</span>, <span class="hlFld-ContribAuthor ">Yanzhou  Liu</span>, <span class="hlFld-ContribAuthor ">Paul  Beroza</span>, <span class="hlFld-ContribAuthor ">Donglu  Zhang</span>, <span class="hlFld-ContribAuthor ">Shuguang  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Homodimer Metabolites of GDC-0994 via Cytochrome P450–Catalyzed Radical Coupling. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2020,</strong> <em>48 </em>
                                    (6)
                                     , 521-527. <a href="https://doi.org/10.1124/dmd.119.090019" title="DOI URL">https://doi.org/10.1124/dmd.119.090019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.119.090019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.119.090019%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DNovel%252BHomodimer%252BMetabolites%252Bof%252BGDC-0994%252Bvia%252BCytochrome%252BP450%2525E2%252580%252593Catalyzed%252BRadical%252BCoupling%26aulast%3DTakahashi%26aufirst%3DRyan%2BH.%26date%3D2020%26date%3D2020%26volume%3D48%26issue%3D6%26spage%3D521%26epage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carolien  van Alphen</span>, <span class="hlFld-ContribAuthor ">Jacqueline  Cloos</span>, <span class="hlFld-ContribAuthor ">Robin  Beekhof</span>, <span class="hlFld-ContribAuthor ">David G.J.  Cucchi</span>, <span class="hlFld-ContribAuthor ">Sander R.  Piersma</span>, <span class="hlFld-ContribAuthor ">Jaco C.  Knol</span>, <span class="hlFld-ContribAuthor ">Alex A.  Henneman</span>, <span class="hlFld-ContribAuthor ">Thang V.  Pham</span>, <span class="hlFld-ContribAuthor ">Johan  van Meerloo</span>, <span class="hlFld-ContribAuthor ">Gert J.  Ossenkoppele</span>, <span class="hlFld-ContribAuthor ">Henk M.W.  Verheul</span>, <span class="hlFld-ContribAuthor ">Jeroen J.W.M.  Janssen</span>, <span class="hlFld-ContribAuthor ">Connie R.  Jimenez</span>. </span><span class="cited-content_cbyCitation_article-title">Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">Molecular & Cellular Proteomics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (5)
                                     , 884-899. <a href="https://doi.org/10.1074/mcp.RA119.001504" title="DOI URL">https://doi.org/10.1074/mcp.RA119.001504</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/mcp.RA119.001504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fmcp.RA119.001504%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520%2526%2520Cellular%2520Proteomics%26atitle%3DPhosphotyrosine-based%252BPhosphoproteomics%252Bfor%252BTarget%252BIdentification%252Band%252BDrug%252BResponse%252BPrediction%252Bin%252BAML%252BCell%252BLines%26aulast%3Dvan%2BAlphen%26aufirst%3DCarolien%26date%3D2020%26volume%3D19%26issue%3D5%26spage%3D884%26epage%3D899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H. S.  Abd-Elghaffar</span>, <span class="hlFld-ContribAuthor ">M. A.  El-Hashash</span>, <span class="hlFld-ContribAuthor ">S. F.  Mohamed</span>, <span class="hlFld-ContribAuthor ">A. A.  Ibrahim</span>, <span class="hlFld-ContribAuthor ">A. E.  Amr</span>, <span class="hlFld-ContribAuthor ">M. A.  Al-Omar</span>, <span class="hlFld-ContribAuthor ">E. S.  Nossier</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Anti-Proliferative Activity of Novel Tricyclic Compounds Derived from 2-Substituted 1,3-Indandione. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of General Chemistry</span><span> <strong>2020,</strong> <em>90 </em>
                                    (4)
                                     , 686-696. <a href="https://doi.org/10.1134/S1070363220040209" title="DOI URL">https://doi.org/10.1134/S1070363220040209</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070363220040209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070363220040209%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520General%2520Chemistry%26atitle%3DSynthesis%252Band%252BAnti-Proliferative%252BActivity%252Bof%252BNovel%252BTricyclic%252BCompounds%252BDerived%252Bfrom%252B2-Substituted%252B1%25252C3-Indandione%26aulast%3DAbd-Elghaffar%26aufirst%3DH.%2BS.%26date%3D2020%26date%3D2020%26volume%3D90%26issue%3D4%26spage%3D686%26epage%3D696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shelly  Pathania</span>, <span class="hlFld-ContribAuthor ">Ravindra K  Rawal</span>. </span><span class="cited-content_cbyCitation_article-title">An update on chemical classes targeting ERK1/2 for the management of cancer. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>200 </em><a href="https://doi.org/10.4155/fmc-2019-0339" title="DOI URL">https://doi.org/10.4155/fmc-2019-0339</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0339%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DAn%252Bupdate%252Bon%252Bchemical%252Bclasses%252Btargeting%252BERK1%25252F2%252Bfor%252Bthe%252Bmanagement%252Bof%252Bcancer%26aulast%3DPathania%26aufirst%3DShelly%26date%3D2020%26date%3D2020%26volume%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea  Varga</span>, <span class="hlFld-ContribAuthor ">Jean-Charles  Soria</span>, <span class="hlFld-ContribAuthor ">Antoine  Hollebecque</span>, <span class="hlFld-ContribAuthor ">Patricia  LoRusso</span>, <span class="hlFld-ContribAuthor ">Johanna  Bendell</span>, <span class="hlFld-ContribAuthor ">Shih-Min A.  Huang</span>, <span class="hlFld-ContribAuthor ">Marie-Claire  Wagle</span>, <span class="hlFld-ContribAuthor ">Kwame  Okrah</span>, <span class="hlFld-ContribAuthor ">Lichuan  Liu</span>, <span class="hlFld-ContribAuthor ">Elaine  Murray</span>, <span class="hlFld-ContribAuthor ">Sandra M.  Sanabria-Bohorquez</span>, <span class="hlFld-ContribAuthor ">Michael  Tagen</span>, <span class="hlFld-ContribAuthor ">Hatem  Dokainish</span>, <span class="hlFld-ContribAuthor ">Lars  Mueller</span>, <span class="hlFld-ContribAuthor ">Howard  Burris</span>. </span><span class="cited-content_cbyCitation_article-title">A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2020,</strong> <em>26 </em>
                                    (6)
                                     , 1229-1236. <a href="https://doi.org/10.1158/1078-0432.CCR-19-2574" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-19-2574</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-19-2574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-19-2574%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DA%252BFirst-in-Human%252BPhase%252BI%252BStudy%252Bto%252BEvaluate%252Bthe%252BERK1%25252F2%252BInhibitor%252BGDC-0994%252Bin%252BPatients%252Bwith%252BAdvanced%252BSolid%252BTumors%26aulast%3DVarga%26aufirst%3DAndrea%26date%3D2020%26date%3D2019%26volume%3D26%26issue%3D6%26spage%3D1229%26epage%3D1236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Longfei  Miao</span>, <span class="hlFld-ContribAuthor ">Hongqi  Tian</span>. </span><span class="cited-content_cbyCitation_article-title">Development of ERK1/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Drug Targeting</span><span> <strong>2020,</strong> <em>28 </em>
                                    (2)
                                     , 154-165. <a href="https://doi.org/10.1080/1061186X.2019.1648477" title="DOI URL">https://doi.org/10.1080/1061186X.2019.1648477</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1061186X.2019.1648477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1061186X.2019.1648477%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Drug%2520Targeting%26atitle%3DDevelopment%252Bof%252BERK1%25252F2%252Binhibitors%252Bas%252Ba%252Btherapeutic%252Bstrategy%252Bfor%252Btumour%252Bwith%252BMAPK%252Bupstream%252Btarget%252Bmutations%26aulast%3DMiao%26aufirst%3DLongfei%26date%3D2020%26date%3D2019%26volume%3D28%26issue%3D2%26spage%3D154%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shripad V.  Bhagwat</span>, <span class="hlFld-ContribAuthor ">William T.  McMillen</span>, <span class="hlFld-ContribAuthor ">Shufen  Cai</span>, <span class="hlFld-ContribAuthor ">Baohui  Zhao</span>, <span class="hlFld-ContribAuthor ">Matthew  Whitesell</span>, <span class="hlFld-ContribAuthor ">Weihua  Shen</span>, <span class="hlFld-ContribAuthor ">Lisa  Kindler</span>, <span class="hlFld-ContribAuthor ">Robert S.  Flack</span>, <span class="hlFld-ContribAuthor ">Wenjuan  Wu</span>, <span class="hlFld-ContribAuthor ">Bryan  Anderson</span>, <span class="hlFld-ContribAuthor ">Yan  Zhai</span>, <span class="hlFld-ContribAuthor ">Xiu-Juan  Yuan</span>, <span class="hlFld-ContribAuthor ">Meghann  Pogue</span>, <span class="hlFld-ContribAuthor ">Robert D.  Van Horn</span>, <span class="hlFld-ContribAuthor ">Xi  Rao</span>, <span class="hlFld-ContribAuthor ">Denis  McCann</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Dropsey</span>, <span class="hlFld-ContribAuthor ">Jason  Manro</span>, <span class="hlFld-ContribAuthor ">Jennie  Walgren</span>, <span class="hlFld-ContribAuthor ">Eunice  Yuen</span>, <span class="hlFld-ContribAuthor ">Michael J.  Rodriguez</span>, <span class="hlFld-ContribAuthor ">Gregory D.  Plowman</span>, <span class="hlFld-ContribAuthor ">Ramon V.  Tiu</span>, <span class="hlFld-ContribAuthor ">Sajan  Joseph</span>, <span class="hlFld-ContribAuthor ">Sheng-Bin  Peng</span>. </span><span class="cited-content_cbyCitation_article-title">ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (2)
                                     , 325-336. <a href="https://doi.org/10.1158/1535-7163.MCT-19-0183" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-19-0183</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-19-0183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-19-0183%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DERK%252BInhibitor%252BLY3214996%252BTargets%252BERK%252BPathway%2525E2%252580%252593Driven%252BCancers%25253A%252BA%252BTherapeutic%252BApproach%252BToward%252BPrecision%252BMedicine%26aulast%3DBhagwat%26aufirst%3DShripad%2BV.%26date%3D2020%26date%3D2019%26volume%3D19%26issue%3D2%26spage%3D325%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew M.  Kidger</span>, <span class="hlFld-ContribAuthor ">Joanne M.  Munck</span>, <span class="hlFld-ContribAuthor ">Harpreet K.  Saini</span>, <span class="hlFld-ContribAuthor ">Kathryn  Balmanno</span>, <span class="hlFld-ContribAuthor ">Emma  Minihane</span>, <span class="hlFld-ContribAuthor ">Aurelie  Courtin</span>, <span class="hlFld-ContribAuthor ">Brent  Graham</span>, <span class="hlFld-ContribAuthor ">Marc  O'Reilly</span>, <span class="hlFld-ContribAuthor ">Richard  Odle</span>, <span class="hlFld-ContribAuthor ">Simon J.  Cook</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (2)
                                     , 525-539. <a href="https://doi.org/10.1158/1535-7163.MCT-19-0505" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-19-0505</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-19-0505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-19-0505%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DDual-Mechanism%252BERK1%25252F2%252BInhibitors%252BExploit%252Ba%252BDistinct%252BBinding%252BMode%252Bto%252BBlock%252BPhosphorylation%252Band%252BNuclear%252BAccumulation%252Bof%252BERK1%25252F2%26aulast%3DKidger%26aufirst%3DAndrew%2BM.%26date%3D2020%26date%3D2019%26volume%3D19%26issue%3D2%26spage%3D525%26epage%3D539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hima  Patel</span>, <span class="hlFld-ContribAuthor ">Nour  Yacoub</span>, <span class="hlFld-ContribAuthor ">Rosalin  Mishra</span>, <span class="hlFld-ContribAuthor ">Aaron  White</span>, <span class="hlFld-ContribAuthor ">Long  Yuan</span>, <span class="hlFld-ContribAuthor ">Samar  Alanazi</span>, <span class="hlFld-ContribAuthor ">Joan T.  Garrett</span>. </span><span class="cited-content_cbyCitation_article-title">Current Advances in the Treatment of BRAF-Mutant Melanoma. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (2)
                                     , 482. <a href="https://doi.org/10.3390/cancers12020482" title="DOI URL">https://doi.org/10.3390/cancers12020482</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12020482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12020482%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DCurrent%252BAdvances%252Bin%252Bthe%252BTreatment%252Bof%252BBRAF-Mutant%252BMelanoma%26aulast%3DPatel%26aufirst%3DHima%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D2%26spage%3D482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingbin  Kong</span>, <span class="hlFld-ContribAuthor ">Rong  Huang</span>, <span class="hlFld-ContribAuthor ">Haodan  He</span>, <span class="hlFld-ContribAuthor ">Yunxiang  Fan</span>, <span class="hlFld-ContribAuthor ">Jun  Lin</span>, <span class="hlFld-ContribAuthor ">Shengjiao  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-component solvent-free cascade reaction of 2-cyanoacetamides: regioselective synthesis of pyridin-2-ones bearing quaternary centers. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2020,</strong> <em>22 </em>
                                    (1)
                                     , 256-264. <a href="https://doi.org/10.1039/C9GC03692J" title="DOI URL">https://doi.org/10.1039/C9GC03692J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9GC03692J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9GC03692J%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DMulti-component%252Bsolvent-free%252Bcascade%252Breaction%252Bof%252B2-cyanoacetamides%25253A%252Bregioselective%252Bsynthesis%252Bof%252Bpyridin-2-ones%252Bbearing%252Bquaternary%252Bcenters%26aulast%3DKong%26aufirst%3DLingbin%26date%3D2020%26date%3D2020%26volume%3D22%26issue%3D1%26spage%3D256%26epage%3D264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">V. Prakash  Reddy</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmaceutical applications of organofluorine compounds. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 133-214. <a href="https://doi.org/10.1016/B978-0-12-813286-9.00005-5" title="DOI URL">https://doi.org/10.1016/B978-0-12-813286-9.00005-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-813286-9.00005-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-813286-9.00005-5%26sid%3Dliteratum%253Aachs%26atitle%3DPharmaceutical%252Bapplications%252Bof%252Borganofluorine%252Bcompounds%26aulast%3DReddy%26aufirst%3DV.%2BPrakash%26date%3D2020%26spage%3D133%26epage%3D214%26pub%3DElsevier%26atitle%3DOrganofluorine%252BChemistry%26date%3D2020%26volume%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karina  Smorodinsky-Atias</span>, <span class="hlFld-ContribAuthor ">Nadine  Soudah</span>, <span class="hlFld-ContribAuthor ">David  Engelberg</span>. </span><span class="cited-content_cbyCitation_article-title">Mutations That Confer Drug-Resistance, Oncogenicity and Intrinsic Activity on the ERK MAP Kinases—Current State of the Art. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2020,</strong> <em>9 </em>
                                    (1)
                                     , 129. <a href="https://doi.org/10.3390/cells9010129" title="DOI URL">https://doi.org/10.3390/cells9010129</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells9010129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells9010129%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DMutations%252BThat%252BConfer%252BDrug-Resistance%25252C%252BOncogenicity%252Band%252BIntrinsic%252BActivity%252Bon%252Bthe%252BERK%252BMAP%252BKinases%2525E2%252580%252594Current%252BState%252Bof%252Bthe%252BArt%26aulast%3DSmorodinsky-Atias%26aufirst%3DKarina%26date%3D2020%26date%3D2020%26volume%3D9%26issue%3D1%26spage%3D129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daiane J.  Viegas</span>, <span class="hlFld-ContribAuthor ">Terri G.  Edwards</span>, <span class="hlFld-ContribAuthor ">David C.  Bloom</span>, <span class="hlFld-ContribAuthor ">Paula A.  Abreu</span>. </span><span class="cited-content_cbyCitation_article-title">Virtual screening identified compounds that bind to cyclin dependent kinase 2 and prevent herpes simplex virus type 1 replication and reactivation in neurons. </span><span class="cited-content_cbyCitation_journal-name">Antiviral Research</span><span> <strong>2019,</strong> <em>172 </em>, 104621. <a href="https://doi.org/10.1016/j.antiviral.2019.104621" title="DOI URL">https://doi.org/10.1016/j.antiviral.2019.104621</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.antiviral.2019.104621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.antiviral.2019.104621%26sid%3Dliteratum%253Aachs%26jtitle%3DAntiviral%2520Research%26atitle%3DVirtual%252Bscreening%252Bidentified%252Bcompounds%252Bthat%252Bbind%252Bto%252Bcyclin%252Bdependent%252Bkinase%252B2%252Band%252Bprevent%252Bherpes%252Bsimplex%252Bvirus%252Btype%252B1%252Breplication%252Band%252Breactivation%252Bin%252Bneurons%26aulast%3DViegas%26aufirst%3DDaiane%2BJ.%26date%3D2019%26volume%3D172%26spage%3D104621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pablo  de María</span>, <span class="hlFld-ContribAuthor ">Gonzalo  de Gonzalo</span>, <span class="hlFld-ContribAuthor ">Andrés  Alcántara</span>. </span><span class="cited-content_cbyCitation_article-title">Biocatalysis as Useful Tool in Asymmetric Synthesis: An Assessment of Recently Granted Patents (2014–2019). </span><span class="cited-content_cbyCitation_journal-name">Catalysts</span><span> <strong>2019,</strong> <em>9 </em>
                                    (10)
                                     , 802. <a href="https://doi.org/10.3390/catal9100802" title="DOI URL">https://doi.org/10.3390/catal9100802</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/catal9100802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcatal9100802%26sid%3Dliteratum%253Aachs%26jtitle%3DCatalysts%26atitle%3DBiocatalysis%252Bas%252BUseful%252BTool%252Bin%252BAsymmetric%252BSynthesis%25253A%252BAn%252BAssessment%252Bof%252BRecently%252BGranted%252BPatents%252B%2525282014%2525E2%252580%2525932019%252529%26aulast%3Dde%2BMar%25C3%25ADa%26aufirst%3DPablo%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D10%26spage%3D802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhe  Cao</span>, <span class="hlFld-ContribAuthor ">Qianjin  Liao</span>, <span class="hlFld-ContribAuthor ">Min  Su</span>, <span class="hlFld-ContribAuthor ">Kai  Huang</span>, <span class="hlFld-ContribAuthor ">Junfei  Jin</span>, <span class="hlFld-ContribAuthor ">Deliang  Cao</span>. </span><span class="cited-content_cbyCitation_article-title">AKT and ERK dual inhibitors: The way forward?. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2019,</strong> <em>459 </em>, 30-40. <a href="https://doi.org/10.1016/j.canlet.2019.05.025" title="DOI URL">https://doi.org/10.1016/j.canlet.2019.05.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2019.05.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2019.05.025%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DAKT%252Band%252BERK%252Bdual%252Binhibitors%25253A%252BThe%252Bway%252Bforward%25253F%26aulast%3DCao%26aufirst%3DZhe%26date%3D2019%26volume%3D459%26spage%3D30%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laurel M.  Pegram</span>, <span class="hlFld-ContribAuthor ">Jennifer C.  Liddle</span>, <span class="hlFld-ContribAuthor ">Yao  Xiao</span>, <span class="hlFld-ContribAuthor ">Maria  Hoh</span>, <span class="hlFld-ContribAuthor ">Johannes  Rudolph</span>, <span class="hlFld-ContribAuthor ">Dylan B.  Iverson</span>, <span class="hlFld-ContribAuthor ">Guy P.  Vigers</span>, <span class="hlFld-ContribAuthor ">Darin  Smith</span>, <span class="hlFld-ContribAuthor ">Hailong  Zhang</span>, <span class="hlFld-ContribAuthor ">Weiru  Wang</span>, <span class="hlFld-ContribAuthor ">John G.  Moffat</span>, <span class="hlFld-ContribAuthor ">Natalie G.  Ahn</span>. </span><span class="cited-content_cbyCitation_article-title">Activation loop dynamics are controlled by conformation-selective inhibitors of ERK2. </span><span class="cited-content_cbyCitation_journal-name">Proceedings of the National Academy of Sciences</span><span> <strong>2019,</strong> <em>116 </em>
                                    (31)
                                     , 15463-15468. <a href="https://doi.org/10.1073/pnas.1906824116" title="DOI URL">https://doi.org/10.1073/pnas.1906824116</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1073/pnas.1906824116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1073%2Fpnas.1906824116%26sid%3Dliteratum%253Aachs%26jtitle%3DProceedings%2520of%2520the%2520National%2520Academy%2520of%2520Sciences%26atitle%3DActivation%252Bloop%252Bdynamics%252Bare%252Bcontrolled%252Bby%252Bconformation-selective%252Binhibitors%252Bof%252BERK2%26aulast%3DPegram%26aufirst%3DLaurel%2BM.%26date%3D2019%26date%3D2019%26volume%3D116%26issue%3D31%26spage%3D15463%26epage%3D15468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul A.  Clarke</span>, <span class="hlFld-ContribAuthor ">Toby  Roe</span>, <span class="hlFld-ContribAuthor ">Kate  Swabey</span>, <span class="hlFld-ContribAuthor ">Steve M.  Hobbs</span>, <span class="hlFld-ContribAuthor ">Craig  McAndrew</span>, <span class="hlFld-ContribAuthor ">Kathy  Tomlin</span>, <span class="hlFld-ContribAuthor ">Isaac  Westwood</span>, <span class="hlFld-ContribAuthor ">Rosemary  Burke</span>, <span class="hlFld-ContribAuthor ">Robert  van Montfort</span>, <span class="hlFld-ContribAuthor ">Paul  Workman</span>. </span><span class="cited-content_cbyCitation_article-title">Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer. </span><span class="cited-content_cbyCitation_journal-name">Oncogene</span><span> <strong>2019,</strong> <em>38 </em>
                                    (25)
                                     , 5076-5090. <a href="https://doi.org/10.1038/s41388-019-0780-z" title="DOI URL">https://doi.org/10.1038/s41388-019-0780-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41388-019-0780-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41388-019-0780-z%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogene%26atitle%3DDissecting%252Bmechanisms%252Bof%252Bresistance%252Bto%252Btargeted%252Bdrug%252Bcombination%252Btherapy%252Bin%252Bhuman%252Bcolorectal%252Bcancer%26aulast%3DClarke%26aufirst%3DPaul%2BA.%26date%3D2019%26date%3D2019%26volume%3D38%26issue%3D25%26spage%3D5076%26epage%3D5090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuzhen  Niu</span>, <span class="hlFld-ContribAuthor ">Xiaojun  Yao</span>, <span class="hlFld-ContribAuthor ">Hongfang  Ji</span>. </span><span class="cited-content_cbyCitation_article-title">Importance of protein flexibility in ranking ERK2 Type I
              1/2
              inhibitor affinities: a computational study. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2019,</strong> <em>9 </em>
                                    (22)
                                     , 12441-12454. <a href="https://doi.org/10.1039/C9RA01657K" title="DOI URL">https://doi.org/10.1039/C9RA01657K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9RA01657K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9RA01657K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DImportance%252Bof%252Bprotein%252Bflexibility%252Bin%252Branking%252BERK2%252BType%252BI%252B1%25252F2%252Binhibitor%252Baffinities%25253A%252Ba%252Bcomputational%252Bstudy%26aulast%3DNiu%26aufirst%3DYuzhen%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D22%26spage%3D12441%26epage%3D12454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting ERK1/2 protein-serine/threonine kinases in human cancers. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2019,</strong> <em>142 </em>, 151-168. <a href="https://doi.org/10.1016/j.phrs.2019.01.039" title="DOI URL">https://doi.org/10.1016/j.phrs.2019.01.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2019.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2019.01.039%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DTargeting%252BERK1%25252F2%252Bprotein-serine%25252Fthreonine%252Bkinases%252Bin%252Bhuman%252Bcancers%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2019%26volume%3D142%26spage%3D151%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paola  Savoia</span>, <span class="hlFld-ContribAuthor ">Paolo  Fava</span>, <span class="hlFld-ContribAuthor ">Filippo  Casoni</span>, <span class="hlFld-ContribAuthor ">Ottavio  Cremona</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the ERK Signaling Pathway in Melanoma. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (6)
                                     , 1483. <a href="https://doi.org/10.3390/ijms20061483" title="DOI URL">https://doi.org/10.3390/ijms20061483</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20061483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20061483%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DTargeting%252Bthe%252BERK%252BSignaling%252BPathway%252Bin%252BMelanoma%26aulast%3DSavoia%26aufirst%3DPaola%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D6%26spage%3D1483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashraf A.  Aly</span>, <span class="hlFld-ContribAuthor ">Essmat M.  El-Sheref</span>, <span class="hlFld-ContribAuthor ">Momtaz E.M.  Bakheet</span>, <span class="hlFld-ContribAuthor ">Mai A.E.  Mourad</span>, <span class="hlFld-ContribAuthor ">Stefan  Bräse</span>, <span class="hlFld-ContribAuthor ">Mahmoud A.A.  Ibrahim</span>, <span class="hlFld-ContribAuthor ">Martin  Nieger</span>, <span class="hlFld-ContribAuthor ">Boyan K.  Garvalov</span>, <span class="hlFld-ContribAuthor ">Kevin N.  Dalby</span>, <span class="hlFld-ContribAuthor ">Tamer S.  Kaoud</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>82 </em>, 290-305. <a href="https://doi.org/10.1016/j.bioorg.2018.10.044" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.10.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.10.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.10.044%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bfused%252Bnaphthofuro%25255B3%25252C2-c%25255D%252Bquinoline-6%25252C7%25252C12-triones%252Band%252Bpyrano%25255B3%25252C2-c%25255Dquinoline-6%25252C7%25252C8%25252C13-tetraones%252Bderivatives%252Bas%252BERK%252Binhibitors%252Bwith%252Befficacy%252Bin%252BBRAF-mutant%252Bmelanoma%26aulast%3DAly%26aufirst%3DAshraf%2BA.%26date%3D2019%26volume%3D82%26spage%3D290%26epage%3D305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dezhong  Ji</span>, <span class="hlFld-ContribAuthor ">Lingzhi  Zhang</span>, <span class="hlFld-ContribAuthor ">Qihua  Zhu</span>, <span class="hlFld-ContribAuthor ">Ying  Bai</span>, <span class="hlFld-ContribAuthor ">Yaoyao  Wu</span>, <span class="hlFld-ContribAuthor ">Yungen  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent, orally bioavailable ERK1/2 inhibitors with isoindolin-1-one structure by structure-based drug design. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>164 </em>, 334-341. <a href="https://doi.org/10.1016/j.ejmech.2018.12.040" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.12.040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.12.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.12.040%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%25252C%252Borally%252Bbioavailable%252BERK1%25252F2%252Binhibitors%252Bwith%252Bisoindolin-1-one%252Bstructure%252Bby%252Bstructure-based%252Bdrug%252Bdesign%26aulast%3DJi%26aufirst%3DDezhong%26date%3D2019%26volume%3D164%26spage%3D334%26epage%3D341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ida  Aronchik</span>, <span class="hlFld-ContribAuthor ">Yumin  Dai</span>, <span class="hlFld-ContribAuthor ">Matt  Labenski</span>, <span class="hlFld-ContribAuthor ">Carmen  Barnes</span>, <span class="hlFld-ContribAuthor ">Terri  Jones</span>, <span class="hlFld-ContribAuthor ">Lixin  Qiao</span>, <span class="hlFld-ContribAuthor ">Lisa  Beebe</span>, <span class="hlFld-ContribAuthor ">Mehnaz  Malek</span>, <span class="hlFld-ContribAuthor ">Winfried  Elis</span>, <span class="hlFld-ContribAuthor ">Tao  Shi</span>, <span class="hlFld-ContribAuthor ">Konstantinos  Mavrommatis</span>, <span class="hlFld-ContribAuthor ">Gordon L.  Bray</span>, <span class="hlFld-ContribAuthor ">Ellen H.  Filvaroff</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Research</span><span> <strong>2019,</strong> <em>17 </em>
                                    (2)
                                     , 642-654. <a href="https://doi.org/10.1158/1541-7786.MCR-17-0554" title="DOI URL">https://doi.org/10.1158/1541-7786.MCR-17-0554</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1541-7786.MCR-17-0554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1541-7786.MCR-17-0554%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Research%26atitle%3DEfficacy%252Bof%252Ba%252BCovalent%252BERK1%25252F2%252BInhibitor%25252C%252BCC-90003%25252C%252Bin%252BKRAS-Mutant%252BCancer%252BModels%252BReveals%252BNovel%252BMechanisms%252Bof%252BResponse%252Band%252BResistance%26aulast%3DAronchik%26aufirst%3DIda%26date%3D2019%26date%3D2018%26volume%3D17%26issue%3D2%26spage%3D642%26epage%3D654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ivana  Zagorac</span>, <span class="hlFld-ContribAuthor ">Sara  Fernandez-Gaitero</span>, <span class="hlFld-ContribAuthor ">Renske  Penning</span>, <span class="hlFld-ContribAuthor ">Harm  Post</span>, <span class="hlFld-ContribAuthor ">Maria J.  Bueno</span>, <span class="hlFld-ContribAuthor ">Silvana  Mouron</span>, <span class="hlFld-ContribAuthor ">Luis  Manso</span>, <span class="hlFld-ContribAuthor ">Manuel M.  Morente</span>, <span class="hlFld-ContribAuthor ">Soledad  Alonso</span>, <span class="hlFld-ContribAuthor ">Violeta  Serra</span>, <span class="hlFld-ContribAuthor ">Javier  Muñoz</span>, <span class="hlFld-ContribAuthor ">Gonzalo  Gómez-López</span>, <span class="hlFld-ContribAuthor ">Jose Francisco  Lopez-Acosta</span>, <span class="hlFld-ContribAuthor ">Veronica  Jimenez-Renard</span>, <span class="hlFld-ContribAuthor ">Albert  Gris-Oliver</span>, <span class="hlFld-ContribAuthor ">Fatima  Al-Shahrour</span>, <span class="hlFld-ContribAuthor ">Elena  Piñeiro-Yañez</span>, <span class="hlFld-ContribAuthor ">Jose Luis  Montoya-Suarez</span>, <span class="hlFld-ContribAuthor ">Juan V.  Apala</span>, <span class="hlFld-ContribAuthor ">Amalia  Moreno-Torres</span>, <span class="hlFld-ContribAuthor ">Ramon  Colomer</span>, <span class="hlFld-ContribAuthor ">Ana  Dopazo</span>, <span class="hlFld-ContribAuthor ">Albert J. R.  Heck</span>, <span class="hlFld-ContribAuthor ">Maarten  Altelaar</span>, <span class="hlFld-ContribAuthor ">Miguel  Quintela-Fandino</span>. </span><span class="cited-content_cbyCitation_article-title">In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2018,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-018-05742-z" title="DOI URL">https://doi.org/10.1038/s41467-018-05742-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-018-05742-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-018-05742-z%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DIn%252Bvivo%252Bphosphoproteomics%252Breveals%252Bkinase%252Bactivity%252Bprofiles%252Bthat%252Bpredict%252Btreatment%252Boutcome%252Bin%252Btriple-negative%252Bbreast%252Bcancer%26aulast%3DZagorac%26aufirst%3DIvana%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Honorine  Lebraud</span>, <span class="hlFld-ContribAuthor ">Olga  Surova</span>, <span class="hlFld-ContribAuthor ">Aurélie  Courtin</span>, <span class="hlFld-ContribAuthor ">Marc  O'Reilly</span>, <span class="hlFld-ContribAuthor ">Chiara R.  Valenzano</span>, <span class="hlFld-ContribAuthor ">Pär  Nordlund</span>, <span class="hlFld-ContribAuthor ">Tom D.  Heightman</span>. </span><span class="cited-content_cbyCitation_article-title">Quantitation of ERK1/2 inhibitor cellular target occupancies with a reversible slow off-rate probe. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2018,</strong> <em>9 </em>
                                    (45)
                                     , 8608-8618. <a href="https://doi.org/10.1039/C8SC02754D" title="DOI URL">https://doi.org/10.1039/C8SC02754D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8SC02754D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8SC02754D%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DQuantitation%252Bof%252BERK1%25252F2%252Binhibitor%252Bcellular%252Btarget%252Boccupancies%252Bwith%252Ba%252Breversible%252Bslow%252Boff-rate%252Bprobe%26aulast%3DLebraud%26aufirst%3DHonorine%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D45%26spage%3D8608%26epage%3D8618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarah G.  Hymowitz</span>, <span class="hlFld-ContribAuthor ">Shiva  Malek</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the MAPK Pathway in RAS Mutant Cancers. </span><span class="cited-content_cbyCitation_journal-name">Cold Spring Harbor Perspectives in Medicine</span><span> <strong>2018,</strong> <em>8 </em>
                                    (11)
                                     , a031492. <a href="https://doi.org/10.1101/cshperspect.a031492" title="DOI URL">https://doi.org/10.1101/cshperspect.a031492</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1101/cshperspect.a031492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1101%2Fcshperspect.a031492%26sid%3Dliteratum%253Aachs%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspectives%2520in%2520Medicine%26atitle%3DTargeting%252Bthe%252BMAPK%252BPathway%252Bin%252BRAS%252BMutant%252BCancers%26aulast%3DHymowitz%26aufirst%3DSarah%2BG.%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D11%26spage%3Da031492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shubham  Pant</span>, <span class="hlFld-ContribAuthor ">Joleen  Hubbard</span>, <span class="hlFld-ContribAuthor ">Erika  Martinelli</span>, <span class="hlFld-ContribAuthor ">Tanios  Bekaii-Saab</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical update on K-Ras targeted therapy in gastrointestinal cancers. </span><span class="cited-content_cbyCitation_journal-name">Critical Reviews in Oncology/Hematology</span><span> <strong>2018,</strong> <em>130 </em>, 78-91. <a href="https://doi.org/10.1016/j.critrevonc.2018.07.011" title="DOI URL">https://doi.org/10.1016/j.critrevonc.2018.07.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.critrevonc.2018.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.critrevonc.2018.07.011%26sid%3Dliteratum%253Aachs%26jtitle%3DCritical%2520Reviews%2520in%2520Oncology%252FHematology%26atitle%3DClinical%252Bupdate%252Bon%252BK-Ras%252Btargeted%252Btherapy%252Bin%252Bgastrointestinal%252Bcancers%26aulast%3DPant%26aufirst%3DShubham%26date%3D2018%26volume%3D130%26spage%3D78%26epage%3D91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongmei  Jiang</span>, <span class="hlFld-ContribAuthor ">Mai  Xu</span>, <span class="hlFld-ContribAuthor ">Lin  Li</span>, <span class="hlFld-ContribAuthor ">Patrick  Grierson</span>, <span class="hlFld-ContribAuthor ">Paarth  Dodhiawala</span>, <span class="hlFld-ContribAuthor ">Maureen  Highkin</span>, <span class="hlFld-ContribAuthor ">Daoxiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Qiong  Li</span>, <span class="hlFld-ContribAuthor ">Andrea  Wang-Gillam</span>, <span class="hlFld-ContribAuthor ">Kian-Huat  Lim</span>. </span><span class="cited-content_cbyCitation_article-title">Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2018,</strong> <em>17 </em>
                                    (10)
                                     , 2144-2155. <a href="https://doi.org/10.1158/1535-7163.MCT-17-1142" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-17-1142</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-17-1142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-17-1142%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DConcurrent%252BHER%252Bor%252BPI3K%252BInhibition%252BPotentiates%252Bthe%252BAntitumor%252BEffect%252Bof%252Bthe%252BERK%252BInhibitor%252BUlixertinib%252Bin%252BPreclinical%252BPancreatic%252BCancer%252BModels%26aulast%3DJiang%26aufirst%3DHongmei%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D10%26spage%3D2144%26epage%3D2155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bijay S.  Jaiswal</span>, <span class="hlFld-ContribAuthor ">Steffen  Durinck</span>, <span class="hlFld-ContribAuthor ">Eric W.  Stawiski</span>, <span class="hlFld-ContribAuthor ">Jianping  Yin</span>, <span class="hlFld-ContribAuthor ">Weiru  Wang</span>, <span class="hlFld-ContribAuthor ">Eva  Lin</span>, <span class="hlFld-ContribAuthor ">John  Moffat</span>, <span class="hlFld-ContribAuthor ">Scott E.  Martin</span>, <span class="hlFld-ContribAuthor ">Zora  Modrusan</span>, <span class="hlFld-ContribAuthor ">Somasekar  Seshagiri</span>. </span><span class="cited-content_cbyCitation_article-title">ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2018,</strong> <em>24 </em>
                                    (16)
                                     , 4044-4055. <a href="https://doi.org/10.1158/1078-0432.CCR-17-3674" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-17-3674</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-17-3674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-17-3674%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DERK%252BMutations%252Band%252BAmplification%252BConfer%252BResistance%252Bto%252BERK-Inhibitor%252BTherapy%26aulast%3DJaiswal%26aufirst%3DBijay%2BS.%26date%3D2018%26date%3D2018%26volume%3D24%26issue%3D16%26spage%3D4044%26epage%3D4055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feifei  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaotong  Yang</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Min  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2018,</strong> <em>8 </em>
                                    (4)
                                     , 552-562. <a href="https://doi.org/10.1016/j.apsb.2018.01.008" title="DOI URL">https://doi.org/10.1016/j.apsb.2018.01.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2018.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2018.01.008%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DTargeting%252BERK%25252C%252Ban%252BAchilles%252527%252BHeel%252Bof%252Bthe%252BMAPK%252Bpathway%25252C%252Bin%252Bcancer%252Btherapy%26aulast%3DLiu%26aufirst%3DFeifei%26date%3D2018%26volume%3D8%26issue%3D4%26spage%3D552%26epage%3D562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew M.  Kidger</span>, <span class="hlFld-ContribAuthor ">James  Sipthorp</span>, <span class="hlFld-ContribAuthor ">Simon J.  Cook</span>. </span><span class="cited-content_cbyCitation_article-title">ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2018,</strong> <em>187 </em>, 45-60. <a href="https://doi.org/10.1016/j.pharmthera.2018.02.007" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2018.02.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2018.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2018.02.007%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DERK1%25252F2%252Binhibitors%25253A%252BNew%252Bweapons%252Bto%252Binhibit%252Bthe%252BRAS-regulated%252BRAF-MEK1%25252F2-ERK1%25252F2%252Bpathway%26aulast%3DKidger%26aufirst%3DAndrew%2BM.%26date%3D2018%26volume%3D187%26spage%3D45%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas  Dompe</span>, <span class="hlFld-ContribAuthor ">Christiaan  Klijn</span>, <span class="hlFld-ContribAuthor ">Sara A.  Watson</span>, <span class="hlFld-ContribAuthor ">Katherine  Leng</span>, <span class="hlFld-ContribAuthor ">Jenna  Port</span>, <span class="hlFld-ContribAuthor ">Trinna  Cuellar</span>, <span class="hlFld-ContribAuthor ">Colin  Watanabe</span>, <span class="hlFld-ContribAuthor ">Benjamin  Haley</span>, <span class="hlFld-ContribAuthor ">Richard  Neve</span>, <span class="hlFld-ContribAuthor ">Marie  Evangelista</span>, <span class="hlFld-ContribAuthor ">David  Stokoe</span>, . </span><span class="cited-content_cbyCitation_article-title">A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2018,</strong> <em>13 </em>
                                    (6)
                                     , e0199264. <a href="https://doi.org/10.1371/journal.pone.0199264" title="DOI URL">https://doi.org/10.1371/journal.pone.0199264</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0199264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0199264%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DA%252BCRISPR%252Bscreen%252Bidentifies%252BMAPK7%252Bas%252Ba%252Btarget%252Bfor%252Bcombination%252Bwith%252BMEK%252Binhibition%252Bin%252BKRAS%252Bmutant%252BNSCLC%26aulast%3DDompe%26aufirst%3DNicholas%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D6%26spage%3De0199264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sobhana Babu  Boga</span>, <span class="hlFld-ContribAuthor ">Abdul-Basit  Alhassan</span>, <span class="hlFld-ContribAuthor ">Alan B.  Cooper</span>, <span class="hlFld-ContribAuthor ">Ronald  Doll</span>, <span class="hlFld-ContribAuthor ">Neng-Yang  Shih</span>, <span class="hlFld-ContribAuthor ">Gerald  Shipps</span>, <span class="hlFld-ContribAuthor ">Yongqi  Deng</span>, <span class="hlFld-ContribAuthor ">Hugh  Zhu</span>, <span class="hlFld-ContribAuthor ">Yang  Nan</span>, <span class="hlFld-ContribAuthor ">Robert  Sun</span>, <span class="hlFld-ContribAuthor ">Liang  Zhu</span>, <span class="hlFld-ContribAuthor ">Jagdish  Desai</span>, <span class="hlFld-ContribAuthor ">Mehul  Patel</span>, <span class="hlFld-ContribAuthor ">Kiran  Muppalla</span>, <span class="hlFld-ContribAuthor ">Xiaolei  Gao</span>, <span class="hlFld-ContribAuthor ">James  Wang</span>, <span class="hlFld-ContribAuthor ">Xin  Yao</span>, <span class="hlFld-ContribAuthor ">Joseph  Kelly</span>, <span class="hlFld-ContribAuthor ">Subrahmanyam  Gudipati</span>, <span class="hlFld-ContribAuthor ">Sunil  Paliwal</span>, <span class="hlFld-ContribAuthor ">Hon-Chung  Tsui</span>, <span class="hlFld-ContribAuthor ">Tong  Wang</span>, <span class="hlFld-ContribAuthor ">Bradley  Sherborne</span>, <span class="hlFld-ContribAuthor ">Li  Xiao</span>, <span class="hlFld-ContribAuthor ">Alan  Hruza</span>, <span class="hlFld-ContribAuthor ">Alexei  Buevich</span>, <span class="hlFld-ContribAuthor ">Li-Kang  Zhang</span>, <span class="hlFld-ContribAuthor ">David  Hesk</span>, <span class="hlFld-ContribAuthor ">Ahmed A.  Samatar</span>, <span class="hlFld-ContribAuthor ">Donna  Carr</span>, <span class="hlFld-ContribAuthor ">Brian  Long</span>, <span class="hlFld-ContribAuthor ">Stuart  Black</span>, <span class="hlFld-ContribAuthor ">Priya  Dayananth</span>, <span class="hlFld-ContribAuthor ">William  Windsor</span>, <span class="hlFld-ContribAuthor ">Paul  Kirschmeier</span>, <span class="hlFld-ContribAuthor ">Robert  Bishop</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 3( S )-thiomethyl pyrrolidine ERK inhibitors for oncology. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (11)
                                     , 2029-2034. <a href="https://doi.org/10.1016/j.bmcl.2018.04.063" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.04.063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.04.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.04.063%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B3%252528%252BS%252B%252529-thiomethyl%252Bpyrrolidine%252BERK%252Binhibitors%252Bfor%252Boncology%26aulast%3DBoga%26aufirst%3DSobhana%2BBabu%26date%3D2018%26volume%3D28%26issue%3D11%26spage%3D2029%26epage%3D2034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiaji G.  Chen</span>, <span class="hlFld-ContribAuthor ">Xia  Liu</span>, <span class="hlFld-ContribAuthor ">Manit  Munshi</span>, <span class="hlFld-ContribAuthor ">Lian  Xu</span>, <span class="hlFld-ContribAuthor ">Nicholas  Tsakmaklis</span>, <span class="hlFld-ContribAuthor ">Maria G.  Demos</span>, <span class="hlFld-ContribAuthor ">Amanda  Kofides</span>, <span class="hlFld-ContribAuthor ">Maria Luisa  Guerrera</span>, <span class="hlFld-ContribAuthor ">Gloria G.  Chan</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Patterson</span>, <span class="hlFld-ContribAuthor ">Kirsten  Meid</span>, <span class="hlFld-ContribAuthor ">Joshua  Gustine</span>, <span class="hlFld-ContribAuthor ">Toni  Dubeau</span>, <span class="hlFld-ContribAuthor ">Patricia  Severns</span>, <span class="hlFld-ContribAuthor ">Jorge J.  Castillo</span>, <span class="hlFld-ContribAuthor ">Zachary R.  Hunter</span>, <span class="hlFld-ContribAuthor ">Jinhua  Wang</span>, <span class="hlFld-ContribAuthor ">Sara J.  Buhrlage</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>, <span class="hlFld-ContribAuthor ">Steven P.  Treon</span>, <span class="hlFld-ContribAuthor ">Guang  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. </span><span class="cited-content_cbyCitation_journal-name">Blood</span><span> <strong>2018,</strong> <em>131 </em>
                                    (18)
                                     , 2047-2059. <a href="https://doi.org/10.1182/blood-2017-10-811752" title="DOI URL">https://doi.org/10.1182/blood-2017-10-811752</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1182/blood-2017-10-811752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1182%2Fblood-2017-10-811752%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%26atitle%3DBTKCys481Ser%252Bdrives%252Bibrutinib%252Bresistance%252Bvia%252BERK1%25252F2%252Band%252Bprotects%252BBTKwild-type%252BMYD88-mutated%252Bcells%252Bby%252Ba%252Bparacrine%252Bmechanism%26aulast%3DChen%26aufirst%3DJiaji%2BG.%26date%3D2018%26volume%3D131%26issue%3D18%26spage%3D2047%26epage%3D2059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joel  Basken</span>, <span class="hlFld-ContribAuthor ">Scott A.  Stuart</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Kavran</span>, <span class="hlFld-ContribAuthor ">Thomas  Lee</span>, <span class="hlFld-ContribAuthor ">Christopher C.  Ebmeier</span>, <span class="hlFld-ContribAuthor ">William M.  Old</span>, <span class="hlFld-ContribAuthor ">Natalie G.  Ahn</span>. </span><span class="cited-content_cbyCitation_article-title">Specificity of Phosphorylation Responses to Mitogen Activated Protein (MAP) Kinase Pathway Inhibitors in Melanoma Cells. </span><span class="cited-content_cbyCitation_journal-name">Molecular & Cellular Proteomics</span><span> <strong>2018,</strong> <em>17 </em>
                                    (4)
                                     , 550-564. <a href="https://doi.org/10.1074/mcp.RA117.000335" title="DOI URL">https://doi.org/10.1074/mcp.RA117.000335</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/mcp.RA117.000335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fmcp.RA117.000335%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520%2526%2520Cellular%2520Proteomics%26atitle%3DSpecificity%252Bof%252BPhosphorylation%252BResponses%252Bto%252BMitogen%252BActivated%252BProtein%252B%252528MAP%252529%252BKinase%252BPathway%252BInhibitors%252Bin%252BMelanoma%252BCells%26aulast%3DBasken%26aufirst%3DJoel%26date%3D2018%26volume%3D17%26issue%3D4%26spage%3D550%26epage%3D564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stergios J.  Moschos</span>, <span class="hlFld-ContribAuthor ">Ryan J.  Sullivan</span>, <span class="hlFld-ContribAuthor ">Wen-Jen  Hwu</span>, <span class="hlFld-ContribAuthor ">Ramesh K.  Ramanathan</span>, <span class="hlFld-ContribAuthor ">Alex A.  Adjei</span>, <span class="hlFld-ContribAuthor ">Peter C.  Fong</span>, <span class="hlFld-ContribAuthor ">Ronnie  Shapira-Frommer</span>, <span class="hlFld-ContribAuthor ">Hussein A.  Tawbi</span>, <span class="hlFld-ContribAuthor ">Joseph  Rubino</span>, <span class="hlFld-ContribAuthor ">Thomas S.  Rush</span>, <span class="hlFld-ContribAuthor ">Da  Zhang</span>, <span class="hlFld-ContribAuthor ">Nathan R.  Miselis</span>, <span class="hlFld-ContribAuthor ">Ahmed A.  Samatar</span>, <span class="hlFld-ContribAuthor ">Patrick  Chun</span>, <span class="hlFld-ContribAuthor ">Eric H.  Rubin</span>, <span class="hlFld-ContribAuthor ">James  Schiller</span>, <span class="hlFld-ContribAuthor ">Brian J.  Long</span>, <span class="hlFld-ContribAuthor ">Priya  Dayananth</span>, <span class="hlFld-ContribAuthor ">Donna  Carr</span>, <span class="hlFld-ContribAuthor ">Paul  Kirschmeier</span>, <span class="hlFld-ContribAuthor ">W. Robert  Bishop</span>, <span class="hlFld-ContribAuthor ">Yongqi  Deng</span>, <span class="hlFld-ContribAuthor ">Alan  Cooper</span>, <span class="hlFld-ContribAuthor ">Gerald W.  Shipps</span>, <span class="hlFld-ContribAuthor ">Blanca Homet  Moreno</span>, <span class="hlFld-ContribAuthor ">Lidia  Robert</span>, <span class="hlFld-ContribAuthor ">Antoni  Ribas</span>, <span class="hlFld-ContribAuthor ">Keith T.  Flaherty</span>. </span><span class="cited-content_cbyCitation_article-title">Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. </span><span class="cited-content_cbyCitation_journal-name">JCI Insight</span><span> <strong>2018,</strong> <em>3 </em>
                                    (4)
                                     <a href="https://doi.org/10.1172/jci.insight.92352" title="DOI URL">https://doi.org/10.1172/jci.insight.92352</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1172/jci.insight.92352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1172%2Fjci.insight.92352%26sid%3Dliteratum%253Aachs%26jtitle%3DJCI%2520Insight%26atitle%3DDevelopment%252Bof%252BMK-8353%25252C%252Ban%252Borally%252Badministered%252BERK1%25252F2%252Binhibitor%25252C%252Bin%252Bpatients%252Bwith%252Badvanced%252Bsolid%252Btumors%26aulast%3DMoschos%26aufirst%3DStergios%2BJ.%26date%3D2018%26volume%3D3%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Myungsun  Shin</span>, <span class="hlFld-ContribAuthor ">Caroline E.  Franks</span>, <span class="hlFld-ContribAuthor ">Ku-Lung  Hsu</span>. </span><span class="cited-content_cbyCitation_article-title">Isoform-selective activity-based profiling of ERK signaling. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2018,</strong> <em>9 </em>
                                    (9)
                                     , 2419-2431. <a href="https://doi.org/10.1039/C8SC00043C" title="DOI URL">https://doi.org/10.1039/C8SC00043C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8SC00043C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8SC00043C%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DIsoform-selective%252Bactivity-based%252Bprofiling%252Bof%252BERK%252Bsignaling%26aulast%3DShin%26aufirst%3DMyungsun%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D9%26spage%3D2419%26epage%3D2431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei-Jen  Chung</span>, <span class="hlFld-ContribAuthor ">Anneleen  Daemen</span>, <span class="hlFld-ContribAuthor ">Jason H.  Cheng</span>, <span class="hlFld-ContribAuthor ">Jason E.  Long</span>, <span class="hlFld-ContribAuthor ">Jonathan E.  Cooper</span>, <span class="hlFld-ContribAuthor ">Bu-er  Wang</span>, <span class="hlFld-ContribAuthor ">Christopher  Tran</span>, <span class="hlFld-ContribAuthor ">Mallika  Singh</span>, <span class="hlFld-ContribAuthor ">Florian  Gnad</span>, <span class="hlFld-ContribAuthor ">Zora  Modrusan</span>, <span class="hlFld-ContribAuthor ">Oded  Foreman</span>, <span class="hlFld-ContribAuthor ">Melissa R.  Junttila</span>. </span><span class="cited-content_cbyCitation_article-title">Kras
              mutant genetically engineered mouse models of human cancers are genomically heterogeneous. </span><span class="cited-content_cbyCitation_journal-name">Proceedings of the National Academy of Sciences</span><span> <strong>2017,</strong> <em>114 </em>
                                    (51)
                                     , E10947-E10955. <a href="https://doi.org/10.1073/pnas.1708391114" title="DOI URL">https://doi.org/10.1073/pnas.1708391114</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1073/pnas.1708391114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1073%2Fpnas.1708391114%26sid%3Dliteratum%253Aachs%26jtitle%3DProceedings%2520of%2520the%2520National%2520Academy%2520of%2520Sciences%26atitle%3DKras%252Bmutant%252Bgenetically%252Bengineered%252Bmouse%252Bmodels%252Bof%252Bhuman%252Bcancers%252Bare%252Bgenomically%252Bheterogeneous%26aulast%3DChung%26aufirst%3DWei-Jen%26date%3D2017%26date%3D2017%26volume%3D114%26issue%3D51%26spage%3DE10947%26epage%3DE10955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sourav  Kalra</span>, <span class="hlFld-ContribAuthor ">Gaurav  Joshi</span>, <span class="hlFld-ContribAuthor ">Anjana  Munshi</span>, <span class="hlFld-ContribAuthor ">Raj  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>142 </em>, 424-458. <a href="https://doi.org/10.1016/j.ejmech.2017.08.071" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.08.071</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.08.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.08.071%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252Binsights%252Bof%252Bcyclin%252Bdependent%252Bkinases%25253A%252BImplications%252Bin%252Bdesign%252Bof%252Bselective%252Binhibitors%26aulast%3DKalra%26aufirst%3DSourav%26date%3D2017%26volume%3D142%26spage%3D424%26epage%3D458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel C.  Kirouac</span>, <span class="hlFld-ContribAuthor ">Gabriele  Schaefer</span>, <span class="hlFld-ContribAuthor ">Jocelyn  Chan</span>, <span class="hlFld-ContribAuthor ">Mark  Merchant</span>, <span class="hlFld-ContribAuthor ">Christine  Orr</span>, <span class="hlFld-ContribAuthor ">Shih-Min A.  Huang</span>, <span class="hlFld-ContribAuthor ">John  Moffat</span>, <span class="hlFld-ContribAuthor ">Lichuan  Liu</span>, <span class="hlFld-ContribAuthor ">Kapil  Gadkar</span>, <span class="hlFld-ContribAuthor ">Saroja  Ramanujan</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model. </span><span class="cited-content_cbyCitation_journal-name">npj Systems Biology and Applications</span><span> <strong>2017,</strong> <em>3 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41540-017-0016-1" title="DOI URL">https://doi.org/10.1038/s41540-017-0016-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41540-017-0016-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41540-017-0016-1%26sid%3Dliteratum%253Aachs%26jtitle%3Dnpj%2520Systems%2520Biology%2520and%2520Applications%26atitle%3DClinical%252Bresponses%252Bto%252BERK%252Binhibition%252Bin%252BBRAF%252BV600E-mutant%252Bcolorectal%252Bcancer%252Bpredicted%252Busing%252Ba%252Bcomputational%252Bmodel%26aulast%3DKirouac%26aufirst%3DDaniel%2BC.%26date%3D2017%26date%3D2017%26volume%3D3%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark  Merchant</span>, <span class="hlFld-ContribAuthor ">John  Moffat</span>, <span class="hlFld-ContribAuthor ">Gabriele  Schaefer</span>, <span class="hlFld-ContribAuthor ">Jocelyn  Chan</span>, <span class="hlFld-ContribAuthor ">Xi  Wang</span>, <span class="hlFld-ContribAuthor ">Christine  Orr</span>, <span class="hlFld-ContribAuthor ">Jason  Cheng</span>, <span class="hlFld-ContribAuthor ">Thomas  Hunsaker</span>, <span class="hlFld-ContribAuthor ">Lily  Shao</span>, <span class="hlFld-ContribAuthor ">Stephanie J.  Wang</span>, <span class="hlFld-ContribAuthor ">Marie-Claire  Wagle</span>, <span class="hlFld-ContribAuthor ">Eva  Lin</span>, <span class="hlFld-ContribAuthor ">Peter M.  Haverty</span>, <span class="hlFld-ContribAuthor ">Sheerin  Shahidi-Latham</span>, <span class="hlFld-ContribAuthor ">Hai  Ngu</span>, <span class="hlFld-ContribAuthor ">Margaret  Solon</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Eastham-Anderson</span>, <span class="hlFld-ContribAuthor ">Hartmut  Koeppen</span>, <span class="hlFld-ContribAuthor ">Shih-Min A.  Huang</span>, <span class="hlFld-ContribAuthor ">Jacob  Schwarz</span>, <span class="hlFld-ContribAuthor ">Marcia  Belvin</span>, <span class="hlFld-ContribAuthor ">Daniel  Kirouac</span>, <span class="hlFld-ContribAuthor ">Melissa R.  Junttila</span>, . </span><span class="cited-content_cbyCitation_article-title">Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2017,</strong> <em>12 </em>
                                    (10)
                                     , e0185862. <a href="https://doi.org/10.1371/journal.pone.0185862" title="DOI URL">https://doi.org/10.1371/journal.pone.0185862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0185862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0185862%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DCombined%252BMEK%252Band%252BERK%252Binhibition%252Bovercomes%252Btherapy-mediated%252Bpathway%252Breactivation%252Bin%252BRAS%252Bmutant%252Btumors%26aulast%3DMerchant%26aufirst%3DMark%26date%3D2017%26date%3D2017%26volume%3D12%26issue%3D10%26spage%3De0185862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chad J.  Miller</span>, <span class="hlFld-ContribAuthor ">Yagmur  Muftuoglu</span>, <span class="hlFld-ContribAuthor ">Benjamin E.  Turk</span>. </span><span class="cited-content_cbyCitation_article-title">A high throughput assay to identify substrate-selective inhibitors of the ERK protein kinases. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2017,</strong> <em>142 </em>, 39-45. <a href="https://doi.org/10.1016/j.bcp.2017.06.127" title="DOI URL">https://doi.org/10.1016/j.bcp.2017.06.127</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2017.06.127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2017.06.127%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DA%252Bhigh%252Bthroughput%252Bassay%252Bto%252Bidentify%252Bsubstrate-selective%252Binhibitors%252Bof%252Bthe%252BERK%252Bprotein%252Bkinases%26aulast%3DMiller%26aufirst%3DChad%2BJ.%26date%3D2017%26volume%3D142%26spage%3D39%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ricarda  Hannen</span>, <span class="hlFld-ContribAuthor ">Maria  Hauswald</span>, <span class="hlFld-ContribAuthor ">Joerg Walter  Bartsch</span>. </span><span class="cited-content_cbyCitation_article-title">A Rationale for Targeting Extracellular Regulated Kinases ERK1 and ERK2 in Glioblastoma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Neuropathology & Experimental Neurology</span><span> <strong>2017,</strong> <em>76 </em>
                                    (10)
                                     , 838-847. <a href="https://doi.org/10.1093/jnen/nlx076" title="DOI URL">https://doi.org/10.1093/jnen/nlx076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/jnen/nlx076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fjnen%2Fnlx076%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Neuropathology%2520%2526%2520Experimental%2520Neurology%26atitle%3DA%252BRationale%252Bfor%252BTargeting%252BExtracellular%252BRegulated%252BKinases%252BERK1%252Band%252BERK2%252Bin%252BGlioblastoma%26aulast%3DHannen%26aufirst%3DRicarda%26date%3D2017%26date%3D2017%26volume%3D76%26issue%3D10%26spage%3D838%26epage%3D847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Bo  Wang</span>, <span class="hlFld-ContribAuthor ">Baichun  Hu</span>, <span class="hlFld-ContribAuthor ">Hailun  Jiang</span>, <span class="hlFld-ContribAuthor ">Bate  Lai</span>, <span class="hlFld-ContribAuthor ">Ning  Li</span>, <span class="hlFld-ContribAuthor ">Maosheng  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">In Silicon Approach for Discovery of Chemopreventive Agents. </span><span class="cited-content_cbyCitation_journal-name">Current Pharmacology Reports</span><span> <strong>2017,</strong> <em>3 </em>
                                    (4)
                                     , 184-195. <a href="https://doi.org/10.1007/s40495-017-0094-1" title="DOI URL">https://doi.org/10.1007/s40495-017-0094-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40495-017-0094-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40495-017-0094-1%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Pharmacology%2520Reports%26atitle%3DIn%252BSilicon%252BApproach%252Bfor%252BDiscovery%252Bof%252BChemopreventive%252BAgents%26aulast%3DWang%26aufirst%3DJian%26date%3D2017%26date%3D2017%26volume%3D3%26issue%3D4%26spage%3D184%26epage%3D195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carly T.  Campbell</span>, <span class="hlFld-ContribAuthor ">Jessica N.  Haladyna</span>, <span class="hlFld-ContribAuthor ">David A.  Drubin</span>, <span class="hlFld-ContribAuthor ">Ty M.  Thomson</span>, <span class="hlFld-ContribAuthor ">Michael J.  Maria</span>, <span class="hlFld-ContribAuthor ">Taylor  Yamauchi</span>, <span class="hlFld-ContribAuthor ">Nigel J.  Waters</span>, <span class="hlFld-ContribAuthor ">Edward J.  Olhava</span>, <span class="hlFld-ContribAuthor ">Roy M.  Pollock</span>, <span class="hlFld-ContribAuthor ">Jesse J.  Smith</span>, <span class="hlFld-ContribAuthor ">Robert A.  Copeland</span>, <span class="hlFld-ContribAuthor ">Stephen J.  Blakemore</span>, <span class="hlFld-ContribAuthor ">Kathrin M.  Bernt</span>, <span class="hlFld-ContribAuthor ">Scott R.  Daigle</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in
              MLL
              -Rearranged Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2017,</strong> <em>16 </em>
                                    (8)
                                     , 1669-1679. <a href="https://doi.org/10.1158/1535-7163.MCT-16-0693" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-16-0693</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-16-0693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-16-0693%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DMechanisms%252Bof%252BPinometostat%252B%252528EPZ-5676%252529%252BTreatment%2525E2%252580%252593Emergent%252BResistance%252Bin%252BMLL%252B-Rearranged%252BLeukemia%26aulast%3DCampbell%26aufirst%3DCarly%2BT.%26date%3D2017%26date%3D2017%26volume%3D16%26issue%3D8%26spage%3D1669%26epage%3D1679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amélie  Boespflug</span>, <span class="hlFld-ContribAuthor ">Julie  Caramel</span>, <span class="hlFld-ContribAuthor ">Stephane  Dalle</span>, <span class="hlFld-ContribAuthor ">Luc  Thomas</span>. </span><span class="cited-content_cbyCitation_article-title">Treatment of
              NRAS
              -mutated advanced or metastatic melanoma: rationale, current trials and evidence to date. </span><span class="cited-content_cbyCitation_journal-name">Therapeutic Advances in Medical Oncology</span><span> <strong>2017,</strong> <em>9 </em>
                                    (7)
                                     , 481-492. <a href="https://doi.org/10.1177/1758834017708160" title="DOI URL">https://doi.org/10.1177/1758834017708160</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1758834017708160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1758834017708160%26sid%3Dliteratum%253Aachs%26jtitle%3DTherapeutic%2520Advances%2520in%2520Medical%2520Oncology%26atitle%3DTreatment%252Bof%252BNRAS%252B-mutated%252Badvanced%252Bor%252Bmetastatic%252Bmelanoma%25253A%252Brationale%25252C%252Bcurrent%252Btrials%252Band%252Bevidence%252Bto%252Bdate%26aulast%3DBoespflug%26aufirst%3DAm%25C3%25A9lie%26date%3D2017%26date%3D2017%26volume%3D9%26issue%3D7%26spage%3D481%26epage%3D492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Highly optimized ERK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. UV traces from incubation of <b>6</b> with hepatocytes at <i>t</i> = 3 h (M3 = compound <b>7</b>): h = human, m = mouse, r = rat, d = dog, c = cynomolgus monkey. The most abundant metabolites M1–M6 are labeled. The first peak common to all five traces represents an internal standard.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Synthesis of THP replacement analogs <b>9</b>–<b>28</b>. Conditions are the following. (a) For 4-aminopyrazoles: (i) Het-NH<sub>2</sub>, <i>s</i>-BuOH, 120 °C; (ii) TBAF, THF. (b) For 5-aminopyrazoles: (i) NaH, DMF, rt or 150 °C; HCl, EtOAc.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structures of <b>22</b> bound to ERK2 (brown) and CDK2 (purple): (A) compound <b>22</b> bound to ERK2; (B) superposition of ERK2 and CDK2 cocrystal structures with compound <b>22</b>. Red dotted lines indicate hydrogen bonds. Red spheres indicate water molecules.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Activity of <b>22</b> against 279 kinases at 1 μM. Illustration reproduced courtesy of Cell Signaling Technology (<a href="http://www.cellsignal.com" class="extLink">www.cellsignal.com</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound exposure vs time in a multidose mouse PK study with compound <b>22</b>, formulated in 40% PEG400/60% (10% HPβCD) water.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. HCT116 study PK/PD analysis with compound <b>22</b>: PK/PD data for <b>22</b> in the HCT116 mouse xenograft model. HCT116 tumors were established in nude mice to a tumor volume of 400–600 mm<sup>3</sup>. Mice were were treated with a single oral dose of <b>22</b> at 15, 30, or 100 mg/kg versus vehicle control alone (40% PEG400/60% (10% HPβCD)) followed by tumor and plasma collection at 2, 8, 16, and 24 h postdose. Tumor levels of phosphorylated p90RSK (pRSK) relative total p90RSK (tRSK) were measured by quantitative Western blot and were normalized to vehicle control at 2 h postdose (set to 100%). Plasma and tumor concentrations were measured by LC–MS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. HCT116 mouse xenograft data with compound <b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/medium/jm-2016-00389k_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Mean <b>22</b> (±SD) human PK concentrations at steady state by dose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-12/acs.jmedchem.6b00389/20160617/images/large/jm-2016-00389k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00389&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i32">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08344" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08344" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 27 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3291</span><span class="NLM_x">–</span> <span class="NLM_lpage">3310</span><span class="refDoi"> DOI: 10.1038/sj.onc.1210422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1038%2Fsj.onc.1210422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=17496923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3291-3310&author=P.+J.+Robertsauthor=C.+J.+Der&title=Targeting+the+Raf-MEK-ERK+mitogen-activated+protein+kinase+cascade+for+the+treatment+of+cancer&doi=10.1038%2Fsj.onc.1210422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span></div><div class="casAuthors">Roberts, P. J.; Der, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3291-3310</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in the regulation of normal cell proliferation, survival and differentiation.  Aberrant regulation of MAPK cascades contribute to cancer and other human diseases.  In particular, the extracellular signal-regulated kinase (ERK) MAPK pathway has been the subject of intense research scrutiny leading to the development of pharmacol. inhibitors for the treatment of cancer.  ERK is a downstream component of an evolutionarily conserved signaling module that is activated by the Raf serine/threonine kinases.  Raf activates the MAPK/ERK kinase (MEK)1/2 dual-specificity protein kinases, which then activate ERK1/2.  The mutational activation of Raf in human cancers supports the important role of this pathway in human oncogenesis.  Addnl., the Raf-MEK-ERK pathway is a key downstream effector of the Ras small GTPase, the most frequently mutated oncogene in human cancers.  Finally, Ras is a key downstream effector of the epidermal growth factor receptor (EGFR), which is mutationally activated and/or overexpressed in a wide variety of human cancers.  ERK activation also promotes upregulated expression of EGFR ligands, promoting an autocrine growth loop crit. for tumor growth.  Thus, the EGFR-Ras-Raf-MEK-ERK signaling network has been the subject of intense research and pharmaceutical scrutiny to identify novel target-based approaches for cancer treatment.  In this review, we summarize the current status of the different approaches and targets that are under evaluation and development for the therapeutic intervention of this key signaling pathway in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7hdVDVyRBHrVg90H21EOLACvtfcHk0ljhQeNaJVQewg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D&md5=bf56109e3b4defc12004471da30178c0</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210422%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DTargeting%2520the%2520Raf-MEK-ERK%2520mitogen-activated%2520protein%2520kinase%2520cascade%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3291%26epage%3D3310%26doi%3D10.1038%2Fsj.onc.1210422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Seger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krebs, E. G.</span><span> </span><span class="NLM_article-title">The MAPK signaling cascade</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">726</span><span class="NLM_x">–</span> <span class="NLM_lpage">735</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1096%2Ffasebj.9.9.7601337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=7601337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADyaK2MXmvFCltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1995&pages=726-735&author=R.+Segerauthor=E.+G.+Krebs&title=The+MAPK+signaling+cascade"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The MAPK signaling cascade</span></div><div class="casAuthors">Seger, Rony; Krebs, Edwin G.</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">726-35</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review with 99 refs.  The transmission of extracellular signals into their intracellular targets is mediated by a network of interacting proteins that regulate a large no. of cellular processes.  Cumulative efforts from many labs. over the past decade have allowed the elucidation of one such signaling mechanism, which involves activations of several membranal signaling mols. followed by a sequential stimulation of several cytoplasmic protein kinases collectively known as mitogen-activated protein kinase (MAPK) signaling cascade.  Up to six tiers in this cascade contribute to the amplification and specificity of the transmitted signals that eventually activate several regulatory mols. in the cytoplasm and in the nucleus to initiate cellular processes such as proliferation, differentiation, and development.  Moreover, because many oncogenes have been shown to encode proteins that transmit mitogenic signals upstream of this cascade, the MAPK pathway provides a simple unifying explanation for the mechanism of action of most, if not all, non-nuclear oncogenes.  The pattern of MAPK cascade is not restricted to growth factor signaling and it is now known that signaling pathways initiated by phorbol esters, ionophores, heat shock, and ligands for seven transmembrane receptors use distinct MAPK cascades with little or no cross-reactivity between them.  Emphasis is on the first MAPK cascade to be discovered that uses the MEK and ERK isoforms and their involvement in different cellular processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUHfD1KXEalbVg90H21EOLACvtfcHk0ljX6cjTjzDLhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmvFCltb0%253D&md5=575ee254997b2992062952b598304c61</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1096%2Ffasebj.9.9.7601337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffasebj.9.9.7601337%26sid%3Dliteratum%253Aachs%26aulast%3DSeger%26aufirst%3DR.%26aulast%3DKrebs%26aufirst%3DE.%2BG.%26atitle%3DThe%2520MAPK%2520signaling%2520cascade%26jtitle%3DFASEB%2520J.%26date%3D1995%26volume%3D9%26spage%3D726%26epage%3D735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Lewis, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, N. G.</span><span> </span><span class="NLM_article-title">Signal transduction through MAP kinase cascades</span> <span class="citation_source-journal">Adv. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">139</span><span class="refDoi"> DOI: 10.1016/S0065-230X(08)60765-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1016%2FS0065-230X%2808%2960765-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=9561267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADyaK1cXivVSls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=1998&pages=49-139&author=T.+S.+Lewisauthor=P.+S.+Shapiroauthor=N.+G.+Ahn&title=Signal+transduction+through+MAP+kinase+cascades&doi=10.1016%2FS0065-230X%2808%2960765-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction through MAP kinase cascades</span></div><div class="casAuthors">Lewis, Timothy S.; Shapiro, Paul S.; Ahn, Natalie G.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">49-139</span>CODEN:
                <span class="NLM_cas:coden">ACRSAJ</span>;
        ISSN:<span class="NLM_cas:issn">0065-230X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press, Inc.</span>)
        </div><div class="casAbstract">A review with many refs., on the title topic, discussing the MAP kinase (MAPK) module; mammalian MAPK pathways; regulation of MAPK pathways by protein phosphatases; ce;;i;ar substrates pf <AP kinases; responses to MAPK pathways: growth and differentiation; yeast MAPK pathways; intracellular targeting and spatial regulation MAPK pathway components; and future perspectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5MNvA1uEbjbVg90H21EOLACvtfcHk0ljX6cjTjzDLhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXivVSls70%253D&md5=32d30666cdf7cf8c2f08d48132af76e4</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0065-230X%2808%2960765-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-230X%252808%252960765-4%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DT.%2BS.%26aulast%3DShapiro%26aufirst%3DP.%2BS.%26aulast%3DAhn%26aufirst%3DN.%2BG.%26atitle%3DSignal%2520transduction%2520through%2520MAP%2520kinase%2520cascades%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D1998%26volume%3D74%26spage%3D49%26epage%3D139%26doi%3D10.1016%2FS0065-230X%2808%2960765-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Pearson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karandikar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobb, M. H.</span><span> </span><span class="NLM_article-title">Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions</span> <span class="citation_source-journal">Endocr. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span><span class="refDoi"> DOI: 10.1210/edrv.22.2.0428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1210%2Fedrv.22.2.0428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=11294822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsFSntL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2001&pages=153-183&author=G.+Pearsonauthor=F.+Robinsonauthor=T.+B.+Gibsonauthor=B.+Xuauthor=M.+Karandikarauthor=K.+Bermanauthor=M.+H.+Cobb&title=Mitogen-activated+protein+%28MAP%29+kinase+pathways%3A+regulation+and+physiological+functions&doi=10.1210%2Fedrv.22.2.0428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions</span></div><div class="casAuthors">Pearson, Gray; Robinson, Fred; Gibson, Tara Beers; Xu, Bing-E.; Karandikar, Mahesh; Berman, Kevin; Cobb, Melanie H.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-183</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review with 445 refs.  Mitogen-activated protein (MAP) kinases comprise a family of ubiquitous proline-directed, protein-serine/threonine kinases, which participate in signal transduction pathways that control intracellular events including acute responses to hormones and major developmental changes in organisms.  MAP kinases lie in protein kinase cascades.  This review discusses the regulation and functions of mammalian MAP kinases.  Nonenzymic mechanisms that impact MAP kinase functions and findings from gene disruption studies are highlighted.  Particular emphasis is on ERK1/2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8XhR5CgJu3bVg90H21EOLACvtfcHk0ljX6cjTjzDLhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsFSntL4%253D&md5=9b32d20e4d606ec928759848c6542e78</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1210%2Fedrv.22.2.0428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fedrv.22.2.0428%26sid%3Dliteratum%253Aachs%26aulast%3DPearson%26aufirst%3DG.%26aulast%3DRobinson%26aufirst%3DF.%26aulast%3DGibson%26aufirst%3DT.%2BB.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DKarandikar%26aufirst%3DM.%26aulast%3DBerman%26aufirst%3DK.%26aulast%3DCobb%26aufirst%3DM.%2BH.%26atitle%3DMitogen-activated%2520protein%2520%2528MAP%2529%2520kinase%2520pathways%253A%2520regulation%2520and%2520physiological%2520functions%26jtitle%3DEndocr.%2520Rev.%26date%3D2001%26volume%3D22%26spage%3D153%26epage%3D183%26doi%3D10.1210%2Fedrv.22.2.0428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasothan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Vemurafenib</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">811</span><span class="NLM_x">–</span> <span class="NLM_lpage">812</span><span class="refDoi"> DOI: 10.1038/nrd3579</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1038%2Fnrd3579" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=22037033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyis77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=811-812&author=K.+T.+Flahertyauthor=U.+Yasothanauthor=P.+Kirkpatrick&title=Vemurafenib&doi=10.1038%2Fnrd3579"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Vemurafenib</span></div><div class="casAuthors">Flaherty, Keith. T.; Yasothan, Uma; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">811-812</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAFV600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjMMlDZWY_BbVg90H21EOLACvtfcHk0ljX6cjTjzDLhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyis77I&md5=571edc546d25485f37890e3d62ea90a1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd3579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3579%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DVemurafenib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D811%26epage%3D812%26doi%3D10.1038%2Fnrd3579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Ballantyne, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnock-Jones, K. P.</span><span> </span><span class="NLM_article-title">Dabrafenib: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1367</span><span class="NLM_x">–</span> <span class="NLM_lpage">1376</span><span class="refDoi"> DOI: 10.1007/s40265-013-0095-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1007%2Fs40265-013-0095-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=23881668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWmtLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1367-1376&author=A.+D.+Ballantyneauthor=K.+P.+Garnock-Jones&title=Dabrafenib%3A+first+global+approval&doi=10.1007%2Fs40265-013-0095-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib: First Global Approval</span></div><div class="casAuthors">Ballantyne, Anita D.; Garnock-Jones, Karly P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1367-1376</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Dabrafenib (Tafinlar), a mutant-BRAF kinase inhibitor, emerged from GlaxoSmithKline's research program for the discovery of selective inhibitors of mutant BRAF kinase activity, for the treatment of solid tumors; mutations in the BRAF gene are assocd. with increased growth and proliferation of cancer cells.  GlaxoSmithKline has focused the development of dabrafenib on the treatment of malignant melanoma, as BRAF mutations are present in 50 % of these cancers.  Dabrafenib is approved in the US as a single agent treatment for unresectable or metastatic melanoma in patients with the BRAF V600E mutation, and has received a pos. opinion in the EU in this indication.  Submissions have also been made in the US and the EU for the use of dabrafenib in combination with trametinib for the treatment of metastatic melanoma with a BRAF V600E/K mutation.  Global phase III development of dabrafenib as a monotherapy and as a combination therapy is ongoing in the treatment of malignant melanoma.  Phase II development is ongoing for the treatment of malignant melanoma that has metastasised to the brain, and for colorectal and non-small cell lung cancers.  Dabrafenib is intended to treat the patient population with a BRAF V600E/K mutation.  GlaxoSmithKline's dabrafenib application in the US included the treatment of this population as detected by a US FDA-approved test.  GlaxoSmithKline, in collaboration with bioMerieux and Response Genetics, has developed a mol. theranostic test to identify BRAF V600E/K mutations.  Pre-Market approval of the test has been granted by the FDA.  This article summarises the milestones in the development of dabrafenib leading to this first approval as a single agent treatment for unresectable or metastatic melanoma in patients with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4KpEYZJGtALVg90H21EOLACvtfcHk0liTSavA6vph8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWmtLzN&md5=60ccc73dcdbbe08426a3e288fa5db56d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0095-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0095-2%26sid%3Dliteratum%253Aachs%26aulast%3DBallantyne%26aufirst%3DA.%2BD.%26aulast%3DGarnock-Jones%26aufirst%3DK.%2BP.%26atitle%3DDabrafenib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1367%26epage%3D1376%26doi%3D10.1007%2Fs40265-013-0095-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Wright, C. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormack, P. L.</span><span> </span><span class="NLM_article-title">Trametinib: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1245</span><span class="NLM_x">–</span> <span class="NLM_lpage">1254</span><span class="refDoi"> DOI: 10.1007/s40265-013-0096-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1007%2Fs40265-013-0096-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=23846731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A280%3ADC%252BC3sfgtFSjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1245-1254&author=C.+J.+M.+Wrightauthor=P.+L.+McCormack&title=Trametinib%3A+first+global+approval&doi=10.1007%2Fs40265-013-0096-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Trametinib: first global approval</span></div><div class="casAuthors">Wright Cameron J M; McCormack Paul L</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1245-54</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Trametinib is an orally bioavailable mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor with antineoplastic activity.  The compound specifically binds to MEK1 and MEK2, resulting in inhibition of growth factor-mediated cell signalling and cellular proliferation in various cancers.  Originally developed by Japan Tobacco, GlaxoSmithKline has licensed exclusive worldwide rights to the compound and conducted development in a number of different cancer types.  Trametinib, as a monotherapy, has been approved in the US for the treatment of unresectable or metastatic malignant melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.  The compound, as a monotherapy, has also been submitted for regulatory review in the EU for BRAF mutation-positive malignant melanoma, and is in phase III development in Europe, Argentina, Canada and Oceania.  Phase II development is underway for pancreatic cancer, non-small cell lung cancer and relapsed or refractory leukaemias.  GlaxoSmithKline is also developing trametinib for use in combination with dabrafenib in BRAF V600 mutation-positive metastatic cutaneous melanoma; the combination is at the preregistration stage in the EU and a phase III clinical programme is underway worldwide.  Phase II development for this combination is also underway in colorectal cancer.  Several phase I trials have also been initiated to evaluate trametinib in combination with other drugs for the treatment of various solid tumours and haematological malignancies.  A paediatric oral solution formulation has been assessed against the oral tablet formulation in a phase I trial.  This article summarizes the milestones in the development of trametinib leading to this first approval for unresectable or metastatic BRAF mutation-positive malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRw3yHtWXvrR2BAiYWy6n3SfW6udTcc2eah3RULUMGvh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfgtFSjtg%253D%253D&md5=133d953030ec0c3f62fbba730fabbfa9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0096-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0096-1%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DC.%2BJ.%2BM.%26aulast%3DMcCormack%26aufirst%3DP.%2BL.%26atitle%3DTrametinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1245%26epage%3D1254%26doi%3D10.1007%2Fs40265-013-0096-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Garnock-Jones, K. P.</span><span> </span><span class="NLM_article-title">Cobimetinib: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1823</span><span class="NLM_x">–</span> <span class="NLM_lpage">1830</span><span class="refDoi"> DOI: 10.1007/s40265-015-0477-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1007%2Fs40265-015-0477-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=26452567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1yltbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1823-1830&author=K.+P.+Garnock-Jones&title=Cobimetinib%3A+first+global+approval&doi=10.1007%2Fs40265-015-0477-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cobimetinib: First Global Approval</span></div><div class="casAuthors">Garnock-Jones, Karly P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1823-1830</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Genentech (a subsidiary of Roche) and Exelixis are developing cobimetinib, an orally available small mol., for the treatment of various cancers, including malignant melanoma and breast cancer.  Cobimetinib inhibits the MEK (mitogen-activated protein kinase) component of the MAPK/ERK signalling pathway, which is frequently over-activated in human tumors.  The product has been approved in Switzerland in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-pos. melanoma, and is under regulatory review for the same indication in several countries, including the USA and the EU.  This article summarizes the milestones in the development of cobimetinib leading to this first approval for unresectable or metastatic BRAF V600 mutation-pos. melanoma melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_AwqkxEJ58rVg90H21EOLACvtfcHk0liTSavA6vph8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1yltbrI&md5=de1c1a3f2d81b0cc2bde73d6994f8250</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0477-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0477-8%26sid%3Dliteratum%253Aachs%26aulast%3DGarnock-Jones%26aufirst%3DK.%2BP.%26atitle%3DCobimetinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1823%26epage%3D1830%26doi%3D10.1007%2Fs40265-015-0477-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Moriceau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hugo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samatar, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanlou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruchalski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seifert, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlman, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Algazi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span> </span><span class="NLM_article-title">Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span><span class="refDoi"> DOI: 10.1016/j.ccell.2014.11.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1016%2Fj.ccell.2014.11.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=25600339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKgtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=240-256&author=G.+Moriceauauthor=W.+Hugoauthor=A.+Hongauthor=H.+Shiauthor=X.+Kongauthor=C.+C.+Yuauthor=R.+C.+Koyaauthor=A.+A.+Samatarauthor=N.+Khanlouauthor=J.+Braunauthor=K.+Ruchalskiauthor=H.+Seifertauthor=J.+Larkinauthor=K.+B.+Dahlmanauthor=D.+B.+Johnsonauthor=A.+Algaziauthor=J.+A.+Sosmanauthor=A.+Ribasauthor=R.+S.+Lo&title=Tunable-combinatorial+mechanisms+of+acquired+resistance+limit+the+efficacy+of+BRAF%2FMEK+cotargeting+but+result+in+melanoma+drug+addiction&doi=10.1016%2Fj.ccell.2014.11.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction</span></div><div class="casAuthors">Moriceau, Gatien; Hugo, Willy; Hong, Aayoung; Shi, Hubing; Kong, Xiangju; Yu, Clarissa C.; Koya, Richard C.; Samatar, Ahmed A.; Khanlou, Negar; Braun, Jonathan; Ruchalski, Kathleen; Seifert, Heike; Larkin, James; Dahlman, Kimberly B.; Johnson, Douglas B.; Algazi, Alain; Sosman, Jeffrey A.; Ribas, Antoni; Lo, Roger S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-256</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Combined BRAF- and MEK-targeted therapy improves upon BRAF inhibitor (BRAFi) therapy but is still beset by acquired resistance.  We show that melanomas acquire resistance to combined BRAF and MEK inhibition by augmenting or combining mechanisms of single-agent BRAFi resistance.  These double-drug resistance-assocd. genetic configurations significantly altered mol. interactions underlying MAPK pathway reactivation. V600EBRAF, expressed at supraphysiol. levels because of V600EBRAF ultra-amplification, dimerized with and activated CRAF.  In addn., MEK mutants enhanced interaction with overexpressed V600EBRAF via a regulatory interface at R662 of V600EBRAF.  Importantly, melanoma cell lines selected for resistance to BRAFi+MEKi, but not those to BRAFi alone, displayed robust drug addiction, providing a potentially exploitable therapeutic opportunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWdJyJ2wlmALVg90H21EOLACvtfcHk0ljFBgd3RyKsfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKgtrg%253D&md5=42788605b6c22cf70ff49304bf65ca19</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2014.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2014.11.018%26sid%3Dliteratum%253Aachs%26aulast%3DMoriceau%26aufirst%3DG.%26aulast%3DHugo%26aufirst%3DW.%26aulast%3DHong%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DC.%2BC.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26aulast%3DKhanlou%26aufirst%3DN.%26aulast%3DBraun%26aufirst%3DJ.%26aulast%3DRuchalski%26aufirst%3DK.%26aulast%3DSeifert%26aufirst%3DH.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDahlman%26aufirst%3DK.%2BB.%26aulast%3DJohnson%26aufirst%3DD.%2BB.%26aulast%3DAlgazi%26aufirst%3DA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DTunable-combinatorial%2520mechanisms%2520of%2520acquired%2520resistance%2520limit%2520the%2520efficacy%2520of%2520BRAF%252FMEK%2520cotargeting%2520but%2520result%2520in%2520melanoma%2520drug%2520addiction%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D27%26spage%3D240%26epage%3D256%26doi%3D10.1016%2Fj.ccell.2014.11.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Sale, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, S. J.</span><span> </span><span class="NLM_article-title">Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">776</span><span class="NLM_x">–</span> <span class="NLM_lpage">783</span><span class="refDoi"> DOI: 10.1042/BST20140129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1042%2FBST20140129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=25109957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlWktLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=776-783&author=M.+J.+Saleauthor=S.+J.+Cook&title=Intrinsic+and+acquired+resistance+to+MEK1%2F2+inhibitors+in+cancer&doi=10.1042%2FBST20140129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer</span></div><div class="casAuthors">Sale, Matthew J.; Cook, Simon J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">776-783</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent clin. data with BRAF and MEK1/2 [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase 1/2] inhibitors have demonstrated the remarkable potential of targeting the RAF-MEK1/2-ERK1/2 signalling cascade for the treatment of certain cancers.  Despite these advances, however, only a subset of patients respond to these agents in the first instance, and, of those that do, acquired resistance invariably develops after several months.  Studies in vitro have identified various mechanisms that can underpin intrinsic and acquired resistance to MEK1/2 inhibitors, and these frequently recapitulate those obsd. clin.  In the present article, we review these mechanisms and also discuss recent advances in our understanding of how MEK1/2 inhibitor activity is influenced by pathway feedback.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkmrcuVF7iqLVg90H21EOLACvtfcHk0ljFBgd3RyKsfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlWktLzM&md5=98e908f603f5d0ee2cd747610531b968</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1042%2FBST20140129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20140129%26sid%3Dliteratum%253Aachs%26aulast%3DSale%26aufirst%3DM.%2BJ.%26aulast%3DCook%26aufirst%3DS.%2BJ.%26atitle%3DIntrinsic%2520and%2520acquired%2520resistance%2520to%2520MEK1%252F2%2520inhibitors%2520in%2520cancer%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2014%26volume%3D42%26spage%3D776%26epage%3D783%26doi%3D10.1042%2FBST20140129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">603</span><span class="NLM_x">–</span> <span class="NLM_lpage">604</span><span class="refDoi"> DOI: 10.1016/j.ccell.2014.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1016%2Fj.ccell.2014.10.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=603-604&author=P.+B.+Chapmanauthor=D.+B.+Solitauthor=N.+Rosen&title=Combination+of+RAF+and+MEK+inhibition+for+the+treatment+of+BRAF-mutated+melanoma%3A+feedback+is+not+encouraged&doi=10.1016%2Fj.ccell.2014.10.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2014.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2014.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DCombination%2520of%2520RAF%2520and%2520MEK%2520inhibition%2520for%2520the%2520treatment%2520of%2520BRAF-mutated%2520melanoma%253A%2520feedback%2520is%2520not%2520encouraged%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26spage%3D603%26epage%3D604%26doi%3D10.1016%2Fj.ccell.2014.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Yu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lv, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span> </span><span class="NLM_article-title">The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles of effective cancer therapy</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">–</span> <span class="NLM_lpage">289</span><span class="refDoi"> DOI: 10.4155/fmc.14.143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.4155%2Ffmc.14.143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=25826360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFaltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=269-289&author=Z.+Yuauthor=S.+Yeauthor=G.+Huauthor=M.+Lvauthor=Z.+Tuauthor=K.+Zhouauthor=Q.+Li&title=The+RAF-MEK-ERK+pathway%3A+targeting+ERK+to+overcome+obstacles+of+effective+cancer+therapy&doi=10.4155%2Ffmc.14.143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy</span></div><div class="casAuthors">Yu, Zutao; Ye, Shiqi; Hu, Gaoyun; Lv, Meng; Tu, Zhijun; Zhou, Kun; Li, Qianbin</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-289</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Aim: Currently, dozens of BRAF inhibitors and MEK inhibitors targeting RAF-MEK-ERK pathway have been introduced into clin. trials for cancer therapy.  However, after 6-8 mo of initial response, acquired drug resistance among the majority of those treated patients sharply diminished their clin. efficacy.  Discussion: Important mechanisms responsible for acquired resistance of BRAF inhibitors and MEK inhibitors have been elucidated.  Continually, ERK1/2 locates in the crit. position and features unique characteristics, such as activating hundreds of substrates, participating in feedback regulation, being catalyzed by MEK specifically and no acquired resistant mutation.  Conclusion: Taking in account the inspiring outcomes of ERK inhibitors in preclin. research, ERK1/2 might be the optimal target to overcome acquired drug resistance in RAF-MEK-ERK pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYVooAYz4COrVg90H21EOLACvtfcHk0ljFBgd3RyKsfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFaltbY%253D&md5=7f7253af9023521511a9504c42cd6199</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.143%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DLv%26aufirst%3DM.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DQ.%26atitle%3DThe%2520RAF-MEK-ERK%2520pathway%253A%2520targeting%2520ERK%2520to%2520overcome%2520obstacles%2520of%2520effective%2520cancer%2520therapy%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D269%26epage%3D289%26doi%3D10.4155%2Ffmc.14.143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Goetz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghandi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treacy, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagle, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span> </span><span class="NLM_article-title">ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">7079</span><span class="NLM_x">–</span> <span class="NLM_lpage">7089</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-2073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1158%2F0008-5472.CAN-14-2073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=25320010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVWhsrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=7079-7089&author=E.+M.+Goetzauthor=M.+Ghandiauthor=D.+J.+Treacyauthor=N.+Wagleauthor=L.+A.+Garraway&title=ERK+mutations+confer+resistance+to+mitogen-activated+protein+kinase+pathway+inhibitors&doi=10.1158%2F0008-5472.CAN-14-2073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors</span></div><div class="casAuthors">Goetz, Eva M.; Ghandi, Mahmoud; Treacy, Daniel J.; Wagle, Nikhil; Garraway, Levi A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7079-7089</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Identification of ERK1/2 mutations may provide insights for resistance to therapies targeting this pathway.  The use of targeted therapeutics directed against BRAFV600-mutant metastatic melanoma improves progression-free survival in many patients; however, acquired drug resistance remains a major medical challenge.  By far, the most common clin. resistance mechanism involves reactivation of the MAPK (RAF/MEK/ERK) pathway by a variety of mechanisms.  Thus, targeting ERK itself has emerged as an attractive therapeutic concept, and several ERK inhibitors have entered clin. trials.  We sought to preemptively det. mutations in ERK1/2 that confer resistance to either ERK inhibitors or combined RAF/MEK inhibition in BRAFV600-mutant melanoma.  Using a random mutagenesis screen, we identified multiple point mutations in ERK1 (MAPK3) and ERK2 (MAPK1) that could confer resistance to ERK or RAF/MEK inhibitors.  ERK inhibitor-resistant alleles were sensitive to RAF/MEK inhibitors and vice versa, suggesting that the future development of alternating RAF/MEK and ERK inhibitor regimens might help circumvent resistance to these agents.  Cancer Res; 74(23); 7079-89. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTZOJd289ow7Vg90H21EOLACvtfcHk0lhvASQblS5TEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVWhsrjF&md5=7902051fc3fe20837e2377cb14bb81a9</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-2073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-2073%26sid%3Dliteratum%253Aachs%26aulast%3DGoetz%26aufirst%3DE.%2BM.%26aulast%3DGhandi%26aufirst%3DM.%26aulast%3DTreacy%26aufirst%3DD.%2BJ.%26aulast%3DWagle%26aufirst%3DN.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26atitle%3DERK%2520mutations%2520confer%2520resistance%2520to%2520mitogen-activated%2520protein%2520kinase%2520pathway%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D7079%26epage%3D7089%26doi%3D10.1158%2F0008-5472.CAN-14-2073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Yap, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worlikar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKerell, A. D.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, S.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors of the ERK signaling pathway: towards novel anticancer therapeutics</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">48</span><span class="refDoi"> DOI: 10.1002/cmdc.201000354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1002%2Fcmdc.201000354" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=38-48&author=J.+L.+Yapauthor=S.+Worlikarauthor=A.+D.+MacKerellauthor=P.+Shapiroauthor=S.+Fletcher&title=Small-molecule+inhibitors+of+the+ERK+signaling+pathway%3A+towards+novel+anticancer+therapeutics&doi=10.1002%2Fcmdc.201000354"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000354%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DJ.%2BL.%26aulast%3DWorlikar%26aufirst%3DS.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26aulast%3DShapiro%26aufirst%3DP.%26aulast%3DFletcher%26aufirst%3DS.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520the%2520ERK%2520signaling%2520pathway%253A%2520towards%2520novel%2520anticancer%2520therapeutics%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26spage%3D38%26epage%3D48%26doi%3D10.1002%2Fcmdc.201000354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Aronov, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germann, U. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maltais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Botella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namchuk, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X.</span><span> </span><span class="NLM_article-title">Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1280</span><span class="NLM_x">–</span> <span class="NLM_lpage">1287</span><span class="refDoi"> DOI: 10.1021/jm061381f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061381f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1280-1287&author=A.+M.+Aronovauthor=C.+Bakerauthor=G.+W.+Bemisauthor=J.+Caoauthor=G.+Chenauthor=P.+J.+Fordauthor=U.+A.+Germannauthor=J.+Greenauthor=M.+R.+Haleauthor=M.+Jacobsauthor=J.+W.+Janetkaauthor=F.+Maltaisauthor=G.+Martinez-Botellaauthor=M.+N.+Namchukauthor=J.+Straubauthor=Q.+Tangauthor=X.+Xie&title=Flipped+out%3A+structure-guided+design+of+selective+pyrazolylpyrrole+ERK+inhibitors&doi=10.1021%2Fjm061381f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm061381f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061381f%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DBaker%26aufirst%3DC.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DFord%26aufirst%3DP.%2BJ.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DHale%26aufirst%3DM.%2BR.%26aulast%3DJacobs%26aufirst%3DM.%26aulast%3DJanetka%26aufirst%3DJ.%2BW.%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DMartinez-Botella%26aufirst%3DG.%26aulast%3DNamchuk%26aufirst%3DM.%2BN.%26aulast%3DStraub%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DXie%26aufirst%3DX.%26atitle%3DFlipped%2520out%253A%2520structure-guided%2520design%2520of%2520selective%2520pyrazolylpyrrole%2520ERK%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1280%26epage%3D1287%26doi%3D10.1021%2Fjm061381f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span>Biomed Valley Discoveries, BVD-523. <a href="https://biomed-valley.com/portfolio/bvd-523" class="extLink">https://biomed-valley.com/portfolio/bvd-523</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Biomed+Valley+Discoveries%2C+BVD-523.+https%3A%2F%2Fbiomed-valley.com%2Fportfolio%2Fbvd-523."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Bagdanoff, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madiera, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poon, D.</span><span> </span><span class="NLM_article-title">Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3788</span><span class="NLM_x">–</span> <span class="NLM_lpage">3792</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1016%2Fj.bmcl.2015.07.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=26259804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KrtLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3788-3792&author=J.+T.+Bagdanoffauthor=R.+Jainauthor=W.+Hanauthor=S.+Zhuauthor=A.-M.+Madieraauthor=P.+S.+Leeauthor=X.+Maauthor=D.+Poon&title=Tetrahydropyrrolo-diazepenones+as+inhibitors+of+ERK2+kinase&doi=10.1016%2Fj.bmcl.2015.07.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase</span></div><div class="casAuthors">Bagdanoff, Jeffrey T.; Jain, Rama; Han, Wooseok; Zhu, Shejin; Madiera, Ann-Marie; Lee, Patrick S.; Ma, Xiaolei; Poon, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3788-3792</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of structure based drug design hypotheses and focused screening efforts led to the identification of tetrahydropyrrolo-diazepenones with striking potency against ERK2 kinase.  The role of fluorination in mitigating microsomal clearance was systematically explored.  Ultimately, it was found that fluorination of a cyclopentanol substructure provided significant improvement in both potency and human metabolic stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHXEHIlXy0QLVg90H21EOLACvtfcHk0ljSmkqLn9PT2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KrtLnF&md5=d94c52debb8203a3b9e655319ea32754</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.091%26sid%3Dliteratum%253Aachs%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DJain%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DMadiera%26aufirst%3DA.-M.%26aulast%3DLee%26aufirst%3DP.%2BS.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DPoon%26aufirst%3DD.%26atitle%3DTetrahydropyrrolo-diazepenones%2520as%2520inhibitors%2520of%2520ERK2%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3788%26epage%3D3792%26doi%3D10.1016%2Fj.bmcl.2015.07.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Morris, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Restaino, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayananth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNunzio, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windsor, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angagaw, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinheiro, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipps, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hruza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paliwal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babu, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daublain, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutterbach, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelletier, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philippar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siliphaivanh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschmeier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zawel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fawell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samatar, A. A.</span><span> </span><span class="NLM_article-title">Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1158%2F2159-8290.CD-13-0070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=23614898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=742-750&author=E.+J.+Morrisauthor=S.+Jhaauthor=C.+R.+Restainoauthor=P.+Dayananthauthor=H.+Zhuauthor=A.+Cooperauthor=D.+Carrauthor=Y.+Dengauthor=W.+Jinauthor=S.+Blackauthor=B.+Longauthor=J.+Liuauthor=E.+DiNunzioauthor=W.+Windsorauthor=R.+Zhangauthor=S.+Zhaoauthor=M.+H.+Angagawauthor=E.+M.+Pinheiroauthor=J.+Desaiauthor=L.+Xiaoauthor=G.+Shippsauthor=A.+Hruzaauthor=J.+Wangauthor=J.+Kellyauthor=S.+Paliwalauthor=X.+Gaoauthor=B.+S.+Babuauthor=L.+Zhuauthor=P.+Daublainauthor=L.+Zhangauthor=B.+A.+Lutterbachauthor=M.+R.+Pelletierauthor=U.+Philipparauthor=P.+Siliphaivanhauthor=D.+Witterauthor=P.+Kirschmeierauthor=W.+R.+Bishopauthor=D.+Hicklinauthor=D.+G.+Gillilandauthor=L.+Jayaramanauthor=L.+Zawelauthor=S.+Fawellauthor=A.+A.+Samatar&title=Discovery+of+a+novel+ERK+inhibitor+with+activity+in+models+of+acquired+resistance+to+BRAF+and+MEK+inhibitors&doi=10.1158%2F2159-8290.CD-13-0070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors</span></div><div class="casAuthors">Morris, Erick J.; Jha, Sharda; Restaino, Clifford R.; Dayananth, Priya; Zhu, Hugh; Cooper, Alan; Carr, Donna; Deng, Yongi; Jin, Weihong; Black, Stuart; Long, Brian; Liu, Jenny; DiNunzio, Edward; Windsor, William; Zhang, Rumin; Zhao, Shuxia; Angagaw, Minilik H.; Pinheiro, Elaine M.; Desai, Jagdish; Xiao, Li; Shipps, Gerald; Hruza, Alan; Wang, James; Kelly, Joe; Paliwal, Sunil; Gao, Xiaolei; Babu, Boga Sobhana; Zhu, Liang; Daublain, Pierre; Zhang, Ling; Lutterbach, Bart A.; Pelletier, Marc R.; Philippar, Ulrike; Siliphaivanh, Phieng; Witter, David; Kirschmeier, Paul; Bishop, W. Robert; Hicklin, Daniel; Gilliland, D. Gary; Jayaraman, Lata; Zawel, Leigh; Fawell, Stephen; Samatar, Ahmed A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">742-750</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway.  Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clin. efficacy in patients with melanoma.  However, the majority of responses are transient, and resistance is often assocd. with pathway reactivation of the extracellular signal-regulated kinase (ERK) signaling pathway.  Here, we describe the identification and characterization of SCH772984, a novel and selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors.  SCH772984 has nanomolar cellular potency in tumor cells with mutations in BRAF, NRA5, or KRAS and induces tumor regressions in xenograft models at tolerated doses.  Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor-resistant models as well as in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors.  These data support the clin. development of ERK inhibitors for tumors refractory to MAPK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4HJ4HhYmLL7Vg90H21EOLACvtfcHk0lgRdwiEkSFJ6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE&md5=1f26a4a5bb1fab64bdd6c38c16b3f4e3</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0070%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DE.%2BJ.%26aulast%3DJha%26aufirst%3DS.%26aulast%3DRestaino%26aufirst%3DC.%2BR.%26aulast%3DDayananth%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDiNunzio%26aufirst%3DE.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DAngagaw%26aufirst%3DM.%2BH.%26aulast%3DPinheiro%26aufirst%3DE.%2BM.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DShipps%26aufirst%3DG.%26aulast%3DHruza%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DBabu%26aufirst%3DB.%2BS.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDaublain%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DPelletier%26aufirst%3DM.%2BR.%26aulast%3DPhilippar%26aufirst%3DU.%26aulast%3DSiliphaivanh%26aufirst%3DP.%26aulast%3DWitter%26aufirst%3DD.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DHicklin%26aufirst%3DD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DJayaraman%26aufirst%3DL.%26aulast%3DZawel%26aufirst%3DL.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520ERK%2520inhibitor%2520with%2520activity%2520in%2520models%2520of%2520acquired%2520resistance%2520to%2520BRAF%2520and%2520MEK%2520inhibitors%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D742%26epage%3D750%26doi%3D10.1158%2F2159-8290.CD-13-0070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Challinor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debreczeni, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckersley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairley, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feron, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flemington, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenwood, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopcroft, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renshaw, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snow, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, K.</span><span> </span><span class="NLM_article-title">Structure-guided design of highly selective and potent covalent inhibitors of ERK1/2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4790</span><span class="NLM_x">–</span> <span class="NLM_lpage">4801</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00466</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00466" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVChs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4790-4801&author=R.+A.+Wardauthor=N.+Colcloughauthor=M.+Challinorauthor=J.+E.+Debreczeniauthor=K.+Eckersleyauthor=G.+Fairleyauthor=L.+Feronauthor=V.+Flemingtonauthor=C.+R.+Grahamauthor=R.+Greenwoodauthor=P.+Hopcroftauthor=T.+D.+Howardauthor=M.+Jamesauthor=C.+D.+Jonesauthor=C.+R.+Jonesauthor=J.+Renshawauthor=K.+Robertsauthor=L.+Snowauthor=M.+Tongeauthor=K.+Yeung&title=Structure-guided+design+of+highly+selective+and+potent+covalent+inhibitors+of+ERK1%2F2&doi=10.1021%2Facs.jmedchem.5b00466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2</span></div><div class="casAuthors">Ward, Richard A.; Colclough, Nicola; Challinor, Mairi; Debreczeni, Judit E.; Eckersley, Kay; Fairley, Gary; Feron, Lyman; Flemington, Vikki; Graham, Mark A.; Greenwood, Ryan; Hopcroft, Philip; Howard, Tina D.; James, Michael; Jones, Clifford D.; Jones, Christopher R.; Renshaw, Jonathan; Roberts, Karen; Snow, Lindsay; Tonge, Michael; Yeung, Kay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4790-4801</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The RAS/RAF/MEK/ERK signaling pathway has been targeted with a no. of small mol. inhibitors in oncol. clin. development across multiple disease indications.  Importantly, cell lines with acquired resistance to B-RAF and MEK inhibitors have been shown to maintain sensitivity to ERK1/2 inhibition by small mol. inhibitors.  There are a no. of selective, noncovalent ERK1/2 inhibitors reported along with the promiscuous hypothemycin (and related analogs) that act via a covalent mechanism of action.  This article reports the identification of multiple series of highly selective covalent ERK1/2 inhibitors informed by structure-based drug design (SBDD).  As a starting point for these covalent inhibitors, reported ERK1/2 inhibitors and a chem. series identified via high-throughput screening were exploited.  These approaches resulted in the identification of selective covalent tool compds. for potential in vitro and in vivo studies to assess the risks and or benefits of targeting this pathway through such a mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLDLwUCW_ANrVg90H21EOLACvtfcHk0lgRdwiEkSFJ6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVChs7c%253D&md5=40b47d8671c966434434f056ac88b3a7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00466%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChallinor%26aufirst%3DM.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DEckersley%26aufirst%3DK.%26aulast%3DFairley%26aufirst%3DG.%26aulast%3DFeron%26aufirst%3DL.%26aulast%3DFlemington%26aufirst%3DV.%26aulast%3DGraham%26aufirst%3DC.%2BR.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DHopcroft%26aufirst%3DP.%26aulast%3DHoward%26aufirst%3DT.%2BD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DJones%26aufirst%3DC.%2BR.%26aulast%3DRenshaw%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DSnow%26aufirst%3DL.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DYeung%26aufirst%3DK.%26atitle%3DStructure-guided%2520design%2520of%2520highly%2520selective%2520and%2520potent%2520covalent%2520inhibitors%2520of%2520ERK1%252F2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4790%26epage%3D4801%26doi%3D10.1021%2Facs.jmedchem.5b00466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudino, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Meese, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chicarelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siedem, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolakowski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacheco, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi-Latham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, J. B.</span><span> </span><span class="NLM_article-title">Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2635</span><span class="NLM_x">–</span> <span class="NLM_lpage">2639</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.04.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1016%2Fj.bmcl.2014.04.068" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2635-2639&author=J.+F.+Blakeauthor=J.+J.+Gaudinoauthor=J.+De+Meeseauthor=P.+Mohrauthor=M.+Chicarelliauthor=H.+Tianauthor=R.+Garreyauthor=A.+Thomasauthor=C.+S.+Siedemauthor=M.+B.+Welchauthor=G.+Kolakowskiauthor=R.+Kausauthor=M.+Burkardauthor=M.+Martinsonauthor=H.+Chenauthor=B.+Deanauthor=D.+A.+Dudleyauthor=S.+E.+Gouldauthor=P.+Pachecoauthor=S.+Shahidi-Lathamauthor=W.+Wangauthor=K.+Westauthor=J.+Yinauthor=J.+Moffatauthor=J.+B.+Schwarz&title=Discovery+of+5%2C6%2C7%2C8-tetrahydropyrido%5B3%2C4-d%5Dpyrimidine+inhibitors+of+Erk2&doi=10.1016%2Fj.bmcl.2014.04.068"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.04.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.04.068%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DGaudino%26aufirst%3DJ.%2BJ.%26aulast%3DDe%2BMeese%26aufirst%3DJ.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DChicarelli%26aufirst%3DM.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DGarrey%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DSiedem%26aufirst%3DC.%2BS.%26aulast%3DWelch%26aufirst%3DM.%2BB.%26aulast%3DKolakowski%26aufirst%3DG.%26aulast%3DKaus%26aufirst%3DR.%26aulast%3DBurkard%26aufirst%3DM.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DDean%26aufirst%3DB.%26aulast%3DDudley%26aufirst%3DD.%2BA.%26aulast%3DGould%26aufirst%3DS.%2BE.%26aulast%3DPacheco%26aufirst%3DP.%26aulast%3DShahidi-Latham%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWest%26aufirst%3DK.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DSchwarz%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%25205%252C6%252C7%252C8-tetrahydropyrido%255B3%252C4-d%255Dpyrimidine%2520inhibitors%2520of%2520Erk2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2635%26epage%3D2639%26doi%3D10.1016%2Fj.bmcl.2014.04.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Ren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudino, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacheco, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi-Latham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, J. B.</span><span> </span><span class="NLM_article-title">Discovery of highly potent, selective and efficacious small molecule inhibitors of ERK1/2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1976</span><span class="NLM_x">–</span> <span class="NLM_lpage">1991</span><span class="refDoi"> DOI: 10.1021/jm501921k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501921k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1976-1991&author=L.+Renauthor=J.+Grinaauthor=D.+Morenoauthor=J.+F.+Blakeauthor=J.+J.+Gaudinoauthor=R.+Garreyauthor=A.+T.+Metcalfauthor=M.+Burkardauthor=M.+Martinsonauthor=K.+Rasorauthor=H.+Chenauthor=B.+Deanauthor=S.+E.+Gouldauthor=P.+Pachecoauthor=S.+Shahidi-Lathamauthor=J.+Yinauthor=K.+Westauthor=W.+Wangauthor=J.+G.+Moffatauthor=J.+B.+Schwarz&title=Discovery+of+highly+potent%2C+selective+and+efficacious+small+molecule+inhibitors+of+ERK1%2F2&doi=10.1021%2Fjm501921k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm501921k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501921k%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DL.%26aulast%3DGrina%26aufirst%3DJ.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DGaudino%26aufirst%3DJ.%2BJ.%26aulast%3DGarrey%26aufirst%3DR.%26aulast%3DMetcalf%26aufirst%3DA.%2BT.%26aulast%3DBurkard%26aufirst%3DM.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DRasor%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DDean%26aufirst%3DB.%26aulast%3DGould%26aufirst%3DS.%2BE.%26aulast%3DPacheco%26aufirst%3DP.%26aulast%3DShahidi-Latham%26aufirst%3DS.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DWest%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26aulast%3DSchwarz%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%2520highly%2520potent%252C%2520selective%2520and%2520efficacious%2520small%2520molecule%2520inhibitors%2520of%2520ERK1%252F2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1976%26epage%3D1991%26doi%3D10.1021%2Fjm501921k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="note"><p class="first last">The projected human dose for <b>6</b> was calculated using the predicted human clearance from simple allometry and the AUC<sub>last</sub> for a dose that effected ∼70% TGI.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Blake, J. F.; Chen, H.; Chicarelli, M. J.; Demeese, J.; Garrey, R.; Gaudino, J. J.; Kaus, R. J.; Kolakowski, G. R.; Marlow, A. L.; Mohr, P. J.; Ren, L.; Schwarz, J.; Siedem, C. S.; Thomas, A. A.; Wallace, E.; Wenglowsky, S. M.</span><span> </span><span class="NLM_article-title">Pyridopyrimidine derivatives as ERK inhibitors and their preparation and use for the treatment of hyperproliferative diseases</span>. PCT Int. Appl. WO 2012118850,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>251 pp.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.+F.+Blake&author=H.+Chen&author=M.+J.+Chicarelli&author=J.+Demeese&author=R.+Garrey&author=J.+J.+Gaudino&author=R.+J.+Kaus&author=G.+R.+Kolakowski&author=A.+L.+Marlow&author=P.+J.+Mohr&author=L.+Ren&author=J.+Schwarz&author=C.+S.+Siedem&author=A.+A.+Thomas&author=E.+Wallace&author=S.+M.+Wenglowsky&title=Pyridopyrimidine+derivatives+as+ERK+inhibitors+and+their+preparation+and+use+for+the+treatment+of+hyperproliferative+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26atitle%3DPyridopyrimidine%2520derivatives%2520as%2520ERK%2520inhibitors%2520and%2520their%2520preparation%2520and%2520use%2520for%2520the%2520treatment%2520of%2520hyperproliferative%2520diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><div class="note"><p class="first last">Expression, purification, and crystallization of CDK2 has been previously described:</p></div><span class="NLM_contrib-group">Hanan, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heald, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lainchbury, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purkey, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seward, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zilberleyb, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span> </span><span class="NLM_article-title">Discovery of selective and noncovalent diaminopyrimdine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">10176</span><span class="NLM_x">–</span> <span class="NLM_lpage">10191</span><span class="refDoi"> DOI: 10.1021/jm501578n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501578n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10176-10191&author=E.+J.+Hananauthor=C.+Eigenbrotauthor=M.+C.+Bryanauthor=D.+J.+Burdickauthor=B.+K.+Chanauthor=Y.+Chenauthor=J.+Dotsonauthor=R.+A.+Healdauthor=P.+S.+Jacksonauthor=H.+Laauthor=M.+D.+Lainchburyauthor=S.+Malekauthor=H.+E.+Purkeyauthor=G.+Schaeferauthor=S.+Schmidtauthor=E.+M.+Sewardauthor=S.+Siderisauthor=C.+Tamauthor=S.+Wangauthor=S.+K.+Yeapauthor=I.+Yenauthor=J.+Yinauthor=C.+Yuauthor=I.+Zilberleybauthor=T.+P.+Heffron&title=Discovery+of+selective+and+noncovalent+diaminopyrimdine-based+inhibitors+of+epidermal+growth+factor+receptor+containing+the+T790M+resistance+mutation&doi=10.1021%2Fjm501578n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm501578n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501578n%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DJackson%26aufirst%3DP.%2BS.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLainchbury%26aufirst%3DM.%2BD.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYeap%26aufirst%3DS.%2BK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DDiscovery%2520of%2520selective%2520and%2520noncovalent%2520diaminopyrimdine-based%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520containing%2520the%2520T790M%2520resistance%2520mutation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10176%26epage%3D10191%26doi%3D10.1021%2Fjm501578n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><div class="note"><p class="first last">A similar strategy was employed to gain selectivity for Plk1 over CDK2:</p></div><span class="NLM_contrib-group">Kothe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohls, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennie, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feru, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y.-H.</span><span> </span><span class="NLM_article-title">Selectivity-determining residues in Plk1</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">540</span><span class="NLM_x">–</span> <span class="NLM_lpage">546</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00594.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1111%2Fj.1747-0285.2007.00594.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=18005335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=540-546&author=M.+Kotheauthor=D.+Kohlsauthor=S.+Lowauthor=R.+Coliauthor=G.+R.+Rennieauthor=F.+Feruauthor=C.+Kuhnauthor=Y.-H.+Ding&title=Selectivity-determining+residues+in+Plk1&doi=10.1111%2Fj.1747-0285.2007.00594.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity-determining residues in Plk1</span></div><div class="casAuthors">Kothe, Michael; Kohls, Darcy; Low, Simon; Coli, Rocco; Rennie, Glen R.; Feru, Frederic; Kuhn, Cyrille; Ding, Yuan-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">540-546</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Polo-like kinase 1 is an important regulator of cell cycle progression whose over-expression is often assocd. with oncogenesis.  Polo-like kinase 1 hence represents an attractive target for cancer intervention.  BI 2536 (Boehringer Ingelheim, Ingelheim, Germany), a Polo-like kinase 1 inhibitor currently in clin. trials, exhibits nanomolar potency against Polo-like kinase isoforms and high selectivity against other kinases.  The authors have previously published the crystal structures of the Polo-like kinase 1 domain in complex with AMPPNP and an Aurora A inhibitor.  In this work, the authors present the cocrystal structure of Polo-like kinase 1 with BI 2536.  The structure, in combination with selectivity data for BI 2536 and related compds., illustrates important features for potency and selectivity.  In particular, the authors show that the methoxy group of BI 2536 is an important specificity determinant against non-Polo-like kinases by taking advantage of a small pocket generated by Leu 132 in the hinge region of Polo-like kinase 1.  The work presented here provides a framework for structure-based drug design of Polo-like kinase 1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjA3mwWD7K0bVg90H21EOLACvtfcHk0ljSNfQxmcwR-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsbrJ&md5=0f976bb98fe7d0413e8d2314abc68e2b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00594.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00594.x%26sid%3Dliteratum%253Aachs%26aulast%3DKothe%26aufirst%3DM.%26aulast%3DKohls%26aufirst%3DD.%26aulast%3DLow%26aufirst%3DS.%26aulast%3DColi%26aufirst%3DR.%26aulast%3DRennie%26aufirst%3DG.%2BR.%26aulast%3DFeru%26aufirst%3DF.%26aulast%3DKuhn%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DY.-H.%26atitle%3DSelectivity-determining%2520residues%2520in%2520Plk1%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D70%26spage%3D540%26epage%3D546%26doi%3D10.1111%2Fj.1747-0285.2007.00594.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="note"><p class="first last">The increase in concentration of <b>22</b> at 6–8 h may be due to dose/solubility limited absorption where there is continued absorption during compound transit in the gut.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Diaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allamneni, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarrant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewin-Koh, S.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhawan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cain, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiraragi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bheddah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dambach, D. M.</span><span> </span><span class="NLM_article-title">Phosphorous dysregulation induced by MEK small molecule inhibitors in the rat involves blockade of FGF-23 signaling in the kidney</span> <span class="citation_source-journal">Toxicol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span><span class="refDoi"> DOI: 10.1093/toxsci/kfr263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=10.1093%2Ftoxsci%2Fkfr263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=21976371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFOjtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2012&pages=187-195&author=D.+Diazauthor=K.+Allamneniauthor=J.+M.+Tarrantauthor=S.-C.+Lewin-Kohauthor=R.+Paiauthor=P.+Dhawanauthor=G.+R.+Cainauthor=C.+Kozlowskiauthor=H.+Hiraragiauthor=N.+Laauthor=D.+P.+Hartleyauthor=X.+Dingauthor=B.+J.+Deanauthor=S.+Bheddahauthor=D.+M.+Dambach&title=Phosphorous+dysregulation+induced+by+MEK+small+molecule+inhibitors+in+the+rat+involves+blockade+of+FGF-23+signaling+in+the+kidney&doi=10.1093%2Ftoxsci%2Fkfr263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorous dysregulation induced by MEK small molecule inhibitors in the rat involves blockade of FGF-23 signaling in the kidney</span></div><div class="casAuthors">Diaz, Dolores; Allamneni, Krishna; Tarrant, Jacqueline M.; Lewin-Koh, Sock-Cheng; Pai, Rama; Dhawan, Preeti; Cain, Gary R.; Kozlowski, Cleopatra; Hiraragi, Hajime; La, Nghi; Hartley, Dylan P.; Ding, Xiao; Dean, Brian J.; Bheddah, Sheila; Dambach, Donna M.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">187-195</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">MEK, a kinase downstream of Ras and Raf oncogenes, constitutes a high priority target in oncol. research.  MEK small mol. inhibitors cause soft tissue mineralization in rats secondary to blood serum inorg. phosphorus (iP) elevation, but the mol. mechanism for this toxicity remains undetd.  We performed investigative studies with structurally distinct MEK inhibitors GEN-A and PD325901 (PD-901) in Sprague-Dawley rats.  Our data support a mechanism that involves FGF-23 signal blockade in the rat kidney, causing transcriptional upregulation of 25-hydroxyvitamin D3 1-alpha-hydroxylase (Cyp27b1), the rate-limiting enzyme in vitamin D activation, and downregulation of 1,25-dihydroxyvitamin D3 24-hydroxylase (Cyp24a1), the enzyme that initiates the degrdn. of the active form of vitamin D.  These transcriptional changes increase serum vitamin D levels, which in turn drive the increase in serum iP, leading to soft tissue mineralization in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRrTYSDeZ1nLVg90H21EOLACvtfcHk0lgax8N2tf7unw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFOjtb0%253D&md5=5248ebee99e0c81bbf33cfd5285cb920</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfr263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfr263%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DD.%26aulast%3DAllamneni%26aufirst%3DK.%26aulast%3DTarrant%26aufirst%3DJ.%2BM.%26aulast%3DLewin-Koh%26aufirst%3DS.-C.%26aulast%3DPai%26aufirst%3DR.%26aulast%3DDhawan%26aufirst%3DP.%26aulast%3DCain%26aufirst%3DG.%2BR.%26aulast%3DKozlowski%26aufirst%3DC.%26aulast%3DHiraragi%26aufirst%3DH.%26aulast%3DLa%26aufirst%3DN.%26aulast%3DHartley%26aufirst%3DD.%2BP.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DDean%26aufirst%3DB.%2BJ.%26aulast%3DBheddah%26aufirst%3DS.%26aulast%3DDambach%26aufirst%3DD.%2BM.%26atitle%3DPhosphorous%2520dysregulation%2520induced%2520by%2520MEK%2520small%2520molecule%2520inhibitors%2520in%2520the%2520rat%2520involves%2520blockade%2520of%2520FGF-23%2520signaling%2520in%2520the%2520kidney%26jtitle%3DToxicol.%2520Sci.%26date%3D2012%26volume%3D125%26spage%3D187%26epage%3D195%26doi%3D10.1093%2Ftoxsci%2Fkfr263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K4I" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K4I','PDB','5K4I'); return false;">PDB: 5K4I</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K4J" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5K4J','PDB','5K4J'); return false;">PDB: 5K4J</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i29"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00389">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_32163"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00389">10.1021/acs.jmedchem.6b00389</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental procedures for the crystal structure determination of ERK2 and CDK2 complexes with <b>22</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00389/suppl_file/jm6b00389_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00389/suppl_file/jm6b00389_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00389/suppl_file/jm6b00389_si_001.pdf">jm6b00389_si_001.pdf (116.36 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00389/suppl_file/jm6b00389_si_002.csv">jm6b00389_si_002.csv (1.73 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00389&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00389%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-12%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00389" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a9c3aeb3e3c10","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
